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he is hard up that it is money Conscious of 
their own ignorance, most people are im­
pressed by anyone who pontificates and 
says something that is over their heads
Aristotle, The Nichomachean Ethics, Book 1,v.
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Chapter 1
1.1. Problems with pain relief in cancer patients
In advanced cancer, a large variety of symptoms can occur depending on the prima­
ry tumour process and its metastatic pattern. Anorexia and loss of weight, nausea and 
vomiting, dyspnea, constipation and fatigue are all frequently reported (Vainio et al. 
1996). The presence of pain can be the most distressing complaint and the incidence 
can increase to about two thirds of all patients with advanced disease (Foley 1993). 
Adequate use and individual titration of (combinations of) analgesics including 
morphine, co-analgesics and the use of alternative pain relieving techniques result in 
adequate pain relief in about 70-90% of patients, even in the terminal stages of their 
disease (Lamer 1994). Additional palliative measures can further improve the quality 
of life by providing symptom control, maintenance of function and psychosocial and 
spiritual support for the patient and family (Clinch and Schipper 1993).
Despite this approach, some of the patients fail to achieve adequate pain relief 
during conventional treatment either due to severe unmanageable drug-induced side- 
effects or inadequate drug effect.
Spinal (i.e. epidural or intrathecal ) administration of morphine was promoted in 
such situations (Behar et al. 1979, Wang et al. 1979) and proved to increase the success 
rate of pain treatment (Swarm and Cousins 1993). Recently, a number of reports 
appeared about the inefficacy of epidural (Arnér and Arnér 1985, Samuelsson et al. 
1995 ) and intrathecal (IT) (Sjoberg et al. 1991) morphine in patients with far advanced 
pain syndromes due to cancer. Also, in patients following prolonged treatment with 
morphine by conventional routes, subsequent spinal administration of morphine see­
med to be no longer effective (Max et al. 1985).
In an attempt to reveal the possible causes of differences in responsiveness to 
epidural morphine, the role of the various pain syndromes in progressive cancer was 
stressed (Arnér and Arnér 1985, Samuelsson and Hedner 1991). Furthermore, interin­
dividual differences in morphine metabolism, and specifically its glucuronides, leading 
to a diminished analgesic efficacy were suspected (Tiseo et al. 1995, Faura et al. 1996).
Finally, changes in the nociceptive transmission due to the pain syndrome itself and 
the drugs used leading to a diminished morphine responsiveness, were also introduced 
into the discussion (Arnér and Meyerson 1988, Portenoy et al. 1990).
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In order to overcome a diminished responsiveness, combinations of opioids 
and local anaesthetics were administered epidurally (Hogan et al. 1991) and intrathe­
cally (Sjoberg et al. 1991). This combination of an opioid and a local anaesthetic 
seemed to be very attractive theoretically, firstly to attempt to restore analgesia in pain 
syndromes where opioids have lost their effect and secondly, to prevent a (rapid) dose 
increase as a sign of tolerance development to morphine.
In these studies however, a (randomized) comparison of the effects of IT morphine 
versus IT morphine / bupivacaine was not performed.
1.2 Aims of the study
To investigate the diminished responsiveness of morphine in advanced cancer pain 
syndromes and to develop a modified technique of long-term intrathecal (IT) morphine 
administration to improve pain relief in these patients, the following questions were 
formulated:
1. What is the relationship between the plasma and cerebrospinal fluid levels of 
morphine, morphine-6-glucuronide and morphine-3-glucuronide during chronic use 
of controlled release morphine orally (Chapter 3).
2. What is the present state of the use of IT opioids in pain relief (Chapter 4).
3. What is the efficacy and safety of long-term IT morphine administration in cancer 
patients using a percutaneous catheter technique (Chapter 5).
4. Can co-administration of IT bupivacaine improve analgesia in patients partially 
responsive to IT morphine with an acceptable risk-benefit ratio (Chapter 6).
5. What are the effects of IT bupivacaine on the IT morphine dose progression during 
long-term administration (Chapter 7).
6. What are the side-effects and complications of long-term IT infusion of morphine 
and bupivacaine in progressive cancer pain syndromes and how should they be 
managed (Chapter 8).
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2.1 General aspects
Pain in patients with cancer is caused by a variety of stimuli during the disease 
process. Patients with cancer can present with (sub) acute and chronic pain com­
plaints, or with both at the same time. Generally speaking pain can can be tumour 
related, treatment related, or unrelated to either of the two (Foley 1979, 1993). In the 
latter situation, the presence of a concomitant disease (e.g. a herniated disc, appendi­
citis etc.) as well as psychological disturbances (e.g. anxiety, depression) have to be 
considered (Table 2-I). A careful pain history in combination with a physical 
examination and the use of additional diagnostic tests, can usually reveal the most 
likely cause(s) of the pain syndrome.
T a b le  2-1. P a in  syndrom es in patients w ith  cancer (Fo ley  1979, 1993)
I. Pain  associated w ith  d irect tum ou r involvement
A tumour infiltration o f  bone 
. skull, vertebra 
B tumour infiltration o f  nerve 
. peripheral neuropathy 
. brachial, lumbar, sacral plexopathy 
. meningeal carcinomatosis 
. (epidural) spinal cord compression 
C  tumour infiltration o f  a  hollow viscus
II. P a in  associated w ith cancer treatm ent 
A post-surgery
. post thoracotomy 
. post mastectomy 
. post radical neck dissection 
. phantom lim b pain 
B post-chem otherapy 
. peripheral neuropathy 
. postherpetic 
. aseptic bone necrosis 
C  post-radiotherapy  
. radiation fibrosis o f  plexus 
. radiation myelopathy
. radiation induced peripheral nerve tumours
III. P a in  not related to cancer o r  cancer treatment.
e g:, diabetic neuropathy 
. herniated disc
. rheumatoid arthritis etc. _________________________________
2.2 Tumour related pain
Depending on the origin and site of the tumour and its metastases, different pain 
syndromes can be present separately or in different combinations. In the recent litera­
ture four pain types are discriminated depending on their origin and clinical characte­
ristics: somatic, visceral, neurogenic and non-malignant pain (Arnér and Arnér 1985, 
Ashburn and Lipman 1993) (Table 2-II).
14
Table 2-11: Criteria for the differentiation o f cancer related pain types. (Amer S. 1991)
Pain type Tissue or Organ Clinical Characteristics
Somatic
Deep
Continuous
Bone, Connective tissue 
fascia, muscle, tendons, 
joints etc.
Deep, well localized, constant 
Well detectable precipitating factors. 
Referred pain, sometimes 
radiating
Intermittent same as for continuous Activity related
Cutaneous Skin
(see also: neurogenic int.)
Sore-like, smarting, evoked
Visceral
Continuous Viscera Deep, poorly localized.
Autonomic and somatic reflexes.
Unrelated to movement or load. Referred pain
Intermittent Stretched and distended visceral 
tissues (Intestinal obstruction with 
spasm in intestines and urogenital tract)
Spontaneous interval pattern, spasm. Very high intensity. 
Unrelated to movement or load.
Neurogenic
Continuous Peripheral and/ or central Radiating, neurological symptoms 
Positive provocation test's (Laseque).
Intermittent see above Paroxysmal lancinating pain.
Unrelated to movement and load.
radiating. Somatosensory dysfunction, evoked pain.
(allodynia, dysaesthesia)
Non-malignant Not defined with reference to 
pain mechanism, 
nervous system
Varying
Pain 
in 
patients 
with 
cancer
Chapter 2
2.2.1 Somatic and visceral pain
The majority of tumour related pain syndromes arise either from direct exten­
sion of the tumour process with swelling and ingrowth in the surrounding 
tissues. Also tumour metastases, especially to bone, frequently produce severe 
pain complaints (Ashburn and Lipman 1993). Socalled somatic pain originates 
in the bones, muscles, fascia and connective tissue and results from the stimula­
tion of sensory somatic nerves. These nerves are also involved following acute 
tissue injury. In visceral pain, autonomic nervous system components in visce­
ral structures are stimulated; (Table 2-II). Clinically, this last type of pain can be 
diagnosed from its diffuse character and its location in a bodily region referring 
to the organ involved with concomitant symptoms such as nausea and vomiting. 
Muscle tenderness can accompany a related skin region. Although much re­
search is performed in this area the precise mechanisms of visceral pain remain 
obscure (McMahon et al. 1995).
When paroxysms of pain are present following movement (fractures) or 
during peristalsis (colic) the adjunct "intermittent" or “incident” is used.
2.2.2 Neurogenic pain
An area of much interest, but also controversy, is the so called neurogenic / 
neuropathic pain complex. Differences in definition and difficulty with the 
clinical diagnosis (Vecht 1989), but also conflicting effects of morphine on pain 
relief in these situations, have led to controversy in the recent literature (Arner 
and Meyerson 1988, Portenoy et al. 1990 b, Portenoy 1991). In an attempt to 
prevent further difficulties with the exact definition, the term "opioid non­
responsive pain" was introduced: i.e. pain inadequately relieved by opioid 
analgesics given in a dose that causes intolerable side-effects, despite routine 
measures to control them (Hanks et al 1993, O ’Neill et al. 1993).
Table 2-III. Factors postulated to contribute to the phenomenon o f opioid responsiveness.
(Modified from Portenoy et al. 1990b; with permission.)
P a tien t re la te d fa c to rs
Predisposition to side-effects pharmacokinetics / dynamics
advanced age
diseases o f brain, lung, kidney, etc.
Psychological distress suffering, other emotional factors
Prior opioid exposure
Genetic factors (?)
P ain  re la ted  fa c to rs
Temporal characteristics
Rapid increase in nociception
Pain mechanism
D ru g  se lec tive  e ffe c ts
Receptor subtypes
16
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It was stressed by Portenoy et al. (1990 b), that is important to realize that 
"opioid-responsiveness" may be determined by a variety of factors and is part of 
a continuum of responses (Table 2-III). Due to the occurrence of a number of 
these factors in patients with cancer at the same time, it can be difficult to 
determine the role of each factor alone when side-effects occur.
Pain complaints with neuropathic characteristics can follow lesions from the 
peripheral as well as the central nervous system and usually increase following 
stimulation (movement, increase in intracranial pressure (ICP) as well as 
spontaneously (Arner and Arner 1985, Meyers 1995). Frequently, sensory 
disturbances of the skin accompany radiating pain complaints and neurological 
symptoms (Tables 2-II and 2-IV). In progressive cancer syndromes, however, it 
can be very difficult to discriminate between nociceptive and neuropathic pain
neuroma (amputation, nerve transsection) compression (disc, tumour, scar tissue)
nerve crush, stretching or incomplete transsection ( trauma) inflammation (postherpetic neuralgia)
complaints (Vecht 1989, Tables 2-II and 2-IV).
Destruction of peripheral nerves, both posttraumatically as well as tumour 
induced, can lead to nociceptive input from injured AB and A / fibres. Also, 
extensive changes in the neuronal function in the dorsal horn of the related 
spinal segment can take place (Max et al. 1990). Afferent Ap- fibres, although 
usually not associated with nociception, sprout into lamina II in the spinal cord 
dorsal horn as a result of this injury. This mechanism can thereby explain why 
low-threshold mechanoreception due to nerve damage, can be perceived as 
painful (Meyers 1995). It had been shown previously that these functional 
changes in the spinal cord can persist long after the disappearance of this injury 
(Coderre et al. 1993, Pockett 1995). Dynamic changes in the opioid receptor
17
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system can also occur following neuronal damage (e.g. experimental rhizoto­
my), as a presynaptic loss of opioid receptors on the primary afferent C-fibres 
has also been described (Dickenson 1991).
Finally, studies with an experimentally induced mononeuropathy in rats, demonstra­
ted that these changes in the neuronal transmission as discussed above, are similar to 
the changes that take place following extensive exposure to opioids. The main diffe­
rence with the latter situation is, however, that these neuropathy “induced” changes 
may take place without previous opioid use (Mao et al. 1995 b). A diminished respon­
siveness for morphine in a clinical situation where neuropathic pain characteristics are 
present and opioids are frequently administered, can thus be explained by a change in 
receptor population in the dorsal horn due to the nerve damage itself (Stevens et al. 
1991) as well as due to the changes that follow the development of tolerance for the 
opioids that are administered for pain relief. In addition to these changes at the neuro­
nal level, a complex interaction with different peptides (e.g. cholecystokinine (CCK) 
and involvement of the so-called N-methyl-D-aspartate (NMDA) receptor, nitric-oxide 
(NO) and changes in intracellular Proteinkinase-C (PKC) further substantiate this 
close correlation between the presence of opioid induced hyperalgesia and the deve­
lopment of morphine tolerance (Mao et al. 1995 b). Clinically, this problem is overco­
me by increasing the dose of analgesics and administering "co-analgesics": e.g. 
antidepressants, anti-convulsants or corticosteroids.
Recently, it was shown that the class of NMDA antagonistic drugs can produce 
antinociception in neuropathic pain states and diminish tolerance development. Their 
clinical applicability, however, is still limited due to their side-effects (Meyer et al. 
1995, Luczak et al. 1995).
A diminished morphine efficacy in neuropathic pain states, was shown in a clinical 
study, demonstrating that morphine mainly influences the emotional, affective ("suffe­
ring") component of pain, while the sensory component of the perception (pain inten­
sity) remains largely unchanged (Arner and Meyerson 1988, Kupers et al. 1991).
Another phenomenon which can become manifest, closely related to the problems 
of neuropathic pain in cancer patients, is “breakthrough pain” defined as: a transitory 
exacerbation of pain that occurs on a background of otherwise stable pain during 
treatment. Although pain severity and characteristics will vary per patient, 
breakthrough pain presents in about 60 % of cancer patients (Portenoy and Hagen 
1990). A relationship with the primary tumour or the metastases is frequently apparent 
(76%), although tumour treatment (20%) or unknown factors (4%) can be the cause as
18
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well (Portenoy and Hagen 1990). Finally, when discussing a diminished analgesic 
effect of opioids, a large variety of other factors should be considered in these “diffi­
cult to treat pain problems” (Portenoy 1994, O’Neill et al. 1993) (see also Chapter 6; 
Table 6-I).
2.3 Pain syndromes related to tumour treatment
Due to more extensive surgical, chemotherapeutical, radiotherapeutical and other 
curative treatment forms, longer survival with cancer has become possible (Doyle et 
al. 1993 (a)). Despite this, more frequently, treatment related symptoms and complex 
pain syndromes become manifest necessitating diagnostic considerations following 
cancer treatment (Payne and Gonzales 1993). Surgery, radiotherapy and chemotherapy 
can all result in (sub) acute as well as chronic pain syndromes. A schematic overview
Table 2-V: Pain syndromes related to cancer treatment (Foley 1993)
Surgery post mastectomy 
post radical neck dissection 
post thoracotomy 
phantom limb pain 
stump pain
Chemotherapy headache
mono-/ poly-neuropathy 
musculo-skeletal pain 
corticosteroid induced pain
Radiotherapy piexopathy/ fibrosis 
myelopathy 
secondary malignancy
is given in Table 2-V.
2.4 Pain syndromes not related to tumour or tumour treatment
In cancer patients, any concomitant disease can occur. Lumbar disc degeneration 
and osteoporosis are frequent co-existing complaints in the elderly. Herpes zoster and 
postherpetic neuralgia can also present in cancer patients. Opioid induced constipati­
on, although not related to the tumour or its treatment, may give rise to abdominal 
pain complaints. Many more examples of these causes exist (duodenal/ gastric ulcera­
tion, osteo-arthritis etc.).
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2.5 Psychological factors contributing to pain in cancer patients
Pain in cancer is the result of a complex interaction between physical, affective and 
cognitive components leading to behavioural changes. As treatment of merely one 
aspect can lead to inadequate pain relief, a multidimensional pain concept was adopted 
in the past. In this concept all the above mentioned factors can interact (Ahles et al. 
1983). Symptoms of depression, anxiety and fear are frequent in cancer patients. In a 
recent review (Breitbart et al.1995) depression in advanced cancer was mentioned to 
have negative effects on both pain relief and overall morbidity. However, a major 
problem with the diagnosis is that somatic, disease related symptoms (constipation, 
loss of appetite etc.) frequently mimic the psychiatric symptoms of depression and 
fear. Discriminating tools have either not been designed specifically to be used in this 
population with malignant disease, are time-consuming or are not yet validated for 
Dutch cancer patients (Fishman et al. 1987). Despite the necessity to treat the symp­
toms, their presence may never be used as an explanation for the inadequacy of pain 
relief (Breithart and Passik 1993). Depression is the most frequent psychiatric symp­
tom in cancer patients and its incidence is estimated to be about 50-60%, followed by 
an incidence of 40% for organic brain syndrome (Levine et al. 1978). Despite this 
high incidence of depression, the use of antidepressants in cancer patients is usually - 
low, ranging from 3-5 % of the patients in the terminal phase. This last category is of 
specific importance because of the possible reversibility of the symptoms, once they 
are diagnosed and treated. Another problem interfering with the presence of depressi­
on and fear is that, despite a rational explanation due to physical deterioration and 
impending death, psychiatric symptoms can also be caused by brain metastases and are 
sometimes also the result of metabolic, infectious processes and intoxications. 
Furthermore, the majority of diagnostic tools for depression and anxiety were not 
specifically developed for patients with cancer in whom extensive drug use is fre­
quently necessary (opioids, corticosteroids etc.).
2.6 Pain measurement in cancer
Taking the multidimensional character of cancer pain into account, measurement of 
the physical components (pain intensity) of cancer pain is of primary importance to 
determine the severity of the complaints and the effect of pain relieving interventions.
20
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Numerous methods to measure pain intensity are present and six of these (a) Visual 
Analoque Scale (VAS); (b) 101-point Numerical Rating Scale (NRS 101); (c) 11-point 
Box Scale (BS-11); (d) six-point Behavioral Rating Scale (BRS-6); (e) four-point 
Verbal Rating Scale (VRS-4); and (f) five-point Verbal Rating Scale (VRS-5), were 
studied in 75 chronic pain patients (Jensen et al. 1986). In this study, specific attention 
was paid to the ease of administration and scoring, the relative rate of correct respon­
ding and the sensitivity to detect a treatment effect with the scale.
Although all these scales were able to measure pain intensity reliably there were 
some important findings. It appeared that the VAS was especially difficult to comple­
te for elderly patients. The NRS 101, in which scale the patient is asked to rate the 
pain intensity from "0" to "100" ( "0" is no pain and "100" denotes the most severe 
pain), appeared to have several practical advantages over the other scales. The admini­
stration and explanation appeared to be extremely simple and scoring could be accom­
plished verbally (e.g. by phone) as well as in writing. Difficulties with the the scale 
did not correlate with the age as with the VAS. Considering these criteria the NRS 
101 appeared to be the most applicable and was therefore also used during follow-up 
of our patients during the studies.
In more advanced cancer syndromes it can be difficult to determine the presence 
and intensity of pain complaints due to problems of cognition and communication 
(Shannon et al. 1995) Furthermore, there seems to be a low correlation between the 
verbal (sensory) expression of the patient's pain complaint and the specific cause of 
the pain (Deschamps et al. 1988, Teaman and Cleeland 1990). This should be kept in 
mind, as even in advanced cancer syndromes (progression of) pain complaints are not 
always the result of progressive disease. As the meaning of the pain complaint may 
not always be apparent to the doctor immediately, a careful explanation of possible 
pain causes could reduce the suffering of patients and the relatives.
2.7 Treatment of cancer related pain
Although the overall cure rates for cancer in the industrialised world are 40-50 %, 
most cancer patients do not survive their disease (Mac Donald 1993). Pain complaints 
during the illness are frequent and usually the incidence approaches 90% of all cancer 
patients in the terminal phase (Cleeland et al. 1994). In a recent study in Germany 
pain treatment according to the WHO guidelines resulted in adequate relief in the 
majority (76%) of patients, even in the terminal phase.
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The main causes of treatment failure were (Zech et al. 1995): 
a: pain related (breakthrough pain, neuropathic pain) 
b: drug-related (side-effects, tolerance)
c: patient related factors (accompanying symptoms, poor compliance).
This study showed that despite the availability of a variety of analgesics, adequate 
information for the patient and the relatives about the use of analgesics and co-analge­
sics is mandatory to achieve optimal pain relief.
2.7.1 Pain relief by chemotherapy and radiotherapy
When curative treatment is no longer feasible, a variety of (combination of ) treat­
ments, e.g (palliative) chemo-, hormonal or radiation therapy, neural blockades, 
(neuro) surgical procedures and psychological interventions can all result in (adequa­
te) pain relief (Patt 1994). Generally speaking, pain diminishes following tumour 
removal or shrinkage. This last effect is the option when using chemotherapy for 
palliation. Especially when infiltration of bone, nerves, skin, tumour ulceration or 
lymph node enlargement is present, chemotherapy is usually followed by pain relief. A 
number of other mechanisms have to be considered contributing to chemotherapy 
induced pain relief, as pain relief frequently precedes changes in tumour size; e.g. 
decrease of oedema (corticosteroids), blocking of the synthesis of cytokines and a 
reduction in the amount of nociceptive chemicals produced. Finally, it is postulated 
that transfer of cytotoxic drugs across the blood-brain barrier influences central neuro­
transmitter systems (Mac Donald 1993). In these situations, however, it is essential to 
predict if the patient will tolerate palliative chemotherapy. Usually this is done by 
determining the performance status of the patient (Mor et al. 1984) (e.g. Karnofsky 
Performance status scale: see also Appendix I)
Radiotherapy for pain relief should be considered for localized metastases especial­
ly in bones such as the extremities, ribs and the vertebrae. Here also, the pathogenesis 
of the pain relief is still unclear. Both tumour destruction and interference with noci­
ceptive pathways and mediators are considered to be of importance (Hoskin 1993) 
whereby a balance is found between the destruction of the tumour cells and the adver­
se events of the radiotherapy on the normal tissues (Jacox et al. 1994).
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2.7.2 Pharmacological treatment of cancer pain
The use of an integrated approach of the cancer patient with all its associated 
problems due to the disease was also recently stressed by “A report by the American 
Society of Anesthesiologists Task Force on Pain management, Cancer Pain Section “ 
(Ferrante et al. 1996). It was stated here that the administration of analgesics in 
appropriate dosages and intervals, according to the World Health Organization’s 
"analgesic ladder", remain the cornerstone of cancer pain management. With this 
approach, analgesics are used stepwise depending on the severity of the pain com­
plaints. Step I consists of a non-opioid (usually acetaminophen or an NSAID) if 
necessary in combination with adjuvant drugs. These classes of drugs, e.g. anti-con- 
vulsants, anti-depressants or corticosteroids, have an analgesic effect in certain painful 
conditions (O’Neill et al. 1993). In step II, non-opioids are combined with a weak 
opioid such as codeine, buprenorphine or tramadol ± adjuvants. When pain relief is 
still inadequate, a stronger opioid, usually morphine, is administered and its dose 
increased until pain relief is adequate or unmanageable side-effects present. This is 
step III. As in advanced, cancer more complex and different pain types can exist 
together, individual titration of analgesics and adjuvant drugs is mandatory and usual­
ly results in overall acceptable relief of pain (O’Neill et al. 1993, Levy 1994, Jacox et 
al. 1994, Cleeland et al. 1994;
Table 2-VI).
Table 2-VI. Different classes of drues for pain in cancer.
Aetiology Drug
bone pain, soft tissue infiltration NSAID's (± opioid)
deafferenti ation pain, tricyclic antidepressants
nerve infiltration/ compression anticonvulsants
raised intracranial pressure
nerve/ spinal cord compression 
hepatomegaly
corticosteroids
tissue damage/ infection antibiotics and analgesics
gastro-intestinal spasm anticholinergics
constipation laxatives
arterial ischaemia vasodilators
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Although the oral route is preferred, inability to ingest or swallow, unconscious­
ness, vomiting and gastrointestinal obstruction as well as a poor condition of the 
patient can necessitate different routes of administration of various drugs (Table 2- 
VII). Also, the ease of access to the specific receptor systems and the side-effects due 
to systemic uptake is very important in these considerations.
T ab le  2-V II. Routes for drug administration and techniques for pain re lie f in cancer 
(from: Ferrante et al, ASA Task Force, 1996)_______________________________________________________
In d ire c t D irect
Systemic absorbtion Neuraxial drug delivery
- o ra l, buccal - epidural
- sublingual, intranasal - intrathecal
- rectal - intraventricular
Via depot formation Neuroablation
- transdermal - chemical
- intramuscular - thermal
- subcutaneous - surgical
Intravenous administration
Due to a diminished first-pass effect, rectal administration of analgesics usually 
results in plasma levels exceeding those obtained by oral administration. The variabili­
ty in the uptake in the rectal veins, however, remains an unpredictable factor. For 
morphine, the bioavailabilty is similar for the oral and the rectal route (Inturissi and 
Hanks 1993). NSAID’s are also administered rectally at the same dosage as orally. As 
an alternative, parenteral administration is possible to overcome problems with the 
oral or rectal route. Continuous (intravenous, subcutaneous) infusion of drug(s) results 
in stable plasma levels and thereby acceptable analgesia. Recently, the transdermal 
route was added as an alternative to the parenteral route. Due to the lipophilic opioid 
fentanyl, transdermal delivery results in a stable plasma level over a number of days.
Finally, other drugs can be used here as well in order to improve pain relief and 
provide further symptom control (e.g., corticosteroids, droperidol, midazolam).
2.7.2.1 Non Opioids
Classically, three categories of drugs are considered herein: salicylates (e.g. acetyl- 
salicylic acid or aspirin) acetaminophen and the NSAID’s (Non Steroidal Anti-Inflam­
matory Drugs). Since salicylates may have detrimental effects on coagulation and the 
gastric mucosa, these are not considered further here.
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Acetaminophen is a potent analgesic and antipyretic when administered at the right 
dose and interval. It has no anti-inflammatory effects and its analgesia is thought to be 
mediated by inhibition of the enzyme cyclo-oxygenase in the central nervous system. 
The effects on peripheral cyclo-oxygenase are limited and there is no effect on plate­
lets or coagulation. Tolerance and dependence does not occur. Acetaminophen can be 
administered orally and rectally, is rapidly absorbed and can be considered to be a safe 
drug. However, when the maximum dosage is exceeded, fatal hepatic failure can 
ensue due to an interaction between a highly reactive toxic intermediate and the 
glutathion metabolism in the liver.
NSAID’s exert their effect(s) by inhibition of prostaglandin and thromboxane 
biosynthesis (Vane 1996). These compounds can stimulate peripheral nociceptors 
following trauma and inflammation and thereby result in a painful condition. They 
also have an effect on platelet and endothelial function, the integrity of the gastro­
intestinal mucosa and renal function. All of these effects are thought to be mediated by 
the inhibition of the enzyme cyclo-oxygenase (Cox or PGH2 synthetase) which oxidi­
zes arachidonic acid to prostaglandin. Recently, it was shown that Cox can exist in 
two isoforms: Cox-1 which is the “physiological” form and Cox-2, which is induced 
by inflammation. The clinical relevance of this appears to be, that the majority of side- 
effects are considered to be caused by the inhibition of this “physiological” Cox-1 iso­
enzyme, leaving the “pathological”, inducable Cox-2 relatively undisturbed (Vane 
1996). Although the classical NSAID’s have a potent analgesic effect, side-effects can 
limit their use. Two newer NSAID’s (nabumeton and meloxicam) considered to act 
according this Cox-2 principle are available at the moment, but indication for their 
use remains to be established.
2.7.2.2 Weak Opioids
Codeine is the standard weak opioid analgesic producing its effect by a weak 
interaction with the ^-receptor. As the biotransformation of codeine to morphine is 
unpredictable, the analgesic reponse may vary. In combination with a strong constipa­
ting effect, its use in cancer pain seems to be limited. Two such other drugs are availa­
ble viz.: buprenorphine and tramadol. Buprenorphine appears to be a ^-agonistic and 
K-antagonistic drug. It exerts its analgesic effect by this (potent) ^ binding but seems 
to have a maximum (“ceiling”) effect due to the K-antagonism. Although it has lesser 
abuse potential, this advantage is not necessary in cancer patients (Inturrisi and Hanks
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1993). Tramadol is a drug which has analgesic effects due to ^ binding and stimulati­
on of the spinal noradrenergic and serotonergic systems. A low potential for tolerance- 
development and a possible additional effect in neurogenic pain states seems to be an 
advantage.
2.7.2.3 Morphine
Morphine remains the standard analgesic with which other opioids are compared 
(Jaffe et al. 1992, Inturrissi and Hanks 1993). Structurally it belongs to the group of the 
phenantrene alkaloids (hydrophilic, octanol/ water coeff. 1.4 at 37oC; pKa 7.9, 30% 
plasma protein binding, 76 % ionized at physiological pH). Adequately titrated dosa­
ges of oral morphine or use of a slow release formulation, to improve convenience and 
patient compliance, can result in adequate pain relief in the majority of the patients 
(Goughnour et al. 1989, Khojasteh et al. 1987). Following oral administration and 
gastro-intestinal resorption, morphine is extensively metabolised in the liver and 
kidney, generating mainly morphine-3-glucuronide and morphine-6-glucuronide both 
in excess of the plasma morphine concentration (Fig. 2-I; Sâwe et al. 1985, Lehmann 
and Zech 1993, van Dongen et al. 1993).
It has been shown that the relative amount of these metabolites depends on the 
route of morphine administration (Osborne et al. 1990), renal function (Portenoy et 
al. 1991), and the analytical methods used (Hasselstrom and Säwe 1993). Due to 
extensive first-pass effects following oral administration the amount of morphine- 
glucuronides is higher than that after rectal administration (Babul and Darke 1993).
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In order to have analgesic efficacy, the 6-position of the morphine molecule must 
be occupied with a glucuronide moiety. Although the relative contribution of these 
two substances to pain relief remains to be substantiated, it has been shown that both 
morphine and morphine-6-glucuronide are important in the production of a profound 
analgesic effect following different routes of administration both in animals and in 
humans (Pasternak et al. 1987, Hanna et al. 1990, Faura et al.1996).
In contrast, the morphine-3-glucuronide is devoid of any analgesic activity and 
animal experimental research even suggests a functionally antagonistic effect on 
morphine-6-glucuronide induced antinociception by morphine-3-glucuronide (Gong et 
al. 1992). The clinical implications of this effect are, however, not yet clear (Morley et 
al. 1994).
An immediate release formulation has a rapid onset of action (peak plasma concen­
tration within one hour) with a duration of action of about four hours. Slow-release 
tablets have a slower onset, a peaking plasma concentration after 2-4 hours and an 
duration of effect of about 12 hours. Due to morphine's weak basic characteristics, the 
main absorption takes place at the upper level of the small bowel and is almost com­
plete. About 90% is converted to the glucuronides, codeine, normorphine and morphi­
ne etheral sulphate (Inturissi and Hanks 1993). Although the bioavailability ranges 
from 20-40%, there can be a remarkable variation between individuals. Since morphi­
ne metabolites are mainly excreted via the kidney, renal failure can lead to accumulati­
on of the metabolites (mainly glucuronides) and subsequent toxic effects (Portenoy et 
al. 1991)
Subcutaneous administration of morphine especially by continous infusion, results 
in comparable plasma morphine levels with the i.v. route. Since repeated morphine 
administration results in a increased bio-availability of morphine and its metabolites, 
the oral: parenteral dose ratio from 6:1 can be altered to 2:1 or 3:1. Dose dependent 
presystemic metabolism, enterohepatic circulation and accumulation of the active 
morphine-6-glucuronides have all been mentioned as an explanation for this change in 
ratio, although a number of studies could not confirm this ( Sawe et al 1983, Inturrisi 
and Hanks 1993). Therefore, when changing from the oral to the parenteral route, the 
parenteral dosage per day should be lA to D of the previous daily oral dosage (Kaiko 
1986)
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Clinically, morphine is titrated to analgesic effect without having an upper dose 
limit. Unmanageable, undesirable side-effects can present a problem in further dose 
increase. One has to consider, however, that in cancer patients a variety of factors can 
co-exist which all can mimic morphine induced side-effects (Tiseo et al. 1995). There 
is a paucity of studies that compare different opioids and their side-effects as well as 
the side-effects following different routes of the same opioid in these circumstances 
(Vainio and Tigerstedt 1988). The most frequently encountered side-effects are: 
nausea and vomiting, sedation (hallucination, confusion), constipation, urinary retenti­
on, myoclonus, respiratory depression and skin reactions. In summary, the effects of 
morphine can be divided into depressant and stimulating components (Table 2-VIII).
Table 2-V III. Depressant and stimulating effects o f morphine
Depressant Stimulating
Analgesia
Sedation, drowsiness
Euphoria
Miosis
Respiratory depression; increase o f  ICP Stimulation chemoreceptor trigger zone 
Decreased myocardial oxygen demand Increased intestinal smooth muscle tone
Cough suppression 
Decreased peristalsis
Increased tone sphincter of Oddi 
Increased biliary pressure
Inhibition o f fluid secretion in intestines Increased detrusor muscle tone 
Decreased gastric acid secretion Increased vesical sphincter tone
Inhibition o f  emetic centre Increased release o f P R l and ADH
Slight increase in body temperature Proconvulsant (overdose) 
Decreased secretion LH and FSH
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2.8 Opioid receptors
Opioids act by binding to receptors in the central and peripheral nervous system. 
Drugs with a high affinity for these receptors are called ligands. The receptor-ligand 
binding is characterised by stereospecificity, structure-activity relationship, dose 
dependent actions and the presence of a particular antagonist counteracting the previ­
ously produced effect (Hedner and Nordberg 1990).
The discovery of the opioid receptors by Pert and Snyder in 1973 and others there­
after, and the subsequent identification of cerebral and spinal opioid binding sites 
(Yaksh 1981) was followed by a clinical breakthrough by using the epidural and IT 
route in humans. The first reports of the analgesic potency of these routes (Behar et al. 
1979 epidural, Wang et al. 1979 intrathecal) led to a widespread use for all sorts of 
pain syndromes. Numerous receptors and their subtypes were described of which the 
^, k and 5- receptor are considered to be opioid receptors associated with anti­
nociception (Pasternak 1988, Atcheson and Lambert 1994, Table 2-IX).
Table 2-IX. Characterisation of the different opioid receptors and their agonists
(adopted from Dickenson 1994 and Atcheson and Lambert 1994; with permission)
Receptor type Mu Delta Kappa
Endogenous ligand fj-endorphine Enkephalin Dynorphin
Selective agonist Morphine DPDPE Enadoline
Fentanyl DSLET U69593
DAMGO
Antagonist CTAP naltrindole nor-BNI
Effector cAMP cAMP G protein
G protein G protein
opens K opens K closes Ca
channel channel channel
Function analgesia analgesia analgesia
respiratory respiratory diuresis
depression depression? dysphoria
constipation respiratory
depression ?
Subtypes 1 and 2 1 and 2 1,2, and 3
Many of the agonistic and antagonistic drugs mentioned here are limited to the laboratory situation.
DPDPE=[DPen2, D-Pen5] enkekphalin, DAMGO= [D-Ala2, MePhe4, Gly(ol)5]enkephalin, DSLET=[D- 
ser2,leu5,Thr6],enkephalin, NorBNI=norbinaltorphimine, CTOP=D=Phe=Cys=Tyr-D-Trp-Orn-Thr-Pen-Thr- 
Nh2.
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More recent subtyping of these receptors has taken place, based on differences in their 
affinity for different (synthetic) agonists (Table 2-IX). The -^1 (high affinity) receptor 
is postulated to mediate supraspinal analgesia; the ^-2 (low-affinity) receptor is mainly 
associated with respiratory depression and changes in gastro-intestinal motility. The 
precise function of the k -  receptor (and its three subtypes) and their relative contributi­
on to spinal analgesia remains unclear. Animal data show a weak analgesic action in 
combination with psychotomimetic effects and diuresis (Pasternak 1993, Dickenson 
1993). Finally, the 5-receptor is supposed to have a modulatory role at the different 
levels of nociceptive processing.
The highest level of the opioid receptors in the spinal cord is closely related with 
the C-fibre terminal zones in the lamina I and lamina II and III (substantia gelatinosa) 
of the spinal cord. Small numbers of receptors are also found in deeper layers of the 
dorsal horn of the spinal cord. As there exists a substantial interspecies difference in 
the amount and the number of receptors, animal data cannot simply be transformed to 
the human situation (e.g. in the rat spinal cord 70 % ^ receptor, 24% 5 receptors and 
6% k receptors). Furthermore, it is known from the human spinal cord that there exists 
a somatotopic organisation: at the cervical level there are mainly 5 receptors whereas 
at the lumbar level mainly k  receptors are present (Tawfik 1994).
2.8.1 Cellular effects of receptor ligand binding
Binding to all three classes of opioid receptors has an inhibitory effect on synaptic 
transmission in the involved neuronal pathways in the central nervous system (CNS) 
as well the myenteric plexus (Jaffe et al. 1992, Dickenson 1991). At the cellular level 
three distinct locations of action are postulated mediating analgesia and its side-ef- 
fects:
(Dickenson 1994): see also Fig 2-II)
1. A presynaptic site at the neuronal terminals. Binding of opioids at these sites 
reduces the release of neurotransmitters.
2. Postsynaptic hyperpolarization of output neurones, interneurones or dendrites 
thereby reducing evoked activity.
3. Disinhibition of two inhibitory neurones. Inhibition of the first neurone by the 
opioid allows the second, inhibitory, cell to become active. This results in an 
inhibition of activity.
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Figure 2-II. The analgesic actions o f opioids.
In this model three mechanisms are depicted 
in relation to the neurophysiology of the spinal 
cord: presynaptic inhibition o f neurotransmit­
ter release, postsynaptic inhibition o f evoked 
activity and postsynaptic disinhibition.
Opioid receptors can be synthesized in the 
dorsal root ganglia of the C-fibres thereby 
providing a dynamic nociceptive system 
(Reproduced from Dickenson A.H. Where and how 
do opioids act ? Jn: Gebhart G.F, Hammond D.L., 
and Jensen T.S. Eds. Proceedings of the 7th World 
Congress on Pain. Progress in pain research and 
management Vol 2. 1994, pp 525-552. With 
permission).
At the cellular level, (presynaptic) binding to the opioid receptor leads to opening 
of potassium channels (^ and 5 receptor), or closing of a Ca-channel ( k  receptor). 
Both result in diminished Ca influx in the C-fibres, thus decreasing transmitter release 
(e.g. tachykinins, EAA, exitatory peptides; Table 2-IX). Electrophysiological and 
behavioral studies showed activity of opioids on the postsynaptic structures. 
Postsynaptic hyperpolarization is the result of opening of K-channels or the closing of 
Ca-channels. Another postsynaptic indirect action is disinhibition, mediated by GABA 
and enkephalin neurones in the substantia gelatinosa. This also results in diminished 
output of these neurones. Following receptor binding, coupling takes place to G- 
Proteins (guanine nucleotide regulatory proteins) whereby opioids indirectly regulate 
transmembrane signalling systems. Activation of the ^ and k  receptor specifically 
leads to an increased K-influx and subsequent hyperpolarization of the membrane. In 
the brain ^ and 5 receptor activation leads to inhibition of adenylate cyclase. In con­
trast to this, k  receptor binding leads to an increase inward Ca flux. Although theoreti­
cally, also depending on the receptor-ligand specificity, different effects by addressing 
different receptors could be generated in vitro, pharmacological properties of the 
drugs and routes used are clinically equally important. (McQuay et al. 1989).
2.8.2 Spinal action
Due to its anatomic location, the effects opioids can be studied more easily in the 
spinal cord than in the brain. Although it is generally accepted that the ^, 5, and k  
receptors are mostly concerned with morphine induced spinal anti-nociception, the
MECHANISMS OF OPIOID ACTIONS
O PRESYNAPTIC INHIBITION %  POSTSYNAPTIC INHIBITION  
OF TRANSMITTER RELEASE OF EVOKED ACTIVITY
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exact role of the k  receptor remains unclear in this respect.
Despite a rather nonspecific inhibitory effect on neurotransmission in the dorsal 
horn, opioids can have a specific effect on nociception due to their relationship with 
the receptors on C-fibre terminals. Damaging of the afferents caused by a pathologic 
pain state, can thereby lead to a disinhibition and a status of "opioid unresponsive­
ness" (e.g. giving rise to neurogenic pain; Mao et al. 1995 (b)
Potency of the spinally administered opioid depends on the receptor/ opioid binding 
and the correlated (intra) cellular effects in relationship to the number of receptors 
occupied (Dirig and Yaksh 1995). However, following IT administration, the quality 
of this receptor ligand binding is not the only factor of importance. An inverse relati­
onship appears to be present between lipophilicity and potency, indicating that for IT 
use, the more lipophilic, the less potent the IT administered opioid is. This might be 
due to non-specific binding of the ligand to lipid rich structures in the cord and subse­
quent systemic uptake (Kotob et al. 1986, McQuay et al. 1989).
2.8.3 Supraspinal action
Following systemic administration of morphine, a supraspinal (^-1) effect is the 
dominating mechanism for the production of analgesia. Transsection of the spinal cord 
markedly reduces the analgesic effect of morphine, while selective -^1 antagonists 
leave spinal (^ -2 mediated) antinociceptive effects of morphine unaltered (Pasternak 
1993). Although intraventriculair morphine injection results in a profound analgesic 
effect, the precise mechanism of action is still unclear. What has been shown is that 
different areas around the midbrain (periventricular and periaqueductal grey) and 
brain stem (nucleus raphe magnus, rostroventral medulla) have been identified by 
means of their high concentration of endorphins as well as an analgesic effect (antago­
nized by naloxone) after micro-injections of opioids. These effects are considered to 
be mainly influenced by Ö and by ^ receptors; k  receptors have not been widely tested. 
Morphine, thus, influences the descending inhibitory control via an interaction with 
different neurotransmitters (noradrenaline, 5HT, enkephalins, substance P). A simple 
concept here is that supraspinally administered opioids increase the descending, 
inhibitory transmission that subsequently block spinal transmission of nociception.
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Depending on the receptor type addressed and the subsequent inhibitory or excita­
tory effects, the result of morphine administration can vary. Two theories considering 
these supraspinal effects, of opioids are important (Dickenson 1994):
1. Effects of morphine on “diffuse noxious inhibitory control “ (DNIC). It is postula­
ted that the brain receives information from both innocuous and nociceptive neuro­
nes. Due to a nociceptive stimulus, induced at the level of the spinal cord, a descen­
ding inhibitory impulse is formed involving opioid and serotonergic mechanisms. 
Under normal circumstances, nociceptive information in the brain contrasts with 
innocuous information at that moment and a pain stimulus can thus be perceived as 
“painful”. Supraspinal morphine reduces the contrast between these two different 
pools of neurones without diminishing the noxious firing itself and preventing the 
occurrence of DNIC. This results in analgesia.
2. Certain brain stem cells can be turned off due to noxious input. The result of this 
inhibition is disinhibition of another pool of neurones which initiate a reflex at the 
level of the spinal cord. Morphine activates these neurones, thereby diminishing the 
reflex and resulting in analgesia.
Because of systemic uptake, pain relief after epidural morphine administration, will 
therefore, be the result of an interaction of spinal and supraspinal antinociceptive 
mechanisms (Pasternak 1993).
2.8.4 Peripheral action of opioids
Recently, numerous reports have appeared about changes in the number and the 
presence of opioid receptors in the central and peripheral nervous system. It has 
unequivocally been shown that inflammation and its subsequent immunological 
changes can initiate an increase in the number of opioid receptors in the peripheral 
tissues thereby generating a “neuro-immune” link (Stein 1994, 1995). Clinical use of 
this phenomenon is still limited to the perioperative period.
2.8.5 Changes in the opioid system
The nociceptive system responds in a dynamic way to changes in the “pain state” 
(Coderre et al. 1993). This also influences the opioid system: e.g. an increased sensiti­
vity for exogenous administered opioids in situations of peripheral inflammation and a 
decreased sensiivity in neuropathic pain states (Stein 1995, Mayer et al1995).
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Although still controversial in the human situation (Yaksh 1992), numerous theo­
ries for the change of the analgesic response following chronic opioid administration 
have been postulated (see also Chapter 6; 6.1: diminishing effects of opioids) e.g.: loss 
of opioid receptors, presence of anti-opioid peptides, interaction with NMDA recep­
tors and the specific effects of morphine glucuronides. These factors can interfere with 
the normal, physiological, response of the opioid system (Dickenson 1993).
Chapter 2_______________________________________________________
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Appendix I. Performance scales according to Kamofsky
Definition rating % Criteria
Able to carry on normal activity 100 Normal; no complaints.
and to work: no special care No evidence of disease
needed
90 Able to carry on normal 
Activity: minor signs or symptoms 
of disease
80 Normal activity with effort 
Some sign of symptoms or disease
Unable to work: able to live at 70 cares for self; unable to carry on
home and care for most personal normal activity or to do active work
needs: varying amounts of assistance 
needed
50 Requires considerable assistance 
And frequent medical care
Unable to care for self; requires 40 Disabled: requires special care
equivalent of institutional or and assistance
hospital care; disease may be
progressing rapidly 30 Severely disabled; hospital admission 
Is indicated although death not imminent.
20 Very sick: hospital admission necessary 
Active supportive treatment necessary
10 Moribund: fatal process progressing rapidly
0 Dead
Chapter 3
Morphine and morphine-glucuronide concentrations in plasma and CSF 
during long term administration of oral morphine.
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Concentrations of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) 
morphine concentrations (r= 0.94, P= 0.0001) and both correlated with drug dosage 
(r=0.61, P=0.013 and r=0.74, P=0.0001, respectively). M3G and M6G in plasma and CSF 
were correlated (r=0.81 and r=0.82, both P=0.0001). No relationship was apparent 
between M plus M6G concentrations in the CSF and pain scores.
Keywords.
Oral morphine, Morphine glucuronides, Plasma and CSF concentrations, Cancer pain.
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Introduction
After oral administration, morphine (M) is metabolised in the intestinal mucosa and the liver mainl 
M administration [3,4,5]. However, most of these data were obtained during short term 
administration and little is known about the pharmacokinetics of M and its glucuronides 
in plasma and CSF after long-term oral M administration [6].
This study assessed the relationships between plasma and CSF concentrations of M and its glucuro 
Methods.
A tunnelled intrathecal catheter for M administration was placed in each of 16 
patients with cancer who had insufficient pain relief or unmanageable side-effects during 
treatment with oral (controlled-release) M (MS-continR, ASTA, Diemen, The 
Netherlands). During this oral M treatment period (range 9-250 days, mean 57 days, 
median 34 days) the dosage of M was increased gradually. The final daily dosage (range 
60-950 mg day , mean 305 mg, median 200 mg) was constant for at least three days 
before placement of the catheter. All patients (nine male, seven female; age 22-68; mean 
54, median 56) were in the preterminal stage of their life due to tumours of different 
origin but had normal renal and hepatic function. Pain intensity was measured by a visual 
analogue scale (VAS) and clinical pain characteristics were determined according to 
ArnOr & ArnOr [7]. Institutional approval was given for the study and patients were 
included after obtaining verbal and written informed consent. Immediately before 
placement of the catheter, blood was drawn from a peripheral vein within three hours of 
the last oral M dose. Patients were allowed to eat and drink without restriction. After 
placement of the catheter, 0.5-1 ml of CSF was collected, sealed in a glass tube, 
centrifuged and stored at -20oC until assay. M, M3G and M6G concentrations were 
measured using the HPLC method of Koopman-Kimenai et al. [8]. Interday variation in 
the assay was less than 10 % for all analytes. The lower limits of quantitation in plasma 
were 52.5 nmol/ L for M3G, 21 nmol/ L for M6G and for M, 35 nmol/ L.
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Statistics
The relationships between plasma and CSF concentrations of M and its glucuronides were 
examined by linear regression and Pearson correlation coefficients were calculated. A P 
value < 0.05 was considered to be significant.
Results
The concentration of M3G was higher than those of M6G and M in both fluids 
in all patients whereas the CSF/ plasma correlations for M3G ( r = 0.81; P= 0.0001) and 
M6G (r= 0.82; P= 0.0001) had a slope of 0.12 and 0.09, respectively (Table I).
Table I: Mean concentration ratios (standard deviation, range) of morphine and its 3- and 6-glucuronides in plasma and CSF (n= 16) 
PLASMA
M3G/M 29 (14, 11-52)
M6G/M 4.6 (2.8, 2-11)
M3G/M6G 6.7 (1.0, 4.6-8.7)
CSF
M3G/M 7.3 (5.6, 1-23)
M6G/M 0.8 (0.7, 0.1-3)
M3G/M6G 9.2 (2.0,5.6-14)
CSF/PLASMA
M 0.9 (0.3, 0.5-1.7)
M6G 0.09 (0.04,0.03-0.20)
M3G 0.12 (0.05,0.04-0.24)
The relationships between oral M dosage and plasma M concentration ( r =0.61, P= 0.013) 
and CSF M concentration (r =0.74, P= 0.0001) are shown in Fig.1.
M concentrations in plasma and CSF correlated closely (r = 0.94; P = 0.0001). The 
sum of M6G and M concentrations in the CSF did not correlate with the VAS score.
p=0.00013
CSF data (-) r=0.74, P=0.0001.
Fig.l: Relationship between plasma 
[□J and CSF (A)morphine 
concentrations and
daily oral M dose. Lines represent 
regression lines for plasma (-), r=0,61,
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Discussion
This study confirms that there is a direct relationship between oral M dosage and the 
concentration of M in plasma during chronic intake of controlled-release tablets in cancer 
patients [9]. The scatter in Figure 1 is probably due to variation in sampling time as well 
as between-subject differences in the absorption and metabolism of M. CSF M and 
plasma M concentrations correlated closely following long-term oral administration. The 
plasma M3G/ M and M6G/ M ratios were similar to those reported previously by 
McQuay et al. [10] and Somogyi et al. [11] in cancer patients receiving chronic treatment 
with oral M.
The presence of M glucuronides in the CSF can be explained by their diffusion out 
of the plasma through the blood brain barrier, possibly enhanced by coiling of the M3G 
and M6G molecules increasing their lipophilicity [12]. As the extent of plasma binding 
for M3G and M6G is low (10 and 15 %, respectively) [13], and the capacity of the CNS 
to produce M3G and M6G from M is limited [14], their plasma and CSF concentrations 
should eventually reach the same levels. However, an extremely slow access into the CSF 
can be explained both by their low lipid solubility as well as by the presence of a very low 
un-ionised fraction at pH 7.4 of only 0.003 % [15] due to their respective pKa values 
(pKa of M3G 2.83 and M6G 3.23) [12]. Also, elimination of M3G and M6G counteracts 
equilibration and may have attributed to the observed CSF/ plasma gradient.
Because all patients had relatively severe pain, there was probably insufficient 
variability in pain to expect a relationship with CSF concentrations of M and M6G [7, 
11]. Furthermore, CSF concentrations of M6G may not correspond to those at receptor 
sites, especially as tolerance to the analgesic effects of M can be expected after its long 
term administration.
In conclusion, this study shows a close correlation between plasma and CSF M 
concentrations during chronic administration of controlled-release M tablets in cancer 
patients. Marked M3G and M6G plasma/ CSF gradients were observed.
The authors thank E.Robertson M.D., Ph.D. and R.Dirksen M.D., Ph.D. for their assistance with the preparation 
of the manuscript.
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Introduction
The discovery, in the 1970s, of opioid receptors within the central nervous system, 
particularly in the dorsal root entry zone of the spinal cord, prompted clinicians to 
administer opioids spinally.1 In 1979, the first clinical reports appeared on both intrathecal 
and epidural administration of morphine.2 4 The favourable results reported in these 
preliminary studies led to a rapidly expanding use of spinal opioids in clinical practice.
The main indications thereafter included acute (perioperative) pain, obstetric pain 
and chronic -mostly cancer related- pain.
Many studies concerning the use of spinal opioids were in favour of the epidural 
route, probably due to its greater popularity among anaesthetists, whereas, for the 
treatment of chronic pain the intrathecal route was chosen mainly by neurosurgeons. 
Patients with inadequate relief of cancer pain with epidural morphine showed better 
results after the intrathecal route of administration was substituted. This seems attribu­
table to both pharmacological and biomechanical factors. 8,10,11
In the treatment of acute pain, intrathecal administration of opioids is still not 
much used when compared to the epidural route. In 1987 Rawal et al. found in a survey 
in Sweden that 92% of the anaesthetic departments used epidural opioids, while only 26 
% used intrathecal opioids/2 The reason for this was the fear for ventilatory depression, 
which in that survey was found to be four times higher when morphine was given 
intrathecally rather than epidurally.12 No recent survey has been published, but it is our 
impression that the epidural route is still being preferred by most anaesthetists.
Currently, the intrathecal administration of opioids has an important place in the 
treatment of severe acute and chronic pain in clinical practice. The direct injection of 
opioids beyond the blood/brain barrier, thereby bypassing systemic breakdown, offers an 
opportunity to deliver the drug in the direct vicinity of its target: the opioid receptor in the 
central nervous system.
Due to the low dosages needed in intrathecal administration of opioids in 
comparison with those required after systemic administration for equal pain relief, the 
dose related side effects are diminished. However, a final assessment about its superiority 
compared with other routes of administration, especially regarding efficacy and safety, 
still has to be provided.
Finally, the intrathecal route also offers the opportunity to apply combinations of 
opioids with other drugs (e.g. local anesthetics) for which systemic administration is 
either not feasible or is ineffective.14,15
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Pharmacokinetics and pharmacodynamics of intrathecally applied opioids
Early published studies mentioned the unpredictability of intrathecal morphine 
pharmacokinetics, due to numerous factors, such as unequal distribution into the 
cerebrospinal fluid, uptake in the blood and leakage of cerebrospinal fluid. Further 
elaboration of the intrathecal pharmacokinetics of morphine showed an elimination rate 
from the cerebrospinal fluid similar to that from plasma/7 The long duration of action 
after a single injection of intrathecal morphine can therefore be attributed to the high 
initial cerebrospinal fluid morphine concentrations. During intrathecal infusion the main 
pharmacokinetic factors involved are diffusion processes from the drug into the spinal 
cord and subsequent uptake by the blood capillaries draining the cord. Passage through 
the dura into the epidural space also takes place. Finally, the drug is transported rostrally 
to the cisterna magna and the other cephalic cerebrospinal fluid compartments.18
A major role in the pharmacokinetics of intrathecal opioids is attributed to the 
extent of hydrophilicity or lipophilicity of the drug used. Potency of intrathecal 
administered opioids is inversely related to their lipid solubility and thereby differs 
markedly from the situation when adminstered systemically. Regarding these factors 
McQuay et al., extrapolating data obtained from animal studies, concluded that in human 
an intrathecal dose of morphine 0.5 mg is equianalgesic with pethidine 5 mg or 
methadone 8.5 mg intrathecally.19
Initial vascular absorption of intrathecal morphine is significantly less when 
compared with epidural or intramuscular administration, resulting in prolonged retention 
of morphine in the cerebrospinal fluid and a prolonged analgesic action of up to 24 hours 
or more.20
Caut0 et al. compared the pharmacokinetics of isobaric (2 mg morphine in NaCl
0.9%) and hyperbaric morphine (2 mg morphine in 7% glucose) in patients with cancer 
pain. The latter solution presented a more restricted cephalad spread of morphine, with 
an absence of respiratory depression when the patients were in a 40-60 grade head-up 
position. In an other study, morphine in normal saline gave a greater duration of analgesia 
after thoracic surgery compared with morphine in 10% dextrose.22
Little data are available suggesting a greater analgesic potency of the intrathecal 
administration of the metabolite morphine-6-glucuronide compared with morphine. No 
evidence was found of morphine-6-glucuronide formation inside the nervous system.
Some efforts have been made to change the profile of intrathecal morphine by 
adding adrenaline to the morphine solution, which does not seem to be of any clinical 
benefit.
In a study comparing the pharmacokinetics of intrathecal morphine and meperi­
dine, maximum cerebrospinal fluid concentration varied up to a fivefold in various 
subjects, making problematic a prediction on a universally optimal dose/6
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Sufentanil, being highly lipophilic (octanol/water coefficient about 1000 times 
greater than that of morphine) shows a far more rapid cerebrospinal fluid elimination in 
comparison with morphine following intrathecal injection. Data obtained could not be 
expressed by a single exponential expression, indicating the involvement of multiple 
compartments.27 In contrast to morphine and meperidine, the decay of sufentanil levels 
was more rapid in cerebrospinal fluid than in plasma. Single doses of sufentanil, 
therefore, will only provide short lasting analgesic effects limited to 30-90 minutes.27 
Hansdottir et al. postulate, following repeated injections of sufentanil, accumulation can 
occur in plasma but not in cerebrospinal fluid27 Therefore, highly lipophilic opioids play 
a limited role in long-term intrathecal application. Theoretically sufentanil might be 
useful under conditions of limited receptor availability.
Two studies have shown that the addition of hydroxypropyl-beta-cyclodextrin to 
intrathecal sufentanil prolongs the spinal analgesic action of sufentanil and reduces the 
supraspinal actions.29,30 All studies support the view that the intrathecal injection of 
morphine carries a higher risk of late respiratory depression than the more lipophilic 
opioids (e.g. pethidine or sufentanil), especially when administered as bolus injections, 
due to the cephaled spread of hydrophilic morphine. In inducing respiratory depression, 
factors other than lipophilicity might be involved.
Rapid systemic uptake of intrathecal lipophilic opioids, such as sufentanil, can 
result in sufficiently high plasma levels to induce early respiratory depression. Intrathecal 
infusion techniques of sufentanil are not advocated until more pharmacokinetic data 
during steady state conditions are available26
Position of the catheter tip
Theoretically, a position of the catheter tip at a vertebral level corresponding to the 
segments of the site of maximal pain is the most favourable, especially, when lipophilic 
agents are used or local anesthetics are added.7,10,15 When comparing the intrathecal 
injection of morphine with intrathecal methadone at the lumbar level, it has been shown 
that high morphine levels in the cerebrospinal fluid can be detected at cervical level up 
to five hours after injection, whereas the more lipid soluble opioid methadone is removed 
much faster and was not detectable at that time.32
In contrast, however, experimental studies using heat beam dolorimetry showed 
a spinal segmental effect after intrathecal injection of morphine at the lumbar level. After 
injection of morphine 0.4 mg at the L3-L4 level, hypoalgesia has been detected at the 
sacral and lumbar dermatomes but not at the C7 dermatome.33 Another study yielded 
evidence for the permanence of spinal, as well as supraspinal, effects being responsible 
for the occurence of hypoalgesia. In clinical practice, one should weigh the convenience 
and the lower risk of an intrathecal puncture at the lumbar level against the desirability
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of positioning the catheter as close to the painful segments as possible.
Some other authors consider the position of the catheter tip to be of lesser 
importance in the administration of morphine because of the distribution of the morphine 
by the cerebrospinal fluid.35,36 In an elegant study using the radionuclide indium-111- 
diethylenetria-
mine penta-actic acid intrathecally, a steady decline of the radionuclide was demonstrated 
away from the site of the tip of the catheter. With an infusion site at L1, drug con­
centration at T2 amounted 42% of the value at T12. This result is compatible with that 
from other studies reporting lumbar/cisternal morphine ratios of between 4 and 7. In 
line with these results, Kroin et al. noticed that in patients with morphine susceptible pain 
a good effect was obtained from intrathecal administration of morphine at the lumbar 
level. When pain is situated in high thoracic or cervical dermatomes it is advisable to 
multiply morphine dosages by a factor of four or five when infusing intrathecal morphine 
at the lumbar level.35
Use in the perioperative period
In an editorial in 1989, Stoelting promoted the use of intrathecal morphine for pos­
toperative pain management because of its simplicity, reliability and low dose 
requirements, and the absence of the need to place a catheter in the epidural space.38
Which opioid to use ?
As already discussed in the section on the pharmacokinetics of intrathecally applied 
opioids, the opioid of choice for intrathecal administration is morphine, due to its 
hydrophilic nature. There are only a few studies in which other opioids have been 
administered intrathecally.
Diamorphine (heroin) is used frequently in British anaesthetic practice.39 41 It is 
more lipid soluble than morphine and therefore leaves the cerebrospinal fluid more 
rapidly, giving a quicker onset of action and leaving less drug available for cephaled 
spread.39 Its duration of action is similar to morphine, probably because it is metabolized 
to morphine in the spinal cord40 Other opioids that have been studied in man are 
methadone and dermorphine.42,43 The intrathecal use of the highly lipid soluble opioids, 
fentanyl or sufentanil is limited, due to their short duration of action. By using 
combinations of fentanyl and morphine, or the use of continuous intrathecal fentanyl 
infusion the problem of short duration of effect can be solved. The combination of 
fentanyl and morphine has been associated with early respiratory depression/0 Niemi et 
al. found that intrathecal morphine given as a single bolus (0.2 mg) or as a continuous 
infusion (0.2 mg in 24 hours) provided better analgesia than continuous intrathecal 
infusion of fentanyl (0.12 mg in 24 hours),48 while Guinard et al. found that injection of 
intrathecal fentanyl at a mean dose of 0.81 ^g/kg/hour (1.36 mg for 70 kg in 24 hours)
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provided good analgesia after thoracotomy.49
Only for morphine has it been extensively proven that it provides long-acting pain 
relief after a single intrathecal injection, and, if 12-24 hours of pain relief is the goal, 
morphine is the drug of choice.51
Type of surgery
Over the years many reports have been published describing the use of intrathecally 
applied morphine for peri- and postoperative treatment of pain in different types of 
surgery. Although most reports describe the use of intrathecal morphine in adults for 
orthopaedic, urological, gynaecological and general surgical operations, other reports 
describe its use in childeren,5254 head and neck surgery,55 neurosurgery and cardiothoracic 
surgery.
In Table 16168 an overview is given of clinical human studies that have been 
published concerning the perioperative use of single intrathecal injections of morphine: 
only those studies are listed that were randomized, prospective, blinded and compared 
different doses of intrathecal morphine. In this table the "optimum" dose is the dose of 
intrathecal morphine that (according to the authors) gave the best analgesia with the 
lowest incidence of side-effects.
Which dose to choose ?
Wang et al. had already showed in their first report on the use of intrathecal morphine in 
human in 1979 that 1 mg of intrathecal morphine gave no better pain relief in cancer 
patients compared with 0.5 m g2
In 1981 Samii et al. published the first dose-finding study when they compared
0.02 mg/kg of intrathecal morphine with 0.2 mg/kg; the higher dose gave no better 
analgesia than the low dose and more side-effects were noted in the high dose group.61 
Since then, a number of dose-finding studies have been published (see Table 1). All these 
studies differ with respect to patient population, type of surgery, timing of intrathecal 
injection (before or after surgery), combination with local anaesthetics or general 
anaesthesia, and end-points (majority of patients painfree or all patients painfree).
Because of these differences, it is not possible to subtract an "ideal dose" from these 
studies.
An "ideal dose" can be defined as the dose of morphine that gives good analgesia in the majority c
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Although the "ideal dose" doesn't exist, some recommendations can been made based on 
the literature that has already been published:
1) For lower abdominal and lower extremity operations the maxium intrathecal morphine 
dose must not exceed 0.3 mg.
2) For upper abdominal operations and for thoracotomies the maxium intrathecal morphine 
dosage must not exceed 0.5 mg.38
It must be remembered that these recommendations only give the maxium dosage; 
usually, lower doses are efficient in the individual patient; Yamaguchi et al. recommend 
for cholecystectomy a dose of 0.06 - 0.12 mg of intrathecal morphine !.67
Three studies have shown a synergism between morphine and local anaesthetics 
with regard to antinociception.6971 Gjessing reported, in 1981, a tendency to persistent 
curarisation when combining intrathecal morphine with general anesthesia; no further 
reports have been published concerning this possible interaction.
Postoperative care
Should patients who have received intrathecal morphine be intensively monitored in the 
ICU for 24 hours ?.
In the earlier reports on the use of intrathecal morphine such a period of intensive 
observation was advocated.41,72,73 Morgan stated, in 1987; " It cannot be safe to send these 
patients to an ordinary ward or private room where they are not under continuous 
observation".74 After 1987 studies were published that found excellent analgesia after low 
doses of intrathecal morphine without ventilatory depression (see Table 1). Domsky and 
Kwartowitz studied prospectively 275 patients who underwent major surgery and 
received intrathecal morphine with a maximum dose of 0.4 mg.75 They found no instances 
of respiratory depression and concluded, when there are proper trained nurses, that 
intrathecal morphine can be a safe method for postoperative pain control in a community 
hospital. In a retrospective analysis of 442 patients who received intrathecal morphine 
(0.3 - 0.5 mg) or epidural morphine (3 - 5 mg) for cesarean section, no significant 
respiratory depression was found. The authors relied on frequent nursing assesment of 
ventilation or sedation and believe that this represents the safest currently available means 
of monitoring respiratory status.
It is concluded that, when using the recommended low doses of morphine (see 
above), the risk of respiratory depression is small.
Other side-effects of intrathecal opioids, such as pruritis, nausea, urinary retention 
and somnolence are of minor importance, although they can be very troublesome in the 
individual patient. Treatments options for the different side-effects will be discussed later.
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Use of intrathecal opioids in obstetrics
Intrathecal opioids are particulary attractive for pain relief in obstetrics and have been 
widely employed since their first description by Scott et alJ7 An almost complete absence 
of changes in autonomic and motor function, in combination with a low maternal and fetal 
drug level, is highly desirable in the parturient. Intrathecal opioids do not influence the 
progress of labour/0 However, variability in pain relief during the second stage can neces­
sitate further anaesthetic interventions near delivery. This is mainly due to the differential 
effect of opioids on the A-delta and C-fibre input and the inability thereby to provide 
surgical anaesthesia.
Although further research is needed, recent development of very thin catheters 
inserted through specially designed spinal needles, or sequential/ combined spinal-epidu­
ral anaesthesia suggest to overcome the main drawbacks of intrathecal administration in 
parturients. A specific indication for intrathecal opioids is for the relief of post-caesarean 
section pain.
Which opioid to use ?
The choice of an intrathecal opioid in obstetrics is dependent on the desired duration of 
action and the presence of the side-effects. Prospective studies comparing effects of 
different opioids are few.81,82 A specific indication for intrathecal opioids exists in those 
patients with severe cardiac disease, due to the avoidance of large changes in the 
cardiovascular performance using this technique.83,84 
Morphine
Despite a relatively slow onset of pain relief of 15-60 minutes after injection and 
the possibility of late respiratory depression, intrathecal morphine is still widely used. 
Although the initial report by Scott et al. in 12 patients having intrathecal morphine 1.5 
mg showed a good result in the first stage of labour, only 7 patients reported absence of 
pain or an acceptable amount of pain relief in the second stage. This was accompanied 
by a high incidence of itching (100%), nausea in 9 and vomiting in 5 patients. Urinary 
retention was present in 4 patients. Fetal wellbeing was normal.
Because of the high incidence of side-effects, the use of gradually decreasing doses 
has shown that a dose of morphine 0.5-1.0 mg intrathecally is about equally as effective 
during the first stage of labour, until there is distention of the perineum/5 These doses, 
however, were also accompanied by a high incidence of side-effects. Eighty percent of 
patients developed pruritus, 53% nausea or vomiting, (or both), 43% urinary retention, 
and 43% drowsiness. These side-effects were decreased by naloxone, which did not affect 
the degree of analgesia. There was no significant depression of ventilation in any patient. 
Because of the slow onset of morphine and the morphine induced side-effects, combined 
administration of morphine with more lipid soluble opioids, such as fentanyl or sufentanil
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improves the analgesic profile by decreasing the onset time while diminishing the morphi­
ne induced side-effects. The latter situation can also be accomplished by using a 
combination of morphine/ bupivacaine during labour or for post-cesarean section pain.
In a study by Abouleish et al., it was shown that intrathecal morphine 0.2 mg plus 
10 ml of 0.125 % bupivacaine epidurally, using a combined spinal-epidural technique, 
was superior to either drug alone/9 The incidence of nausea, vomiting and pruritis, 
however, was significantly higher when morphine was administered intrathecally. 
Meperidine
In a study by Honet et al. the effects of intermittent intrathecal injections of 
sufentanil 5 g  fentanyl 10^g and meperidine 10 mg were compared during the first stage 
of labour. Due to its local anaesthetic and autonomic actions, meperidine showed to be 
more reliable when nearing the second stage of labour; in all patients side-effects were 
comparable. There was an increase in variable decelerations in fetal heart rate in the 
fentanyl and meperidine group. All neonates had a 5-min APGAR score of 7 or more. 
Sufentanil
The high lipid solubility of sufentanil results in a profound analgesia with a relati­
vely short (1-2 hours) duration of action upon intrathecal injection of a dose of 10 ^ g /3 
Longer intrathecal use of this drug necessitates repeat injections, which could be 
performed by an indwelling catheter.
Fentanyl
A dose of intrathecal fentanyl of 25-50 ^g results in pain relief of 30-120 minutes- 
duration which might be less profound compared with that from sufentanil 10 ^g /4
Post cesarean section pain
Abboud et al. showed that, in combination with 0.75% hyperbaric spinal 
bupivacaine, even a dose as low as intrathecal morphine 0.1 mg resulted in excellent post­
cesarean section pain relief, with minimal or no side-effects.64 Concomitant subcutaneous 
morphine, however, was associated with marked depression of the ventilatory variables. 
Combining morphine 0.2 mg with hyperbaric spinal bupivacaine for cesarean section has 
also been shown to be a safe and effective method of improving intra-operative pain relief 
and providing adequate prolonged postoperative analgesia.
New techniques
Occurrence of the cauda equina syndrome, due the use of extremely thin intrathecal 
catheters has not been described in obstetric patients/5 Complications associated with 
insertion and removal of these catheters, however, can increase morbidity following 
intrathecal injections.
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Possibly the continuous spinal epidural anaesthesia technique may be especially 
worthwile combining the positive aspects of both techniques.96 In the future, prospective, 
comparative studies are needed to establish safety of these developments for mother and 
baby during delivery and caesarean section.
Use of intrathecal opioids in chronic pain
The main indication of long-term intrathecal infusion of opioids is cancer pain not 
amenable to oral analgesics, including morphine. Only a few studies are dealing with 
patients receiving intrathecal opioids for chronic non cancer pain.
The first reports on the intrathecal administration of morphine published in 1979 
were pertinent to single bolus administrations in cancer patients with severe chronic 
pain.23 In these reports patients were submitted to percutaneous single intrathecal injec­
tions of morphine.
The use of an indwelling intrathecal catheter directly connected to a Luer lock 
stopcock, or to a subcutaneous administration port made repeated injections readily 
possible.7,34,35 Patients could thereby be treated by one to four single bolus injections a day 
and had not to be submitted to the inconvenience of a repeated painful injection. 
Drawbacks were the logistics of repeated morphine administration through the catheter, 
the risk of inducing bacterial contamination possibly resulting in meningitis and the fluc- 
tuance in drug levels in the cerebrospinal fluid due to the bolus injections.
The feasibility of long-term intrathecal administration was markedly improved by 
the introduction of an intrathecal infusion technique.6,7,97 An intrathecal catheter was 
tunneled subcutaneously to the anterior thoracic region and connected to an infusion 
pump implanted subcutaneously in the infraclavicular region. Two types of pumps were 
used a gas operated constant flow pump or a battery powered pump with a variable flow 
rate. The latter was programmed by an external device. Other options are the connection 
of a tunneled catheter to a subcutaneous access port connected with an external pump or 
connecting the catheter directly to the portable pump.™101 In cancer patients this method 
compares favourably with implanted pumps regarding feasibility, complication rate and 
cost-effectiveness.
Dosages of morphine and tolerance
Morphine is by far the most used intrathecal opioid for the treatment of chronic pain. 
Initial daily doses of intrathecal morphine are mostly low (1-4 mg) and are related to the 
dosages of oral morphine taken before the installation of an intrathecal catheter. 
Thereafter, however, reported daily intrathecal morphine dosages vary to considerable 
extent and range from 1 to 130 mg.15,97,103,104
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At the beginning of the intrathecal era, limitations of the method became apparent. 
Ventafridda et al. reported in 1979 the development of tolerance to the analgesic effect 
of morphine in eight cancer patients receiving daily intrathecal injections of morphine.3
Following the more widespread use of intrathecal opioids several other reports 
were published and other reasons for dose escalation, such as the entity of opioid 
refractory pain, became increasingly apparent.32,105,106 Max et al. could not achieve 
adequate analgesia with epidural or intrathecal morphine in 17 patients with neurogenic 
pain resistant to high doses or oral morphine.32
The subdivision of pain into various types, as proposed by Arn0r and Arn0r 
proved to be very useful in predicting the susceptibility of pain to opioids in a specific 
patient.107 Neurogenic pain, especially when accompanied by neurological deficit in the 
painful area, responds poorly to opioids, regardless of the route of administration. The 
same holds true for intermittent pain of both somatic and visceral origin: however, 
continuous somatic or visceral pain can usually be relieved by opioids.
Regarding these findings, Ventafridda et al. state that patients who do not obtain 
good pain relief from oral morphine would not be expected to benefit from spinal 
administration of opioids. 108However, Follett et al. reported good results using intrathecal 
morphine alone in 37 patients with pain not manageable by oral opioids.109 Before catheter 
implantation, all these patients, excluding patients with opioid refractory pain, had respon­
ded well to a trial of intrathecal morphine 1-4 mg.
Generally, doses of intrathecal morphine given during treatment with long-term 
continuous infusions have to be increased.102’110,111 Yaksh and Onofrio reported, in a retro­
spective review on 163 patients, a three- to five-fold dose increase over a six-month 
period.104 Other studies o cancer pain emphasize that,once an initial dose is established, 
intrathecal morphine doses remain within relatively narrow margins in a considerable 
proportion of patients.97,103,112 Escalation of intrathecal morphine dosage is considered to 
be mainly encountered in tumour progression, which provokes pain no longer susceptible 
to morphine. Most authors stress the great interindividual variance in this respect.104
Good effects have been reported by introducing 'a drug holiday' for patients with 
rapidly rising daily dosages of intrathecal morphine.113 For a period of one week, 
intrathecal morphine is replaced by the intrathecal administration of a local anaesthetic, 
or intrathecal clonidine, in combination with a reduced dose of morphine. After this 
period, intrathecal morphine administration can be restored at a much lower level, while 
pain relief is adequate. This phenomenon supports the assumption that dose
increase of morphine is at least partly due to pharmacological tolerance and cannot be 
attributed solely to a change in nociceptive input provoked by tumour progression.
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Another approach was chosen by van Dongen et al., by commencing continuous 
intrathecal infusion with morphine and adding bupivacaine in case sufficient analgesia 
was not achieved by morphine alone.103 Other authors advocate to start always with a 
combined use of morphine and bupivacaine in patients with cancer pain, because most of 
them are suffering from mixed pain types including neurogenic pain. The recommended 
ratio here is 1:10, using a solution of morphine 0.5 mg and bupivacaine 4.75 mg per mil­
liliter.
A combination of hydromorphone and clonidine has also been succesfully used in 
a patient with neurogenic pain.
In conclusion, in the literature the existence of pain resistant to intrathecal 
morphine is generally accepted. However, disagreement exists on the question whether 
patients not being succesfully relieved by oral morphine can experience pain relief with 
intrathecal morphine. An important question to be answered in this regard is whether, in 
studies dealing with this last category, patients were treated adequately with oral 
morphine before being switched over to intrathecal morphine.
Concomitant use of opioids by other routes
In the published studies, a considerable percentage of patients on intrathecal morphine 
took opioids by other routes, mostly orally. About 50% in a serie of 37 cancer patients had 
to take also oral opioids to obtain satisfactory pain relief.110 In contrast to epidural 
administration, where plasma morphine levels are comparable to those after intramuscular 
injection, intrathecal administration is accompained by very low plasma levels resulting 
in minimal supraspinal effects.105 The absence of the central effects from oral morphine 
after changing to intrathecal morphine may result in mental depression necessitating the 
use of tricyclic antidepressants or a maintenance dose of oral morphine.
Side-effects
The most feared side-effect of intrathecally applied morphine is respiratory depression, 
which becomes evident within 6-10 hours after an opioid injection.16 Rawal et al. found 
an incidence of 3/1000 following morphine doses of 0.2 - 0.8 m g/2 This risk of 
respiratory depression seems to increase when higher doses of morphine are used.16 
Abboud et al. and Abouleish et al. found no respiratory depression after low dose 
intrathecal morphine (maximum dose 0.25 mg), but it occured after parenteral morphine
64 90was given. ’
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The following treatment options have been published for the different opioid 
induced side-effects; 51’75’117-119
1) Opioid antagonists for pruritus, nausea, urinary retention and somnolence:
* small doses of naloxone (short-acting) (0.04 mg) i.v.
* (long-acting) naltrexone 3 - 6 mg orally
2) Mixed agonist-antagonist for pruritus, nausea, urinary retention, somnolence:
* nalbuphine 5 - 10 mg i.v.
* butorphanol 1 - 2 mg i.v.
3) Symptomatic treatment:
* droperidol 0.5 - 1 mg i.v. for nausea
* transdermal scopolamine for nausea
* metoclopramide 10 mg i.v. for nausea
* small doses of propofol (10 mg) for nausea and pruritus
* diphenhydramine 12.5 - 25 mg i.v. for pruritus
Parenteral naloxone can diminish most opioid induced side-effects after intrathecal 
administration in obstetrics, without detrimental effects on the baby. A bolus dose of 0.4 
mg i.v. followed by a continuous i.v. infusion of 0.4-0.6 mg/hr is reported to have reduced 
the incidence of pruritus, whereas the incidence of nausea, somnolence, dizziness and 
urinary retention was unaffected in 40 women during labour.120 Urinary retention can be 
managed adequately with short-term bladder catheterization. I one study, the addition of 
epinephrine to intrathecal sufentanil increased the incidence of nausea and decreased the 
incidence and severity of pruritis.93
In cancer patients submitted to continuous infusion of morphine, reports on 
respiratory depression are conspiciously absent. Before the installment of intrathecal 
infusion virtually al these patients are using oral morphine in substantial doses, apparently 
minimising the risk of respiratory depression. Respiratory depression may occur 6-10 
hours after starting intrathecal infusion therapy: therafter it is seldomly observed, 
presumably because of the previous use of oral opioids in virtually all patients21,110,121,122
Spinal myoclonus is a rare complication: it occurs mainly in patients with signs of 
spinal cord compression who are submitted to intrathecal morphine doses above 20 
mg/24h. It is suggested that morphine during intrathecal infusion becomes trapped 
below a spinal block during infusion, being provoked by tumour growth giving rise to 
local toxic cerebrospinal fluid-concentrations of morphine and causing seizure-like 
muscular contractions of the lower limbs.
Hyperalgesia is another complication of high-dose intrathecal morphine. After 
cesssation of morphine infusion, the pain diminishes. Infusion of morphine in a reduced
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dose can be restored after a pause of one to two weeks.123
In autopsy material, histological changes attributable to the infusion of morphine 
per se are absent and are virtually always related to the progression of the underlying 
disease (cancer). Long-term indwelling catheters and intrathecal infusion of morphine and 
bupivacaine are remarkedly well tolerated. Even the addition of preservatives and 
antioxidants such as EDTA and sodium metabisulphite did not result in neuropathological 
changes.
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Table 1. Overview of randomized, prospective, blinded, human studies of the perioperative use of intrathecal morphine
Author Year of publication Type of surgery Doses of morphine Number of patients 
receiving morphine
"Optimum" dose
Samii38 1981 Laparotomy or
Thoracotomy 0.02 mg/kg - 0.2 mg/kg 60 0.02 mg/kg
Kalso39 1983 Orthopedic 0 - 0.2 - 0.4 mg 30 0.4 mg
Aun34 1985 CABG 0 - 2 - 4 mg 40 4 mg
Fitzpatrick35 1988 CABG 0 - 1 - 2 mg 30 l g
Jacobson40 1988 Orthopedic 0 - 0.3 - 1 - 2.5 mg 23 0.3 - 1 mg
Abboud41 1988 Cesarean section 0 -0 .1 -0 .2 5  mg 21 0.1 mg
Kirson42 1989 TURP 0 - 0.1 - 0.2 mg 20 0.1 mg
Yamaguchi43 1989 Abdominal
hysterectomy 0 - 0.03 - 0.04 - 0.06 - 0.08 -■0.1 mg 148 0.04 - 0.08 mg
Jacobson15 1989 Orthopedic or
Urological 0.5 - 1 mg 20 0.5 mg
Yamaguchi44 1990 Cholecystectomy 0 - 0 . 0 4 - 0 . 0 6 - 0 . 0 8 - 0 . 1  -
0 .1 2 - 0 .1 5 - 0 .2  mg 119 0.06 - 0.12 mg
Ross33 1991 Lumbar spinal 0 - 0 . 1 2 5 - 0 . 2 5 - 0 . 5  mg 42 0.25 - 0.5 mg
Sarma45 1993 Abdominal
hysterectomy 0-0 . 1  - 0 . 3 - 0 . 5  mg 60 0.3 mg
* Dose in mg/kg. CABG: coronary artery bypass graft. TURP: transurethral resection of prostate
Long-term intrathecal infusion of morphine and morphine/bupivacaine 
mixtures in the treatment of cancer pain; a retrospective analysis of 51 
cases.
R.T.M van Dongen M.D.,B.J.P Crul M.D, Ph.D. and M. de Bock M.D.
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Summary
A retrospective analysis of 51 patients with cancer pain treated with a continuous 
intrathecal morphine infusion through a tunnelled percutaneous catheter was 
undertaken. Because of insufficient pain relief with morphine only, 17 of these 
patients received a morphine/ bupivacaine mixture. Pain relief subsequently improved 
significantly in ten patients and a moderate improvement was present in four patients. 
An additional analgesic effect of bupivacaine was not shown in three patients with 
clinical signs of severe mental depression. Bupivacaine induced side effects were 
absent below a daily dosage of 30 mg by continuous infusion. In all patients a gradual 
dose increment was observed. No serious complications, neurologic sequelae or 
meningitis occurred.
It is concluded that long term intrathecal infusion of morphine through a tunnelled 
catheter can provide adequate pain relief in cancer patients with an acceptable risk­
benefit ratio. The effects of long-term intrathecal co-administration of local 
anesthetics, especially bupivacaine, await further prospective evaluation.
Key Words
Cancer pain, Intrathecal infusion, Morphine/ Bupivacaine combination, Side-effects.
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Introduction
Long-term intrathecal (i.t.) infusion of morphine is used in cancer patients with 
inadequate pain relief, especially in combination with intolerable and unmanageable 
side-effects during conventional opioid administration. (Ventafridda et al. 1987) 
Treatment effectiveness and the incidence of technical and infectious complications, 
vary between authors and techniques applied. (Krames et al. 1985, Schoeffler et al. 
1986, Brazenor 1987, Crul and Delhaas 1991).
Recent experience has suggested that i.t. morphine plus bupivacaine may be useful in 
pain syndromes inadequately relieved by intrathecal morphine alone. (Sjoberg et al.
1991). We retrospectively evaluated the effectiveness of i.t. morphine infusion in 51 
patients. Of these, 17 patients were subsequently treated with a combination of 
morphine and bupivacaine.
Patients and methods
During the period 1988-1991, i.t. catheters were inserted in a total of 51 terminally ill 
cancer patients after informed verbal consent. Four of these patients received i.t. 
treatment after therapeutic failure of previous epidural infusion. (inadequate pain 
relief, two patients; persistent nausea and vomiting, one patient; obstruction of the 
catheter, one patient).
TABLE I
Demographic data, duration of treatment and dosages for the total intrathecal group. (51 patients)
mean age (range) 53 (27-71)
Male /Female 29/ 22
Total treatment duration (1) 3140
Treatment duration morphine/ bupvacaine(1) 1900
Mean treatment duration (2) (range)
morphine group 61 (1-378)
morphine/ bupivacaine group 112 (21-377)
Morphine dose in mg/ day
minimum- maximum (mean) 1-33 (8)
Bupivacaine dose in mg/ day
minimum-maximum (mean) 10-100 (31)
(1) duration of treatment in patient days.
(2) mean duration of treatment in days.
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All patients experienced inadequate pain relief after oral medication and/ or 
manifesed intolerable side-effects. Oral medication consisted of minor analgesics or 
non-steroid anti-inflammatory drugs (NSAID) followed by morphine sulphate slow- 
release tablets in increasing dosages limited only by the occurrence of side-effects. 
Combinations of these drugs, also with co-analgesics, were used frequently. Also 
other anti-tumour therapy (e.g. chemotherapy, radiotherapy) failed to reduce pain 
sufficiently or was no longer applicable at that moment (e.g. neuro-ablative 
treatment). The demographic data of all patients are shown in Table I.
Routine determination of pain relief using the visual analogue scale (VAS) was not 
performed in this patient group and could not be determined afterwards due to the 
retrospective character of the study. Instead, effectiveness of the treatment was judged 
by verbal expression of the patients and the need for additional analgesics as noted in 
the records. Paint relief was rated “good” when patients needed no or only incidental 
concomitant analgesics. Pain relief was rated “moderate” when concomitant 
analgesics were necessary on a more regular basis or when pain persisted during 
movement. When pain was still present during rest, despite regular administration of 
analgesics the result of i.t. treatment was rated “poor”. Occurrence of side-effects and 
technical complications during the whole treatment period was evaluated. Dose 
progression from the start of i.t. treatment was studied during an arbitrarily chosen 
period of 90 days because of the decreasing number of surviving patients thereafter.
Regardless of the localisation of the pain complaints, all catheters were inserted at an 
interspace between the second and the fifth lumbar vertebra using local anaesthesia. 
The catheters were advanced 3 to 5 centimeters into the i.t. space. Subsequently, the 
catheter was tunnelled stepwise subcutaneously to the anterolateral body wall. 
Tunneling took place over a distance distance of 30-40 centimeters by using a 
standard 18-ga epidural needle. After piercing of the skin the catheter was 
exteriorized and fixed with a transparent self-adhesive dressing (Tegadermtm). No 
sutures to fix the catheter or prophylactic antibiotics were used. A closed system was 
obtained by connecting the catheter and an antibacterial filter with an extension 
tubing to the drug reservoir. Due to the selection of a low infusion rate, change of the 
drug reservoir, extension tubing and filter was only necessary every two to three 
weeks, minimizing the risk of contamination of the system. For the same reason, 
change of the self-adhesive dressing was usually performed in combination with the 
change of the drug reservoir or earlier when the dressing was soiled. Preservative-free 
morphine-hydrochloride was diluted in 0.9% NaCl, resulting in a morphine
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of 0.5 - 1 mg/ ml. According to previous clinical experience in our institution, the 
initial i.t. daily morphine dose was 1/60 th. of the current daily oral intake of 
morphine. The intake of oral morphine was gradually diminished in 2-3 days to avoid 
abstinence. (Tung et al. 1980; Messahel and Tomlin 1981). Patients continued their 
analgesic medication until the moment of insertion. Dose adjustments of the i.t. 
infusion rate were made when pain relief was inadequate as judged by the patients, or 
side-effects occurred.
Seventeen patients (Table IV) received a combination of morphine and bupivacaine 
when adequate analgesia could not be achieved by morphine only. Commercially 
available, preservative- free solutions of bupivacaine (0.25% - 0.75% Marcaine R, 
Astra, Rijswijk, Netherlands) were used and diluted to the required volumes and 
concentrations in combination with the desired flow rate of the morphine solution 
(Appelgren et al. 1988, Sjoberg et al. 1991). Usually a bupivacaine concentration of 
1.5- 3 mg/ ml was used.
When attendance at the outpatient clinic was no longer possible, telephone contact 
with the patients, their relatives or general physician guaranteed adequate supervision 
at home. Care of the catheter was provided by the general practioner and the home 
care nurse while logistic supervision and change of the drug reservoir was 
coordinated by a commercial firm specialized in technical assistance during home 
care. Patients were followed until death. The catheters used in our patients are shown 
in tab II.
TABLE II
Technical characteristics of catheters used. (n=51)
material size number
Polyamid 20 G 35
Nylon 24 G 4
Polyurethane 27 G 8
Polyurethane 24 G 4
The mean i.t. morphine dose per day and standard deviation was calculated during a
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90 day study period using Quattro Pro R (Borland International).
Results
The graphic representation of the daily i.t. morphine dose and the progression 
in time during the 90-day study period for all patients is shown in Fig. 1. An initial 
rapid increase in daily dose until day 20 is followed by a more stable dose, slowly 
increasing thereafter.
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Fig. 1. Average daily morphine dose (mg) during a 90-day treatment period for the total intrathecal group (51 
patients). The mean daily close is represented by the solid line with error bars equal to the standard deviation. 
The decreasing number o f patients per day is represented by the dashed line and corresponds to the numbers on 
the right y axis (see also Table 1).
In a number of patients oral morphine and co-analgesics had to be 
administered indicating inadequate pain relief with i.t. treatment only (Table III).
Table III Concomitant analgesic medication during intrathecal treatment in all patients.
In this group of patients oral morphine was given in 12 patients (63 %) with i.t. morphine/ bupivacaine and 
in 7 patients (20 %) with intrathecal morphine only.
Drug Number of patients
no drugs 13(25% )
morphine 19 (37 %)(1)
NSAIDs 10 (20%)
Antidepressants 10 (20%)
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Despite increasing the dosages of i.t. morphine, adequate pain relief could not be 
achieved in 17 patients (Table IV). Subsequently, combined infusion of morphine and 
bupivacaine was started in the dosages as shown (Table IV) because of the pain 
characteristics at that moment. Good pain relief as determined by incidental use of 
concomitant analgesic medication could be accomplished in ten patients (58%).
TABLE IV
Patients treated with a combination of morphine and bupivacaine intrathecally.
Number Age tumor type3 M/Bupil’ daysc resu tf
1 61 pancreas cv/iv 19/36 300 good
2 51 bladder is/in 4/27 76 good
3 53 breast cs/is 12/25 56 moderate,depression
4 60 breast cs/is 6/20 13 poor,depression/ fear
5 63 rectum cv/iv 7/14 98 good
6 63 prostate cs/is 5/15 303 good
7 51 cervix cv/in 10/18 33 poor
8 77 prostate cs/is 12/36 75 good, depression/ fear
9 49 breast cs/in 17/100 337 moderate, spastic jerks
10 66 uterus cs/in 14/45 377 moderate, bilat. PCC/LEB
11 57 pleura cv/iv 33/16 41 good, dyspnea
12 82 rectum cs/in 24/45 21 poor, fear
13 55 esophagus cv 7/22 65 good, fear
14 56 prostate cv/in 6/27 46 moderate, PCC.
15 44 kidney cs/in 12/10 24 good
16 27 gallbladder cv 1/60 33 good, did not tolerate opioids.
17 44 cervix cv/in 14/14 21 good;
A type: pain svndrome according to Amér (1985): c=continuous; i= intermittent, v= visceral, s= somatic,
n= neurogenic.
B M/Bupi: maximum morphine dose (in mg) and bupivacaine dose (in mg) per day during total treatment period.
3 days: total duration of combined morphine/ bupivacaine treatment.
P.C.C: percutaneous cervical cordotomy; In patient 10 P.C.C. bilaterally. LEB; lower end block with phenol 
7% in glycerine.
4 result: an overall estimation of pain relief concerning verbal expression of the patient, V.A.S. if noted 
and use of concomitant medication was made.
A moderate effect of the combination treatment was present in four patients (24 %) 
who needed concomitant analgesics on a more regular basis, while pain frequently 
persisted during movement. Adequate pain relief was not achieved in three patients 
(Table IV, patients 4, 7 and 12;(18 %), all presenting with overt clinical signs of 
mental depression. Despite use of morphine and anti-depressants pain relief was poor 
in these patients.
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In patient 14 and patient 10 (Table IV) a percutaneous cervical cordotomy 
was performed because of persisting unilateral neurogenic pain components during i.t. 
treatment. In patient 10, an additional intrathecal neurolysis using phenol 7% in 
glycerol (lower end block) was neccessary to accomplish acceptable pain relief at the 
price of urinary and faecal incontinence.
Total i.t. treatment duration was 3140 days, while the combination of morphine and 
bupivacaine was administered during a total of about 1900 patient-days. Routinely, a 
combination of morphine 1 mg / ml and bupivacaine 2-4 mg / ml was started with an 
infusion rate derived from the previous oral morphine dose. The initial bupivacaine 
dose was then 10-15 mg/ day, evaluating pain relief and possible side effects. The 
mean daily bupivacaine dose was 31 mg. (range 10-100 mg, median 23 mg.) Finally 
thirty five patients (69%) were discharged and died outside the hospital.
Side effects and technical complications
During the period of treatment most side effects were caused by the 
underlying diseases. Table V shows the side effects and technical problems related to 
the i.t. treatment.
TABLE V
Number of patients with side effects and technical (catheter related) complications (percentage).
See text for further details.
Nausea 11(21)
Sedation 1 (2)
Urinaryretention 5 (l0)a
Headache 5(10)
CSF leakage 3(6)
Epidural bloodpatch 1 (2)
Local infection 2(4)b
Disconnection 9 (17)C
Catheter dislodgement 4 (8)
a:temporary; spontaneously resolving in all but 1 patient; no 14 tab IV.
b:positive culture exit site, treated with antibiotics with catheter remaining in place till death.
C:in polyurethane group predominantly.
In patients with abdominal pain, nausea was frequent and mostly disease related. 
Anti-emetics (metoclopramide, dehydrobenzperidol) were effective. One patient with 
a prostatic carcinoma in the morphine/ bupivacaine group, (Table III, patient 14) 
needed an indwelling suprapubic catheter. Postspinal puncture headache (PSPH) was 
present in five patients (10%), all with a 20-ga polyamid catheter in situ, disappearing 
spontaneously after 48 hours in four patients. Of these, one patient also had an 
external loss of CSF along the catheter tract and was subsequently treated with an 
epidural blood patch. Three other patients had a temporary CSF leakage along the
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catheter tract without concomitant headache, spontaneously resolving in three days. 
No additional neurological symptoms due to the bupivacaine (e.g., progressive 
sensory deficits, motor complaints) developed when the bupivacaine was gradually 
increased to a daily dose of 30 mg by continuous infusion. Also, clinical symptoms of 
autonomic dysfunction (e.g., orthostatic hypotension), urinary or faecal incontinence 
or neurotoxicity were absent in these patients. (Sjoberg et al. 1992).
In one female patient (patient 9, Table IV) with extensive vertebral metastases and 
partial paraplegia due to a breast carcinoma, pain radiating to both legs was 
insufficiently relieved by i.t. morphine. Additional i.t. administration of bupivacaine in 
a dose of 100 mg/ day resulted in progressive motor disturbances in both legs and 
urinary and rectal incontinence. Two patients with accidental disconnection of the 
catheter and acute cessation of bupivacaine infusion suffered intolerable paresthesias, 
disappearing after restoration of the drug infusion.
Local infection of the catheter exit site was seen in two patients. In one case 
treatment was started with antibiotics after obtaining a positive skin culture containing 
a staphylococcus aureus without any sign of systemic infection. During the treatment 
the catheter was not removed. No meningitis occurred in any patient. Pruritis or 
respiratory depression was not encountered.
Catheter related complications
Accidental dislocation of the catheter to the subcutaneous tissue occurred in 
four patients (8%). Two patients rejected catheter reinsertion and opted for s.c. 
morphine infusion in an adjusted dosage while in the other two patients the catheter 
had to be replaced twice. The most important technical problem was catheter- 
connector malfunctioning resulting in both obstruction and disconnection of the 
catheter. The polyurethane catheters were more likely to lead to this problem.
Discussion.
During the period studied, the authors gradually changed from epidural to i.t. 
administration of morphine, both on theoretical grounds as well as on good experience 
with long-term use of i.t. catheters by one of us. (Nordberg 1986; Morgan 1989; Crul 
and Delhaas 1991). Inadequate pain relief with i.t. morphine in some patients and a 
possible potentiation of i.t. morphine by bupivacaine were reasons to add this local 
anesthetic (Âkerman et al. 1988, Appelgren et al. 1988). Also, animal and human 
studies did not show signs of neurotoxicity sofar. (Kroin et al. 1987, Sjoberg et al. 
1991, 1992).
The importance of the clinical evaluation of progressive cancer pain syndromes and 
their responsiveness to opioids is supported by recent experimental animal work 
suggesting a change in receptor population during continuous nociceptive stimulation 
(Duggan and North 1984; Arnér and Arnér 1985; Stevens et al. 1991; Portenoy et al. 
1990; Arnér 1991; Sjoberg et al. 1991). In the 17 patients treated with the morphine/
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bupivacaine mixture (Table IV), neurogenic pain, intermittent visceral pain or pain 
following movement were also present. Remarkably, of the seven patients who had a 
moderate or poor response to additional bupivacaine, five (patient 7, 9, 10, 12, 14) 
showed neurogenic pain characteristics. This suggests a diminished responsiveness of 
this pain syndrome for i.t. morphine and bupivacaine in the dosages used by us.
Prospective studies are needed to determine the indications and timing for the use 
of bupivacaine while in this respect the exact siting of the i.t. catheter tip might be 
important both to pain relief as well as to the severity of side effects. Because of the 
preliminary experiences with this technique during this period (1988-1991) and the 
lumbar placement of all i.t. catheters in the patients studied, this aspect could not be 
evaluated.
The difference in duration of treatment between both groups (61 days for the 
morphine group compared to 112 days for the morphine/ bupivacaine group) might be 
explained by an early insufficient pain relief with conventional morphine treatment in 
these pain syndromes (Ventafridda et al. 1987; Arner 1991) Intrathecal treatment in 
these patients was thus initiated sooner, leading to a longer treatment period.
The rapid dose increment in the first 20 days of i.t. treatment can not be readily 
explained (Fig. I). Possibly the initial i.t. starting dose of morphine based on our 
previous clinical experience was too low. Also, the diminishing effects of morphine 
could lead to a greater apprehension and subsequent changes in mood and emotion 
(Brazenor 1987; Samuelsson et al. 1987; Fedder 1990; Kupers et al. 1991).
Aware of the shortcomings of our retrospective analysis, we suggest that long-term 
use of tunnelled i.t. catheters is accompanied by an acceptable risk-benefit ratio in this 
difficult to treat population of patients. Prospective studies are needed to determine 
the exact indications, clinical effectiveness and practical consequences of combined
i.t. morphine/ bupivacaine infusion.
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6.1 Diminishing effects of opioids in the clinical situation
Chronic administration of opioids by whatever route (oral, i.v, IT., intraventricu- 
lar) ultimately gives rise to a diminished effect and is called tolerance (Yaksh 1991). 
This phenomenon, leading to a dampened or shortened effect of the drug, necessita­
tes a higher dose in order to have the same effect. It is always initiated by the prior 
exposure of the subject to that particular drug (Foley 1991). Although tolerance is 
frequently associated with a decrease of the analgesic effects of an opioid, tolerance 
to sedative and respiratory depressant effects can also take place (Collin and Cesse- 
lin 1991). The majority of tolerance studies are performed in animals devoid of a 
painful pathologic process. In the human situation then, a changing pain state and 
psychological interactions due to the pain complaints are a major difference between 
these clinical and animal experimental data on mechanisms of tolerance develop­
ment (Yaksh 1991).
6.2 Tolerance
A decreasing analgesic effect of opioids can be caused by a variety of reasons 
(Table 6-I). These must be considered before tolerance is suspected (Portenoy 1994, 
Jaffe 1992, Foley 1991). Strictly speaking, an increased need for an opioid due to 
disease progression and correlated nociceptive input may not be called tolerance 
(Portenoy 1994). In cancer patients, therefore, this can be difficult to assess.
Table 6-1. A differential diagnosis for declining analgesic effects in the clinical setting (Portenoy 1994) 
changes ¡^cognitive state leading to altered pain perception or reporting (e.g. delirium)
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Tolerance can be divided into dispositional (changes in the way the ligand re­
aches the receptor) or functional (changes in the receptor-ligand complex per se) 
tolerance. Alterations in the metabolism of the drug or a different distribution over 
the blood-brain-barrier are examples of the former. The latter can be caused by a 
decrease in the number of opioid receptors (“down-regulation”) (Stevens and Yaksh 
1990) although this has never been demonstrated to be the cause for tolerance 
development clinically. A change in the receptor-ligand interaction may also occur. 
Here, coupling of the opioid to the receptor and subsequent intracellular G-Protein 
activation is altered (“desensitization” or uncoupling) (Neil 1990, Collin and Cesse- 
lin 1991). Also, long-term neuropathic stimulation of peripheral nerves may lead to 
a change in the spinal cord opioid receptor population both ipsilateral as well as 
contralateral (Stevens et al. 1991).
Recent studies have elucidated the (sub) cellular mechanism of tolerance develop­
ment and the uncoupling mechanism (Basbaum 1995, Mao et al. 1995 (a,b), Mayer 
et al. 1995). It has been shown that prolonged opioid exposure results in a displace­
ment (translocation) of intracellular protein kinase-C (PKC) specifically in the 
neurones in the superficial layers of the spinal cord dorsal horn (Mao et al. 1995(b)). 
This activates a cascade of intracellular events (Mg blockade removal, NMDA 
receptor activation, Ca-channel opening) finally resulting in an increased intracellu­
lar calcium concentration.
Due to a positive feedback by this intracellular Ca increase, further stimulation of 
PKC formation, NMDA activation and Nitric Oxide (NO) production takes place. 
The net result is a functional uncoupling of the G-protein / ^ receptor complex by 
the PKC, seen clinically as tolerance..
A remarkable similarity seems to exist between the intracellulair changes due to 
prolonged opioid exposure (tolerance) and the development of a neuropathic pain 
state. In both situations, activation of the NMDA receptor takes place as well as an 
intracellular increases in NO and PKC. Also, a reduction of the antinociceptive 
effects of morphine in experimental neuropathy models suggests a similar “final 
common pathway” between the development of tolerance and hyperalgesia (Mao et 
al. 1995 b). Both phenomena may explain why opioids are not always effective in 
neuropathic pain syndromes and, in contrast, why exposure of patients with neuro­
pathic pain to opioids can lead to an enhanced opioid tolerance and subsequent 
hyperalgesia.
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The analgesic effect exerted by an opioid drug is determined by the number of 
receptors occupied by the drug in relation to the total receptor number (FRO: fracti­
onal receptor occupancy), the density of the coupled receptors and the intrinsic ef­
ficacy of the agonist due to receptor binding.
Since tolerance developes faster following high-dose agonist administration, a 
drug with a low FRO and a subsequent large amount of "spare" receptors will result 
in slower tolerance development (Stevens and Yaksh 1989, Sosnowski and Yaksh
1990, Yaksh 1991). Another aspect of a drug with a low FRO is, that a smaller 
amount of the drug will be redistributed thereby mediating less side-effects (Parkin­
son et al. 1990). One method to diminish tolerance development would be decrea­
sing the FRO by the co-administration of synergistic drugs, such as local anaesthe­
tics (see also Chapter 6.3). Of these drugs, most experience in our patients has been 
gained by using local anaesthetics, viz. bupivacaine, intrathecally in combination 
with morphine.
By inhibition of voltage gated sodium channels, local anaesthetics block impulse 
propagation in nervous structures. This reversible conduction blockade interferes 
with the maintenance of the normal membrane potential. Due to the (energy consu­
ming) effects of the membrane bound Na-K ATP ase, normally, sodium is pumped 
out of the cell and potassium in, resulting in a normal resting potential around the K- 
equilibrium potential. Interference with the physiologic function of this Na-channel 
is considered to be of major importance for normal impulse conduction. This, howe­
ver, is probably not the only mechanism responsible for neural blockade since other 
membrane associated proteins are involved, e.g. adenylate cyclase, guanylate cycla­
se, calmoduline sensitive proteins, the Ca / Mg ATP-ase (Butterworth and Strichartz 
1990).
There are some important differences in the effects of local anaesthetics on 
neuronal tissue administered in the epidural or IT space. Despite a distribution of the 
drugs between the nerves and the spinal fluid, the absence of a nerve sheath around 
the IT nerves can lead to a more profound effect of the local anaesthetics deposited 
there. This may therefore explain a ratio of 1:10 for IT versus epidural local anaest­
hetic dosages (Langerman et al. 1994). As the desired end point of our combined IT 
administration was analgesia without increasing the risk of untoward effects, especi­
ally motor blockade, the amide-type local anaesthetic bupivacaine was selected.
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Due to its long duration of action, and assumed differential sensory-motor block­
ade it might theoretically compare favourably with other local anaesthetics.
6.3 Combined effect of drugs administered intrathecally
By definition, two drugs are said to interact when the effect of their combination 
differs from that expected from their individual dose-response curve. Generally 
speaking a combination of drugs can result in a subadditive (diminished), additive 
(summation) or supradditive or synergistic (higher than summation) effect (Beren- 
baum 1989).
Potentiation, often used in the same context, denotes the phenomenon that a drug 
which has no effect on its own can increase the potency of another drug when used 
together (Dickenson and Sullivan 1993).
In order to increase the analgesic effect and diminish toxicity of two (or more) 
drugs, extensive research in this area was performed whereby specific attention was 
given to the synergistic effects of combinations of drugs. An effect is considered to 
be synergistic when this effect can be accomplished by combining lower drug 
dosages that would have produced the same effect if the combination were purely 
additive (e.g. A + B = X: ^A  + ^B > X). Synergy is difficult to demonstrate in the 
intact animal unless standardised tests are used. In cancer patients it is even more 
difficult, due to the presence of psychological factors and progression of the disease 
whereby pain complaints will vary.
Using the inhibitory actions of a combination of drugs, the effect on neurotrans­
mission and specifically nociception can have two (positive) results: (Dickenson and 
Sullivan 1993; Solomon and Gebhart 1993) viz.,
1. Opioid induced si de-effects may be diminished due to a lower dosage of either 
drug needed.
2. Efficacy of the combination of two drugs interfering with the nociceptive system 
at different levels might be improved.
Analgesia in relatively "opioid insensitivity " may follow.
A variety of drugs can be used to produce a synergistic effect. The clinically availa­
ble drugs sofar and their effect in combination with opioids are summarized in Table 
6-II.
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Table 6-II. Combined intrathecal administration of opioids and other drugs on pain relief
Local Anaesthetics positive 
Alpha 2 agonist positive 
M6G positive 
NMDA activ. negative 
M3G negative 
CCK and F8A___________ negative
From Dickenson A.H.: Where and how do opioids act. In Proceedings of the 7th World Congress on Pain; 
Progress in Pain Research and Management; vol 2. IASP Press Seattle (1993) 525-552. With permission.
6.3.1 Combining morphine with local anaesthetics
In this situation, an inhibitory drug (opioid) is combined with a drug which 
diminishes excitability (local anaesthetic). Numerous animal studies have shown an 
increased effect of the combination compared with the individual drugs. Lignocaine, 
produced a dose dependent inhibition of the C-fibre evoked nociceptive A5 and Ap 
inoccuous evoked cell response (Akerman et al. 1988). A more selective response 
for noxious impulses ensued.
Local anaesthetics might also have a beneficial effect on the presence of “Wind­
up” phenomena in persistent (neuropathic) pain states. This would add to an impro­
ved analgesic effect in pain syndromes leading to a diminished opioid responsive­
ness (Dickenson and Sullivan 1993, Mao et al. 1995).
A number of clinical studies concerning this combined administration of morphi­
ne and local anaesthetics especially bupivacaine have been published (Sjoberg et al.
1991, 1994, van Dongen et al., Mercadante 1994). Until now, however, no prospec­
tive studies comparing the effecs of IT morphine with IT morphine/bupivacaine in 
cancer patients have been published..
6.3.2 Combining morphine with a 2 agonists
The combination of opioids and a2 agonists uses the inhibitory, descending, 
noradrenergic system to modulate noxious impulses at the level of the spinal cord. It 
remains controversial if these effects are also exerted via ^ or 5 receptors at the 
spinal level. This group of drugs, however, due to their effect at the adrenergic 
system, has also an effect on the autonomic nervous system and frequently causes 
sedation and hypotension. Clonidine administered IT alone, does not produce surgi­
cal analgesia despite severe sedative effects (Malinovsky and Bernard 1996). The
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evidence for a beneficial effect in clinical practice is scarce. Perhaps drugs which 
are even more selective may be even more specific in their effects.
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Summary
Cancer patients with inadequate pain relief and/or unacceptable opioid induced 
side-effects were selected for intrathecal (IT) treatment and were randomized to 
receive either morphine or a combination of morphine-bupivacaine IT in a double 
blinded prospective study. Quality of pain relief, side-effects and complications 
were noted during continuous infusion via a percutaneous IT catheter. In the morp­
hine group significantly more patients needed unblinding (57% versus 12 % P= 
0.0004; Fisher exact test) due to inadequate relief compared to the morphine-bupiva- 
caine group and showed a high incidence of intermittent and neurogenic pain com­
ponents. Pain relief improved after the co-administration of bupivacaine in the 
majority of these patients. Side-effects of the bupivacaine were minimal and short 
lasting. Technical problems with the IT catheterization mainly concerned short 
lasting postspinal headache and a number of CSF leaks. One patient contracted a 
meningitis, while in another patient a localized paravertebral infection presented. 
Our data confirm the safety of this technique and the risk of failure of IT morphine 
in progressive morphine resistant pain syndromes in cancer patients.
Key words. Cancer pain, intrathecal catheterization, long-term, morphine and 
bupivacaine.
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Introduction.
Although previous studies demonstrated the efficacy of long-term intrathecal (IT) 
morphine administration for pain relief in cancer patients (Onofrio and Yaksh 1990, 
Crul and Delhaas 1991), more recently the usefulness of this technique in complica­
ted pain syndromes has been questioned (Mercadante 1994, Sjöberg et al. 1994). 
Possibly due to the development of morphine resistant pain syndromes and the 
presence of tolerance, the efficacy of IT morphine is reduced (Abram 1993). As 
combinations of an opioid and a local anesthetic have suggested a greater effect on 
pain relief both perioperatively (de Leon-Casasola et al. 1994) as well as in animal 
experimental studies (Âkerman and Arwestrom 1988, Maves and Gebhart 1992), 
this IT technique used was modified for cancer patients unresponsive to IT morphi­
ne, to see if this combination might help (Sjöberg et al. 1991, van Dongen et al. 
1993). Despite an observed improvement of pain relief in a significant number of 
patients in whom the technique of IT morphine failed, long-term efficacy and side- 
effects remained unclear, as well as what were the indications for this technique 
(Sjöberg et al. 1994).
We therefore performed a prospective randomized, double blinded study compa­
ring the efficacy and side-effects of long term IT morphine versus IT morphine- 
bupivacaine in a series of cancer patients.
Methods.
From January 1992 till January 1996, 43 patients entered this double-blinded 
study, for which approval was given by the local Ethical Board .
Design of the study.
Patients were considered for IT treatment when the following inclusion criteria 
were met: pain presented due to cancer and was either (a) unresponsive to conventi­
onal treatment with adequate dosages of oral/ parenteral analgesics including morp­
hine or other opioids and/ or (b) was accompanied by unmanageable, unacceptable 
side-effects (Follett et al. 1992, Ballantyne et al. 1996,). Therapeutic neuro-ablative 
treatment (e.g. celiac plexus block, percutaneous cordotomy) was either not indica­
ted, impossible, refused by the patient, or had failed previously. Co-analgesics were 
also used in adequate dosages before IT treatment was considered, and palliative 
chemotherapy and/ or radiotherapy had been instituted when indicated (Mac Donald 
1993, Hoskin 1993 ).
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When, despite these measures, the patient considered the pain relief as determined 
by verbal rating and/ or VAS (visual analogue scale) or NRS (numerical rating 
scale) still inadequate, or unmanageable side-effects persisted, IT treatment was 
proposed and was initiated after explanation of the procedure and study protocol. 
Only those patients who consented to the study design and were expected to survive 
two weeks or longer after the start of the treatment were considered eligible for the 
double blinded part of the study.
Before final randomization into either the morphine or the morphine-bupivacaine 
group could take place, patients were separated into two groups according to the 
main indication for IT treatment; either (a) inadequate relief or (b) unmanageable 
side effects during conventional treatment (Fig. 1). Thereafter the most prominent 
pain syndrome(s) usually necessitating IT treatment was determined. The pain 
history, physical examination and other additional information (e.g. X-ray, CT scan) 
were used to obtain the most likely cause(s) of the pain complaints (Arner and Arner 
1985). As the patients were already divided into two main groups due to the indica­
tion for IT treatment, a further division according the pain complaints (continuous 
somatic and visceral versus intermittent and neurogenic pain) created a total of four 
sub-groups. Following allocation to one of the treatment groups by a blinded enve­
lope, eight treatment groups were finally formed (Fig. 1).
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This stratification was necessary, since we specifically wanted to study the additi­
onal effect of bupivacaine on pain relief in patients expected to be (relatively) 
unresponsive to IT morphine and also to prevent that the majority of patients with 
relatively morphine insensitive pain syndromes (Arner and Arner 1985) would be 
treated in the morphine group.
All IT catheters were inserted using an aseptic technique without antibiotic pro­
phylaxis under local anesthesia, and if needed, accompanied by sedation. Usually, a 
paramedian (lumbar) approach was used. After identification of the intrathecal space 
by a free flow of cerebrospinal fluid (CSF) the catheter was advanced five to ten 
centimeters intrathecally without using fluoroscopy. Subsequently, the catheters 
were tunnelled subcutaneously to the para-umbilical region to pierce the skin. To 
facilitate inspection and prevent accidental removal, fixation of the catheter at the 
skin took place with a transparant self-adhesive dressing (Tegaderm®) on the abdo­
minal wall, which was only changed when it became loose. No sutures were used 
(van Dongen et al. 1993). The external part of the catheter and anti-bacterial filter 
was taped on the skin, avoiding any local pressure. Since we intended to insert the 
catheter as close to the dermatomes of maximal pain intensity especially when 
administering bupiva-caine (Greene 1983), the catheter was inserted in the thoracic 
region in five patients. Here, the procedure was comparable to the lumbar approach 
except that the
(recumbent) patient was positioned on one side in a slight Trendelenburg position to 
increase the intrathecal pressure. Apart from slight paraesthesias in a number of 
patients of the total group during advancement of the catheter, all procedures were 
uneventful.
The initial morphine dosage of the infusate (morphine-HCl) was determined by 
using the previous oral morphine dosage in mg per day as a guideline (van Dongen 
et al. 1993). Usually, 1/60-1/100 of the previous daily (oral) morphine dose was 
infused IT as morphine-HCl per day. Standard (preservative-free) ampoules of 
morphine-HCl (10-20 mg/ml: Centrafarm, The Netherlands) and bupivacaine (0.5­
0.75% without adrenaline; ASTRA, Rijswijk, The Netherlands) were used and 
diluted with NaCl 0.9% to reach the desired concentrations by the department of 
Clinical Pharmacy to ensure blinding.
The IT morphine concentrations used, ranged from 0.5-1.0 mg/ ml with the lower 
concentration for those patients suffering from possible morphine induced side- 
effects (emesis, vomiting, sedation) at low oral morphine dosages (< 100 mg/day).
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Since our previous experience with this technique (van Dongen et al. 1993), it 
appeared that bupivacaine induced side-effects, especially in ambulatory patients, 
(disturbances in coordination and gait) could present if the bupivacaine dosage was 
increased rapidly. However, these side-effects were usually absent below a dosage 
of 15 mg per day. A high IT morphine infusion rate was therefore combined with a 
lower bupivacaine concentration. Thus, a mean IT morphine dose of 4-5 mg/ day in 
combination with 10-15 mg bupivacaine per day would necessitate a bupivacaine 
concentration ranging 2-3mg/ml (see Table I).
Table I. Relationship between preceding oral morphine dosage in mg. per day and IT morphine and 
bupivacaine concentration during IT treatment. The concentrations of bupivacaine in a 100 ml reservoir were 
prepared using bupivacaine 0.75% either 30 ml or 40 ml (respectively resulting in 2.25 and 3.0 mg/ml)
Initial Oral morphine 
dose/ day
< 100 mg 100-200 mg >200 mg
Intrathecal Morphine in 
mg/ml
0.5 mg/ ml 1 mg/ ml 1 mg/ ml
Intrathecal Bupivacaine 
in mg/ ml
3 mg/ ml 3 mg/ ml 2.25 mg/ ml
Oral morphine was gradually diminished in about two to three days (usually about 
50 % per day depending on the presence of side-effects and the quality of pain 
relief). When pain relief was adequate, other (co) analgesics were diminished and 
stopped whenever possible during hospital stay or soon after discharge. Pain relief 
as measured by verbal rating and NRS, side-effects (urinary retention, nausea / 
vomiting, itching, motor blockade, sensory disturbances, orthostasis and post-spinal 
headache) and the use of co-analgesics and catheter related complications were 
noted daily by the patients. When pain relief was inadequate as expressed verbally 
by the patient (arbitrarily correlated with a NRS decrease of less than two points), 
the pump flow rate was increased by one of us, unaware of the IT drugs used. Usual­
ly the infusion rate was increased using incremental steps of 0.1 ml.hr-1 once or 
twice daily, thereby increasing the total infusion rate per day of the (portable) infusi­
on pump (Pharmacia Deltec®, Woerden, The Netherlands).
The double blinded design was lifted when bupivacaine induced side-effect were 
suspected or when pain was still inadequately relieved despite changes in infusion 
rate. This was usually accompanied by the inability to diminish the (oral) morphine
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and took place within two weeks after the start of IT treatment.
In the M-group bupivacaine could be added subsequently, at the above mentioned 
concentrations (Table I) while the IT morphine dose per day was kept at the same 
rate. In the M/B group the infusion rate could either be increased or the relative 
amount of morphine and bupivacaine was altered to diminish side-effects. When 
these were considered to be mainly bupivacaine related, the local anesthetic was 
omitted in the following drug reservoir.
Patients were discharged when a satisfactory situation was reached concerning 
pain relief and side-effects. All patients were followed until the end of their IT 
treatment or death while they daily registered their pain relief and use of concomi­
tant analgesics (Savarese et al. 1988). Weekly telephone contact was made with the 
patients or their relatives and general practitioner to consider the overall effective­
ness and the presence of complications. If possible, the patients were seen at the 
outpatient clinic. The quality of pain relief (by VRS and NRS) was considered to be 
good, when patients experienced adequate pain relief on IT treatment only without 
additional (oral) morphine. Pain relief was considered to be adequate when a low 
daily additional dosage of (oral) morphine (below 100 mg oral morphine) was still 
necessary. Pain relief was considered to be inadequate or poor, when despite fre­
quent IT dose-adjustments and/or additional oral morphine treatment, pain was still 
insufficiently relieved or severe side-effects persisted. Also, when patients needed 
additional pain treatment (e.g. percutaneous cordotomy, neurolytic blocks), IT 
treatment was considered to have failed. Although infrequently used by most pa­
tients, additional IT bolus injection with the pump (usually the hourly dosage in 
ml/hr, once per hour) could be given. Routine care of the catheters was undertaken 
by the general practitioner or district nurses at home and the catheter was only 
disconnected from the pump reservoir under aseptic conditions (disinfection, wea­
ring gloves) to change the medication reservoir (usually 100 ml), the anti-bacterial 
filter and tubing.
By using a low flow rate a minimal infusion period of seven to ten days was 
usually possible (Krames 1993). Although patients were allowed to shower, taking a 
bath was not advised.
Statistical analysis.
The differences between both groups considering previous morphine use were 
analysed using a t-test. Since it was clinically important to differentiate between the 
group responding "poorly" and the groups responding "good" and "adequate" to IT
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morphine, these last two groups were taken together and compared with the "poor" 
group (see also Table III). Analysis took place by means of a Fisher exact test. Both 
tests considered P< 0.05 statistically significant.
Results
Initially 43 patients entered the double blinded part of the study. Of these, 22 
patients started in the M group and 21 patients in the M/B group. Their demographic 
data and oral morphine intake are shown in Table II.
Table II: Demographic data of total patient group after initial randomisation of tumors per treatment group. 
There are no statistically significantly differences between both groups. Finally the total patient group was followed for a 
total of 3515 treatment days (2610 in the M/B group and 903 in the M group) 1 Median Karnofsky score. 2 mean morphine 
dose per day preceding IT treatment.3 Number of patients presenting with different tumor processes. 4 Pain syndromes 
according to Arner and Arner: C= continuous; I=intermittent; V= visceral, S= somatic, N= neurogenic.
Morphine_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Morphine/ Bupivacaine
Demographic data
Age mean (range) 56 (23-74) 
cf/9 16/6 
Karnofsky1 (range) 60 (50-80) 
Morphine dose2 (range) 244 (30-800)
57 (36-83) 
15/6 
60 (40-80) 
224 (20-700)
Tumor types' prostate ca 8 prostate ca 2
pleuritis ca 2 colon ca 2
rectal ca 2 rectosigmoid ca 3
gastric ca 1 kidney ca 1
esophagus ca 1 breast ca 1
lung ca 1 lung ca 5
Ewing sarcoma 1 endometrial ca 1
adenoca e.c.i. 2 adenoca eci 1
ovary ca 1 urinary bladder ca 1
urinary bladder ca 1 lymphoma 1
pancreas ca 1 gallbladder ca 1
parotid gland 1 melanoma 1
oropharynx ca 1
Pain types1 CV 1 3
CS 3 3
IS 1
CV/CS 5 4
CS/CN 1 2
CV/CS/CN 1
CS/IS 3 5
CS/CN/IN 1
CV/IV 2 2
CS/IS/CN 2
CS/CV/IV 1
CS/IN 1
CS/IS/IN 2
Initial number of patients 22 21
Final number of patients 21 17
Indication for IT treatment
- inadequate analgesia 14 (67%) 13 (76%)
- side-effects 7 (33%) 4 (23%)
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In both groups a preponderance of men was seen. There were no significant 
differences between both groups considering age, Karnofsky status or previous 
morphine intake. Five patients (one in the M and four in the M/B group) could not be 
adequately followed for various reasons: in two patients insufficient data for follow- 
up were available while in another two, after a few days, the catheter appeared to be 
improperly placed (X-ray control because of inadequate relief). One patient died the 
day after the start of IT treatment due to a severe bleeding in her gastric carcinoma. 
These five patients all suffered from pain complaints with continuous visceral or 
somatic components. Finally, 38 patients (21 in the M and 17 in the M/B group) were 
followed prospectively and their data are shown above (Table II).
Overall quality of analgesia.
The overall quality of pain relief can be seen in Table III.
Table III. Quality of pain relief in M (21 patients) versus M/B group (17 patients) as determined by VRS and 
NRS: Good: no oral morphine; 2Adequate: oral morphine < 100mg./day ; 3Poor: despite oral morphine, dose 
adjustments insufficient pain relief by VRS and NRS. A statistically significant larger number of patients in the 
M-group experienced inadequate relief( P= 0.0004: Fisher exact test. Numbers of the “Good/ Adequate” group 
together versus the “Poor” group; see text for details).
Good1 Adequate2 Poor3
M 7 (33%) 2 (10%) 12 (57%)**
M/B 9 (52%) 6 (35%) 2 (12%)
In the M group a significantly larger amount of patients showed inadequate relief 
compared to the M/B group (57% versus 12%; P= 0.0004) despite comparable incre­
ments in IT morphine dosage. In ten patients, during the first five days of treatment 
and in two patients until day 20, pain relief was insufficient despite daily IT dose 
adjustments and additional use of their previous oral morphine, which therefore could 
not be reduced. After lifting the double blinded design, these patients all showed to be 
in the M-group. Since one patient refused a change in IT drugs, the remaining 11 
patients changed subsequently to the combination of morphine/ bupivacaine using the 
dosages as mentioned in Table I. Pain relief thereafter improved dramatically in these 
patients and was good in seven (63%) and adequate in two patients (18%). In two 
patients, however, despite frequent dose adjustments and additional oral morphine, 
pain relief did not improve (Table IV). Except for nine patients who died in the 
hospital due to their disease progression, the majority of patients could be discharged
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Table IV; Demographic data of the patients (n= 11) who failed to achieve adequate analgesia in the M only 
group.M1: morphine dosage in mg. per day (4 mean M dosage o f group) before start o f IT treatment.2 M/B dose: 
daily dosage of morphine and bupivacaine intrathecally.5 fent.: transdermal fentanyl preceding IT treatment, 
'mean bupivacaine dosage in mg per day IT. NRS‘ : b= before bupivacaine; a= after start o f  bupivacaine.
cf/?age Tumor Painsyndrome M 1 M/B dose1 Efficacy bupi NRS’b a Remarks
56 pancreas ca CV/IV 340 15/15 poor 8 8 int. visceral pain
9 55 lung ca CS 720 9.6/15 good 9 3
<f 66 adenocaeci. CS/IS/IV 80 10 /30 good 10 4
? 45 parotid ca CS/IS/IN 200 20/ 20 moderate 9 2 compr. o f spinal cord
ef 64 prostate ca CS/IS/CN 60 28/ 21 moderate 8 2 oral M/ epid.metastases
tf 64 prostate ca CS/IS/IN 480 7.2/21.6 good 10 2
<f 64 prostate ca cs/cv 120 3 0 /4 4 good 8 4 oral dextromoramide
? 23 Ewing sarc. CS/IS/CN 800 10/ 15 good 7 3 som .pain M responsive
¥ 46 ovary ca CS/CN 240 7.2/22 good 9 5
74 rectal ca CS/IN fent.1 3.6/21 good 8 5
if 44 prostate ca CS/CN/IN 200 9.6/9.6 poor 8 7 oral M/ epid.metastases
3444 21*
and died at home.
Side-effects and complications during treatment.
In the M/B-group, bupivacaine was stopped in three patients at their request becau­
se of difficulty in voiding. Two of these patients were bedridden and the change to 
morphine IT resulted in an improvement of these symptoms, while pain relief remai­
ned adequate. It was difficult to determine side-effects induced by either morphine, 
bupivacaine or their combination objectively due to the clinical condition of the in­
dividual patients. Nausea and emesis, possibly also morphine induced, were present in 
both groups whereas patients with intestinal (sub-)obstruction frequently vomited or 
were nauseated before the start of IT treatment. This made it difficult to determine the 
influence of morphine on these symptoms. Muscle weakness, how-ever, being possi­
bly bupivacaine induced appeared to be a more bothersome side-effect. In the total 
group of 38 patients, subjective muscle weakness in the leg(s) was shown in 21 
patients (55%). Of these, five patients were in the M-group. The bupivacaine dosage 
ranged from 9.6-50 mg/day (mean 23 mg/day IT) during the treatment. As in all of 
these patients pain relief was adequate and the weakness did not interfere with careful 
ambulation with a support, or the patient was already bedridden due to the previous 
pain complaints, bupivacaine could be continued. In the M/B group, nine patients 
showed a slight diminishment in sensation to pin-prick below the level of the groin on 
both sides, while this was present in three patients in the M group. Paraesthesia was 
present in five patients in the M/B and two patients in the M group. No treatment was 
required for this.
A more upsetting finding in two patients in the M/B group was a progressive
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neurological deficit with hypesthesia and paralysis of one or both legs resembling 
paraplegia. Neurologic and radiologic (CT and MRI scanning) evaluation confirmed 
metastatic compression of the cauda equina and the spinal cord at the high lumbar 
level in these patients respectively. After cessation of the bupivacaine administration, 
the addition of corticosteroids and radiotherapy, these symptoms were partly reversi­
ble. As a common finding beforehand, these patients all had severe, progressive back 
pain without remarkable neurologic findings before the start of IT treatment.
Urological side-effects mainly presented as urinary retention or urinary/ fecal 
incontinence. In the M group, continuous urinary bladder catheterisation was necessa­
ry in three patients (twice urinary and fecal, once isolated urinary incontinence) while 
this was necessary in three patients in the M/B-group as well. There were no clinical 
signs of bupivacaine induced orthostasis. Due to the IT catherisation, postspinal 
headache, visible loss of CSF along the catheter and signs of infection were the most 
bothersome complications. Their incidence is shown in Table V. In one patient a 
meningitis developed at day 160 shortly after an accidental disconnection of the IT 
catheter at home, while another patient obtained a paravertebral abcess after an une­
ventful IT treatment for more than a year. After appropriate treatment both patients 
made an uneventful recovery.
Table V: Side effects in total intrathecal patient group ( n=38)
Postspinal headache 14 (37%)
Epidural bloodpatch 5 (13%)
CSF loss in tunnel tract 3 (8%)
meningitis 1 (2%)
paravertebral abcess 1 (2%)
local infection tunnel tract 1 (2%)
Discussion.
This study shows that in a substantial number of patients adequate analgesia with 
IT morphine alone could not be reached, despite frequent dose adjustments, whereas 
in the patients receiving morphine/ bupivacaine the number of patients with inadequa­
te pain relief was significantly smaller (57% versus 12 %; P= 0.004). In the majority 
of the patients unresponsive to morphine alone, IT co-administration of bupivacaine 
subsequently improved pain relief.
Unresponsiveness to epidural (Arnér and Arnér 1985) and IT morphine in progres­
sive cancer syndromes was shown previously (Ventafridda et al. 1987, Mercandante 
1993, van Dongen et al. 1993, Sjoberg et al. 1994) and various causes must be consi­
dered e.g. presence of pain syndromes which are relatively morphine unresponsive
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due to a change in pain characteristics as a result of the tumor progression, as
well as tolerance for the analgesic effect of morphine. Also, psychological factors can
contribute to inadequate pain relief (Yaksh 1992, Portenoy 1994).
In the clinical situation an increase in pain intensity due to tumor progression 
usually responds to an increment of the IT morphine dosage. However, due to the 
alterations in the pain characteristics in cancer, especially following prolonged neuro­
pathic stimulation, dynamic changes in the nociceptive pathways in the nervous 
system may ensue (Meyers 1995) and it appears that this may lead to a diminished 
effect of morphine in these pain syndromes even without previous exposure to this 
drug (Mao et al. 1995a). At the same time, adaptation of the nociceptive system due 
to the administration of morphine may also interact, which was substantiated by a 
number of studies clearly showing that both prolonged neuropathic stimulation as 
well as tolerance for morphine are associated with similar subcellular changes i.e. a 
translocation of proteinkinase- C (PKC) (Mao et al. 1995 b, Mayer et al. 1995). This 
hypothesis, then, provides us with a theoretical basis for the clinical observation of 
the inefficacy of morphine in (cancer) patients with neuropathic pain who are also 
extensively exposed to morphine. Also, from these findings it is clear that it may be 
virtually impossible to determine clinically the relative contribution of the alterations 
in pain intensity, changes in the pain syndrome and morphine tolerance and their 
interaction to these subcellular effects.
The problems we encountered in the M-group refer to the mechanisms mentioned 
above; patients switching to the M/B group because of inadequate relief (Table IV), 
appeared to have more prominent intermittent and neurogenic pain components and 
used a higher oral morphine dose before the start of IT treatment compared with the 
other patients groups. However, this difference did not reach statistical significance 
(oral morphine in mg/ day: M-unresponsive group: mean 344 mg (range 60-800 mg) 
versus 244 mg (range 30-800 mg) in the total M group respectively (t-test, P= 0.14).
To improve pain relief in these patients, either an increase of the IT morphine 
dosage or a combination of drugs intrathecally can be selected.
Considering the mechanisms described above, increasing the dosage of IT mor­
phine is not only irrational, but also carries the risk of serious side-effects (Yaksh et 
al. 1986). Since our previous experience showed good results with a combined IT 
administration of morphine and bupivacaine, the second option was selected.
Combining drugs intrathecally may be considered for two important reasons (Dic­
kenson and Sullivan 1993). Firstly, due to their different effects on spinal noci
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ceptive processing the analgesic efficacy of the combination of the drugs can be 
synergistic (Berenbaum 1989) while, secondly, a combined administration can impro­
ve the quality of analgesia because a decrease in dosage and subsequent side-effects 
becomes possible. Both mechanisms can thereby lead to an improvement of pain 
relief when IT morphine alone, is no longer effective. Morphine leads to a hyperpola­
rization of the neuronal membrane, opening of the K-channels and subsequent reduc­
tion of the transmembranous Ca-flux (Dickenson 1991).
Additional blocking of Na channels by the local anesthetic and a decrease of 
impulse propagation may lead to a “complete” conduction blockade (Fraser et al.
1992).Visceral nociception might be more sensitive to this combined blocking effect 
than somatic nociception (Maves and Gebhart 1992) due to a specific influence on the 
C-fibres in particular (Penning and Yaksh 1992).
Although a synergistic effect for combinations of local anesthetics and morphine 
intrathecally in animal experimental (Maves and Gebhart 1992 , Akerman and Arwes- 
trom 1988, Penning and Yaksh 1992) and postoperative pain studies was substantia­
ted (de Leon-Casasola et al. 1994), a comparable study in cancer patients has not been 
reported previously. Long-term, prospective (double-) blinded studies, are difficult to 
perform in cancer patients, both due to the multifactorial nature of cancer pain but 
also due to the relatively short treatment period (Yaksh 1992).
Another drawback of these studies is that the stage of the disease, its progression 
and the related pain syndromes are unique for the individual patient, making randomi­
zation of treatments difficult (Max and Portenoy 1994). In order to circumvent part of 
this methodological problem the patients were stratified according to their (most 
prominent) pain characteristics, so that morphine resistant pain syndromes were 
equally divided between both groups. Following cross-over to the other (treatment) 
group, the patients could also act as their own control (McQuay 1991). As a specific 
problem in this study we were confronted with the frequent inadequacy of IT morphi­
ne only in the M group. We therefore stopped the double blinded part of the study 
after this series of 43 patients for ethical reasons, although we intended to include 60 
patients for statistical reasons.
The causes of the muscle weakness could not easily be determined objectively. 
Apart from the IT administration of bupivacaine, other factors such as a diminished 
physical condition (Karnofsky status) muscle wasting, prolonged bed-rest, catabolism 
or psychological factors (depression) have to be considered as well (Doyle 1993).
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The development of paraplegic symptoms in a number of patients in the M/B 
group was more distressing. They all initially presented with progressive back-pain 
which can be a diagnostic pit-fall in cancer patients especially when neurologic 
symptoms are subtle and thereby overlooked. Therefore, progressive morphine resis­
tant back-pain complaints should alert the clinician for possible compression of the 
spinal cord or cauda equina (Portenoy et al. 1987, van Dongen et al. 1997).
The most annoying catheter related side-effects were the presence of postspinal 
headache and persistent CSF leakage along the IT catheter (Table V). Remarkably, 
visible loss of CSF along the catheter tract was not synonymous with postspinal 
headache (PSH). Although in the majority of patients this symptom disappeared 
spontaneously, five patients needed treatment with an epidural blood patch. In one 
patient a meningitis developed associated with a recent, accidental disconnection of 
the catheter and leakage of CSF. In another patient, a paravertebral abcess presented 
which needed surgical treatment by incision. This appeared to be associated with 
accidental luxation of the catheter by the patient about a week previously. Treatment 
with systemic antibiotics following removal of the catheters led to an uneventful 
recovery in both patients. Although a number of disconnections took place in a few 
other patients at home, this did not result in infectious complications.
From these results its is concluded that the impossibility to alleviate pain with 
conventional routes of morphine administration, predicts unresponsiveness of IT 
morphine as well. One should even question whether IT administration of morphine 
is indicated in these patients. Although additional IT bupivacaine can improve pain 
relief it is important to consider neurologic complications due to the cancer process 
and changes of the pain characteristics as a cause for the progressive pain complaints 
first. Long-term IT morphine and bupivacaine administration by a continuous infusi­
on by an externalized catheter and pump, is an effective alternative with an acceptable 
risk-benefit ratio in patients with pain due to cancer. Future research should focus on 
the mechanisms of the interaction of different drugs administered intrathecally, 
providing a more rational application of combinations of these and other drugs 
(Yaksh 1991).
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Objective: To determine prospectively, a difference in intrathecal morphine dose progression 
between a continuous intrathecal infusion of a morphine/ bupivacaine mixture versus 
morphine, for pain relief in patients with cancer.
Setting: Institute for Anesthesiology, dept. of Pain Treatment, University Hospital Nijmegen, 
St Radboud, The Netherlands.
Patients: Twenty patients selected for intrathecal treatment because of either side-effects or 
inadequate relief during conventional pain treatment.
Outcome measures: Progression of intrathecal morphine dose during a phase of adequate 
analgesia in both groups following regression analysis and analysis of possible treatment 
related side-effects.
Results: The combination of intrathecal morphine plus bupivacaine resulted in a diminished 
progression of the intrathecal morphine dose (slope of regression line 0.0003 vs. 0.005, 
P=0.0001) during a phase of stable analgesia in comparison with the morphine group. No 
serious side-effects presented.
Conclusion: The diminished increase in the combination group is considered to be due to a 
synergistic effect of bupivacaine on the intrathecal morphine induced anti-nociception. 
Besides progression of the disease, tolerance to intrathecally administered morphine necessi­
tating a dose increment, can also develop during long-term intrathecal infusion in cancer 
patients.
Key words: Cancer pain, continuous infusion, intrathecal morphine and bupivacaine, 
synergism, tolerance
Introduction.
Long-term intrathecal (IT) morphine infusion can be considered for pain relief 
in cancer patients when inadequate analgesia or intolerable side-effects accompany 
conventional morphine administration (1). Also, failure to reach adequate analgesia 
during epidural administration of morphine may be considered another indication for 
the IT route (2,3).
A gradual increase of the IT morphine requirement has been shown in cancer 
patients during long-term IT treatment (4). Tolerance for morphine due to its previous 
exposure, changes in pain modality or intensity and psychological factors may all be 
equally important (5, 6). However, in patients with cancer, due to the progressive 
nature of the disease various reasons for this increase may be present simultaneously 
and it may be difficult to substantiate the cause(s). Although usually an increase of the 
IT morphine dose restores pain relief, the potential development of spinal excitatory 
phenomena makes this approach less attractive and should therefore be prevented in
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our view (7,8).
Combining IT morphine with a drug showing a synergistic effect on pain 
relief (9), can offer several advantages of specific importance in cancer patients. 
Firstly, due to the lower dose needed, side-effects of the individual drugs may 
diminish while, secondly, tolerance may develop at a slower pace (10). Finally, since 
local anesthetics possess a well documented synergistic effect on morphine induced 
spinal anti-nociception (11,12,13), pain syndromes which are less morphine sensitive 
might respond better to this combined administration (14). Despite the widespread 
clinical use of this combined (morphine/bupivacaine) technique a clear advantage of 
this approach in comparison with IT morphine alone, has not been substantiated in 
cancer patients mainly because it is usually difficult to determine a “stable” phase 
with adequate pain relief during the progression of the disease.
In order to determine whether a combination of morphine/ bupivacaine IT 
compares favourably with IT morphine with specific attention to the morphine dose 
increase with time, we propectively studied twenty cancer patients, all experiencing 
adequate pain relief during IT treatment. Special attention was paid to the dose 
progression of the IT morphine during treatment.
Methods.
Twenty patients were studied (Table 1) of whom 15 participated in a larger, 
prospective double blinded study, considering the long-term effects of IT treatment 
with morphine versus morphine/ bupivacaine. Approval for the study was given by 
the local ethical committee of the University Hospital Nijmegen and each patient 
entering the double-blinded study also gave written informed consent. During this 
study period, five patients, were treated in an "open" way as they were considered to 
have a poor prognosis due to the stage of their illness. The same IT technique, dose 
regimen and criteria for the increase of the infusion rate as in the double blinded part 
of the study were followed and after explanation these patients also gave their 
(verbal) consent for the IT treatment.
All patients were in the final stage of their life due to their progressive, 
frequently disseminated cancer (Table 1; see below).
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T a b le  I .  D e m o g ra p h ic  d a ta  o f  p a tie n ts  p re c e d in g  (p re  IT )  a n d  d u r in g  in tr a th e c a l  (IT )  t r e a tm e n t .
Morphine group
p a in d ru g s m o rp h in e 1 d a y s d ru g s
sexe age tu m o r s y n d ro m e ' b e fo re  1T! m a t  (m g) N R S 4 IT(ringc) d u r in g  IT 1 sid e -e ffec ts !
1 M  62 prostate IS A .B .D .E 200 6 191 B -
2 M 56 p leu ritis  ca. C V D .E .F 120 5 55 D urinary  ret
3 M 65 prostate C S A.D .G 60 7 61 nausea
4 M  66 eso p h ag u s CS/1S C E .P C C SO 8 57 C PSH
J  M 60 p leu ritis  ca, CV/1V B D .G 60 6 51 0 w eakness arm
6  M  59 proslate CS B .D .E .G 80 8 113 G depression /fear
7 F 82 uterus C S/C N B,H - 9 69 B sedation
8 F 40 cerv ix cs/cv epid. cath. -- 6 88 ■
9  M  49 urinary  b ladder C S iC V i.v. m orphine 600 8 82 E. •
M e in  60(40-12) 171 (60-600) 85(51-191)
(n u e )
Morphine/ S u p i m i n t  group E u p i m m e 1
10 M  53 colon CV B -C -D G 360 10 142 B (C .)G 27 PS H /B P , w eakness leg
1 1 F  4 0 m am m a C S/IS A .D .G 20 8 52 A .G 23 nausea/fear
12 M  67 colon C M S C .D 20 7 36 A .E 21 ■
13 F  41 cerv ix C V /C N D .E 500 9 46 ■ 10 PSH
14 F  54 pancreas cm Fint/PCB 180 7 29 ■ 5 ■
15 M  47 stom ach cm epid. cath. 6 33 • 14 *
16 F 40 colon C S/1S/CV B .D .G 210 6 41 G 28 n au sea /d ep re ss io n  (M > M /B )
w eakness  leg
17 F  35 cerv ix C V /IN B.D 200 6 40 • 36 - (M > M /B )
18 F  54 lung C S B D .E .G .I 280 9 22 • 10 w eakness  leg (M >M /B )
19 M  66 lung C S/IS/1V A .D .E 200 10 44 A .E .G 28 fear (M > M /B )
2 0  M  64 prostate CS/1S/IN A ,D .E .F 120 7 154 A 14 - <M >M /B)
M e m  S I  (35-67) 221(20-5«)) 58 (22-154) 20  (5-36)
1 C lin ic a l pa in  c h arac teristics a cc o rd in g  to  A m ir  (198S), S=  som atic , Vs  v isc era l, N =  n e u rogen ic : O  con tin o u s, I *  in le m i t le n t .1 D rugs before  and  du rin g  IT  trea tm en t: A : a ce tam inophen ; B: N S A ID ; C: 
b u p ren o rp b in e ; D : m orph ine ; E: an tldep ressan l/benzod iiH ep ines; F :a n lk o n v u ls a n t ;  G: c o rtico s te ro id ; H ; antipsychD lies; I: an ii-arry thm ics, PCC; p e rc u tan e o u s ce rv ica l co rd o to m y ; PCS', ce liac  p lex us b lock . Ftitt. 
I ran sdem ial f c n ia n y l .1 m orp h in e  m a s .: m ax im um  e q u iv a le n t o f  o ral m orph ine  dose  a t s ta r t IT  trea tm en t. ‘ N R S  a t s ta r t IT  t r e a tm e n t! jid e -e f le c ts  du rin g  IT  trea tm e n t PSH : p o s t sp inal h e adache ; B P: ep idura l 
b lo o d p a tch ;.1 m ax im um  b u p iv a ca in e  dose  in  m g per day. PSH : p o s t sp inal h e adache  BP: ep id u ra l b lo o d p a tch . pa tien ts co n v erted  from  M to  M /B g roup
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Conventional pain relief by the use of different drugs following the "analgesic 
ladder" and/ or neurolytic techniques when applicable always preceded the initiation 
of the IT treatment as described previously (15). When adequate pain relief (by verbal 
rating and/or VAS rating) could not be accomplished (16 patients) or unacceptable 
side effects (sedation in three patients, nausea in one patient) persisted, IT treatment 
was considered to be appropriate and initiated. In 18 patients the IT catheter was 
inserted at the lumbar level while in two patients the catheter was inserted at the 
thoracic level to make a segmental administration of additional bupivacaine possible 
(16). A paramedian approach under local anesthesia with sedation when necessary, 
was used and the catheter was tunnelled stepwise to the patients flank where it pierced 
the skin. The preservative-free IT drugs (MorphineHCl Centrapharm, Haarlem, 
bupivacaine 0.75 % ASTRA, Rijswijk, The Netherlands) were prepared by a person 
not being involved in the treatment after randomization of the patient in the double­
blinded group. As the starting IT dose per day, the previous total daily oral morphine 
intake in mg was divided by 60 and infused using a syringe driver (15). When 
adequate analgesia was reached, the syringe driver was replaced by a portable pump 
(Pharmacia Deltec R), usually with an initial flow rate of 0.1-0.3 ml.hr -1 (2.4-7.2 
ml.day -1).
In the M group, usually a solution containing 0.5-1.0 mg.ml-1 morphine in 
saline was used. In the M/B group, the bupivacaine concentration amounted 2.25-3.0 
mg.ml-1 in combination with the morphine concentration mentioned above. The lower 
bupivacaine concentration was used for those patients who needed a higher infusion 
rate due to their previous high conventional morphine intake. These infusion rates 
therefore resulted in a daily IT morphine dose ranging 1.2-7.2 mg.day-1 and bupiva­
caine ranging about 5-21.6 mg.day -1 .
Oral morphine intake was diminished by 50 % per day and was stopped at day 
three when possible. At the same time, the infusion rate of the pump was gradually 
increased at the patients' request (usually once daily, 0.1 ml/hr-1), until adequate anal­
gesia as determined by verbal or numerical rating was present.
When, despite these dose increases during the first week usually by doubling 
or tripling the total daily infusion rate, pain relief was still inadequate the double­
blinded treatment phase ended. If  morphine alone had been used, bupivacaine could 
then be added. This occurred in five patients, all in the morphine group, and they were 
followed and analyzed separately. When bothersome bupivacaine induced side-effects 
were suspected, either the infusion rate could be decreased, or the double blinded
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phase was stopped. Acetaminophen and NSAID's were continued unless side effects 
were present. Antidepressants or anticonvulsants were stopped whenever possible 
(Table 1). Intercurrent treatment with chemotherapy and/or radiotherapy to improve 
pain relief was not indicated in these patients (17). The contents of all the (blinded) 
cassettes were prepared by the Department of Clinical Pharmacy in our hospital. 
Change of the drug reservoir and disconnection of tubing could be kept to a minimum 
to avoid possible contamination by selecting a low infusion rate of the pump (18)
Standard catheter care was provided at home by the general practitioner or the 
district nurse, while logistic supervision was provided by a commercial firm speci­
alized in home care. Following telephone contact with the patient or their relatives, 
the pump flow rate (with morphine and bupivacaine doses in mg.hr-1.), use of conco­
mitant analgesics, side-effects and (infectious) complications were noted once 
weekly. Quality of analgesia was determined by a verbal rating scale (VRS) and a 
numerical rating scale (NRS) and, if  possible, by a VAS. Also use of concomitant 
analgesics, especially opioids was considered to reflect adequacy of pain relief. A 
general impression of the overall quality of pain relief was determined by telephone 
interview of the general physician of the patient. If possible, patients visited the 
outpatient clinic, however, during the final week or days before death, no visits were 
paid to the hospital unless catheter dysfunction as a cause for pain increase was 
suspected.
Of the total group of 20 patients, finally nine patients entered the M group and 
eleven were treated in the M/B group (Table 1).
All twenty patients studied here experienced adequate pain relief during IT 
treatment from day 10 to day 45. They were selected from a group of patients who 
entered a double-blinded study as mentioned previously while five patients were 
added to this study group and could be followed prospectively as well. These latter 
patients were treated in an open way in order not to unduly lengten their hospital stay. 
This explains the uneven distribution between the M and the M/B group in Table 1. 
Since we were specifically interested in the progression of the IT morphine in either 
group, the mean morphine dose in mg.hr-1 was calculated for each group and plotted 
against time during the study period by use of Quattro ProR. Because the five patients 
who failed to reach adequate analgesia were all in the M group and were converted to 
the M/B group before day five, their data were added to and analyzed in the M/B 
group from day one. Following linear regression analysis of the mean morphine dose, 
the increase in IT morphine dose was determined by the slope of the regression line.
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Since the number of patients gradually diminished during follow-up, especially in the 
M/B group after day 40 (from nine to five patients), and frequent IT dose increments 
were necessary during the first ten days due to tapering of the conventional morphine, 
linear regression analysis was performed from day 10 to day 30 in both groups. Inter­
group differences were calculated by ANOVA considering a P < 0.05 significant.
Results
Nine patients (Table 1) in the M group were treated with a mean duration of 
85 days (total duration of treatment 767 days) while 11 patients were treated with a 
mean duration of 58 days (total duration of treatment 639 days) in the M/B group 
respectively. Their demographic data, tumor types and pain characteristics and drugs 
before and during IT treatment are shown in Table 1. The five patients in the M group 
who were converted to the M/B group are shown as patient number 16-20.
In all patients IT treatment during the study phase resulted in good pain relief 
as determined by the numerical rating at the start and during a phase of stable treat­
ment as shown in Figure 1.
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F ig u re  1. Pain intensity as expressed by num erical rating scale (N RS) before and during stable I T  treatm ent (day
10- day  40) in the M (left) and  the M/B (right) group.Both treatment regim ens resulted in adequate pain re lief as
shown by a decrease in N RS and by verbal rating o f  the patients and the need fo r concom itant analgesics (see
also T able I)
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In both groups, a gradual increase in the IT morphine dose in mg.hr-1 was seen during 
the treatment. As the IT morphine dose at the start of the treatment was calculated 
directly from the previous oral morphine intake and this appeared to be lower in the 
M group, the initial IT morphine dose was significantly lower in the M group than in 
the M/B group (0.11 versus 0.16 mg.hr-1; P=0.0001). The dose progression of morphi­
ne in the M group, as expressed by the slope of the regression line from day 10 to day 
30 was higher than the dose progression of morphine in the M/B group (slope 0.005 
versus 0.0003, P=0.0001, respectively Fig. 2).
Since Figure 2. shows all patients in both groups, and the M/B group contains 
a subset of five patients who, due to inadequate analgesia switched from the M to the 
M/B group, these patients were shown separately (mentioned “failure group”) in 
Figure 3. Their data are shown in comparison with the "total" and "initial" M/B group 
(those patients that started and remained in the M/B group during their treatment). As 
can be seen, the slope of the M/B" initial" group is flatter than the "total" M/B group.
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0 .10-1---- I---- T-------.-------T---- .---- ,---- ,---- T---- .----
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days
F ig u re  3 . T h e  M /B  g ro u p  is su b d iv id ed  in to  th ree  g ro u p s  here. A n  u p p er line (fa ilu res  M , fiv e  p a tien ts) d ep ic ­
tin g  pa tie n ts  w h o  fa iled  on  M - o n ly  an d  w ere  co nverted  to  th e  M /B  g roup ; a  m idd le , d ash ed  line  (to ta l, 1 1 
p a tien ts) sam e pa tien ts  as show n  in F igure  2 fo r th e  to ta l M /B  group ; a  low er line  (in itia l M /B  g ro u p ) sh o w in g  
six  pa tien ts  w h o  started  and  rem ained  in the  M /B  g ro u p  w ith  ad eq u a te  re lie f. S ince  the  d iffe ren ce  be tw een  the  
reg ressio n  lines o f  the  M  and  the  M /B  g ro u p  w as a lready  statistica lly  d iffe ren t (F igu re  2 ), n o  fu rther reg ressio n  
an a ly sis  w as  p e rfo rm ed  be tw een  th is  initial M /B  g ro u p  w ith  the  M  g ro u p  from  F ig u re  2.
In only one patient in the M group (patient no 2; table 1) was oral morphine 
necessary to achieve adequate analgesia. All the other patients did not use additional 
morphine after day three. In the M/B group, five patients achieved adequate analgesia 
with IT treatment only without use of any other analgesic. This occurred in two 
patients in the M group (Table 1).
In patient no 10 (M/B group) objective unilateral muscular weakness was 
demonstrated at a bupivacaine dose of 21 mg.day-1. This, however, did not interfere 
with walking. Subjective weakness was present in three other patients (two in the 
M/B group in the legs and one in the M group in the arm). Due to their poor clinical 
condition, interference with walking could not be determined. No local infection or 
meningitis was encountered. All patients were discharged when pain relief was 
adequate.They all died at home except one patient in the M group (patient no 6) who 
died in our hospital.
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Discussion.
In this analysis, we were interested in the effect of IT co-administration of 
bupivacaine on the rate of IT morphine dose-progression in cancer patients experien­
cing adequate analgesia. Both the M as well as the M/B group showed a gradual 
increase in the IT morphine dose, however, in the M/B group the rate of increase was 
less. The main reason for this difference between both groups, was considered to be - 
caused by the intrathecal co-administration of bupivacaine.
However, there may be various other explanations for the differences observed 
here, such as the morphine responsiveness of the pain syndrome, the rate of progressi­
on of the disease itself, a previous high conventional morphine intake causing 
tolerance and, finally, psychological factors.
Since relatively morphine resistant pain syndromes (5) were about equally 
divided between both groups (Table 1), the larger morphine dose progression in the 
M-group was probably not caused by major differences in pain characteristics. Since 
an increase in nociceptive stimulation necessitates a higher IT morphine dose (19), 
one might consider the differences in dose increase to be the result of a difference in 
disease progression between both groups. This, however, is in contrast with the 
shorter mean survival time in the M/B group which suggests a more rapid disease pro­
gression in this group. This appeared not to be associated with the need for a higher 
IT morphine dose, making it unlikely that the differences in dose increment seen 
would reflect a change in the disease progression and the performance status of the 
patient.
Tolerance for oral morphine may be associated with a diminished efficacy of 
IT morphine and thus a more rapid dose escalation (19). However, despite the higher 
(calculated) IT morphine starting dose, the rate of the increase of the IT morphine in 
the M/B group was smaller than in the M group. Finally, although patients did not 
undergo extensive routine psychological testing to determine a difference between 
both groups, clinically both groups were comparable (Table 1) .
From these findings we postulate that the differences in morphine dose 
progression as seen here, were caused by a synergistic effect of the bupivacaine on the 
morphine induced anti-nociception (20). Animal and human studies of mainly short­
term IT morphine/ local anesthetic administration also confirm these augmentive 
effects of local anesthetics on morphine induced anti-nociception (11,12,13). An 
explanation is sought in the respective cellular effects of both compounds.
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Since m orphine opens K- channels in the neuronal m em branes leading to 
cellular hyperpolarisation and local anesthetics, by blocking the Na- channels in their 
turn, dim inish the calcium  flux through them, their com bination w ill lead to a further 
im pedim ent o f  im pulse generation and propagation. Im provem ent o f  anti-nociception 
follow ing com bined IT adm inistration w ill ensue (20). Also, an interference w ith 
nociceptive processing in different areas in the dorsal horn o f  the spinal cord (12) can 
explain the im proved efficacy o f  this com bination. Since it has been shown that the 
rate o f  tolerance developm ent is closely associated w ith the am ount o f  receptors 
occupied in order to reach the desired effect, ( i.e. analgesia (9)) a drug w hich needs a 
low  fraction o f  receptors occupied (FRO) w ill result in a slow developm ent o f  
tolerance. This has been substantiated for IT sufentanil com pared to IT m orphine
(22). A ccording to this concept, the developm ent o f  tolerance for m orphine could thus 
be influenced by  a technique o f  a com bination o f  drugs w hich  possess a synergistic 
anti-nociceptive effect, thereby decreasing the am ount o f  m orphine needed to  bind to 
the receptors to initiate an antinociceptive effect.
A nother consideration here is that a com bination o f  synergistic drugs IT could 
have a beneficial effect on the quality  o f  pain re lie f and thereby also on the rate o f  
m orphine increase w ith tim e as shown here (10,13,20). Since clinical studies o f  long­
term  IT m orphine/ bupivacaine adm inistration are usually lim ited to preterm inal 
cancer patients responding inadequately to previous conventional analgesic treatm ent
(23), a selection o f  patients w ho are em otionally disturbed due to pain com plaints, - 
m ay take place. This m ay be another reason w hy IT  m orphine only, fails after 
extensive pre-treatm ent w ith  m orphine in these patients.
To our know ledge, to date, despite a large num ber o f  open studies no 
prospective clinical studies com paring the effect o f  M  versus M /B intrathecally have 
been perform ed in cancer patients. In this respect it is o f  im portance that this potentia­
ting effect already presents at relatively low  daily dosages o f  bupivacaine (Table 1) 
w ithout causing serious side-effects. This can be a m ain draw back w hen bupivacaine 
is used at h igh doses (23).
Despite the shortcom ings o f  our study, such as the small num ber o f  patients in 
both  groups and a relatively short treatm ent period, w e conclude that bupivacaine has 
a synergistic effect on IT m orphine induced analgesia in these patients.
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Since it is shown here that this technique can influence tolerance development, 
it may be considered to start with this combined technique, even in morphine respon­
sive pain syndromes, from the beginning of IT treatment. Furthermore, this approach 
could also prevent the development of excitatory phenomena associated with high IT 
morphine doses (8). It remains to be shown if the efficacy of this combined admini­
stration may improve the quality of pain relief in relatively morphine unresponsive 
pain syndromes. Although severe neurological deficits due to the bupivacaine could 
not be demonstrated here, clinical assessment of possible side-effects has to be 
undertaken during this IT treatment to differentiate from tumor associated neurologic 
complications (23,25). A prospective study especially considering these side-effects 
and analgesic efficacy of higher doses of bupivacaine is currently under way.
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Abstract
Adequate pain relief in patients with far advanced cancer sometimes requires 
intrathecal (IT) administration of a combination of opioids and local anesthestics. 
Tumor progression as well as the IT administration of local anesthetics can lead to 
neurologic dysfunction during treatment. Five patients showed symptoms of compres­
sion of the cauda equina or spinal cord shortly after the start of combined IT 
administration of morphine and bupivacaine in a dosage usually not associated with 
neurologic symptoms. Unexpectedly, neurologic evaluation suggested compression of 
the cauda equina and spinal cord, which was confirmed radiographically. Manifestati­
on of new neurologic symptoms during low dose bupivacaine infusion intrathecally 
might therefore be an early indicator of space occupying processes within the spinal 
canal in cancer patient s
Key words: Intrathecal morphine/ bupivacaine; metastatic cancer; neurologic dys­
function; spinal cord and cauda equina compression
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l.Introduction
In about 15% of cancer patients, neurologic symptoms can be present during 
the course of the disease (Posner 1995). Compression of the spinal cord or cauda 
equina manifests clinically in about 5% of cancer patients (Gilbert et al., 1978, Schiff 
et al., 1995) and is usually accompanied by pain complaints in the back, with or 
without radiation into an extremity. Frequently, sensory disturbances, motor weakness 
ultimately leading to paralysis, and problems with fecal and urinary continence can 
follow if left untreated (Portenoy, 1987).
In some of these patients, pain relief can either remain inadequate despite the 
administration of various analgesics including opioids or can be accompanied by 
intolerable side-effects. Spinal (i.e. epidural, intrathecal (IT)) administration of 
morphine may then be considered (Krames et al., 1985, Onofrio and Yaksh, 1990) 
although neurogenic pain components do not always respond favourably (Arnér and 
Arnér, 1985; Max et al., 1985). Recently a combination of intrathecally administered 
morphine and bupivacaine (an amide-type local anesthetic) was proposed as a step 
forward toward the solution of these intractable pain problems (van Dongen et al., 
1993; Sjoberg et al., 1994). Usually a wide dosage range of IT bupivacaine is tolera­
ted without severe side-effects below a bupivacaine dosage of 45 mg.day-1 (Sjoberg et 
al., 1994), but individual titration remains mandatory to prevent neurologic dys­
function. We report five cancer patients who developed unexpected, severe, neuro­
logic disturbances during continuous, low-dose, IT morphine/ bupivacaine infusions. 
The clinical signs, differential diagnosis and management are described.
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2. Case Histories
2.1 Patient nol
A 63 year old man suffered from increasing back pain, radiating into the anterior side 
of both legs despite high oral morphine (480 mg.day-1) intake. The pain was related to wide­
spread bone metastases of a prostatic carcinoma. Diffuse vertebral metastases were shown 
previously on bone scan. Neurologic function was normal. A lumbar IT catheter was inserted. 
As an initial IT infusion of morphine (9.6 mg.day-1) did not result in adequate pain relief, 
bupivacaine (15 mg.day-1) was added to the infusion. Pain relief improved but was accompa­
nied by complete motor and sensory block of the left leg below the L2 dermatome and urinary 
incontinence. CT scanning performed thereafter was suspicious for epidural compression of 
the cauda equina at the level of Th12-L3 (Fig. 1). Systemic corticosteroids and radiotherapy 
resulted in relief of the pain and partial restoration of motor function thereafter. The IT 
infusion was continued until death, due to repiratory insufficiency, two weeks later, without 
progression of motor weakness in the legs.
Fig 1. CT-scan (transverse plane) at the 
level of Thl2 of patient I showing pa­
thologic changes in the posterolateral 
border o f the corpus o f the vertebra, 
lining the spinal canal (asterisk). Disap­
pearance o f the epidural fat is highly 
suggestive for epidural metastasis here.
The white dot (arrow) in the anterior 
part of the spinal canal is the IT cathe­
ter.
2.2 Patient no 2
A 45-year-old woman presented with vertebral metastases, nine years after primary 
resection and radiotherapy of an adenocystic carcinoma of the parotid gland. One year before 
the start of the IT infusion for pain relief, radiotherapy to the vertebral column was started for 
complete destruction of the body of the LI vertebra. At that time, a pathological fracture of LI 
with compression of the cauda equina and the spinal cord with weakness of both legs was 
present.
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Following radiotherapy and corticosteroids, an initial deterioration in neurologic 
function, with progressive motor weakness of the legs and problems with micturition, were 
present but these symptoms gradually disappeared with minimal radiation of pain into the 
right leg in the weeks thereafter. On readmission one year later, a "belt-like" pain in the lower 
back and legs had returned despite high doses of oral morphine, dextromoramide, car- 
bamazepine and tricyclic antidepressants. Slight paraesthesiae were present in the right leg 
without signs of motor weakness. A lumbar IT catheter was inserted and as morphine only 
(7.2 mg.day-1) did not result in adequate pain relief, a mixture of morphine/ bupivacaine was 
infused continuously thereafter. At a dosage of 7.2 mg morphine and 21.6 mg bupivacaine per 
day, the patient experienced severe muscular weakness in both legs and inability to walk 
alone. Diminishing the daily IT bupivacaine to 7.2 mg, adding clonidine (150 ^g.day-1) and 
increasing the morphine (14.4 mg.day-1), resulted in improved motor performance and 
adequate pain relief. During palliative treatment at home, paraplegia probably due to ongoing 
spinal cord compression presented before death.
2.3.Patient no 3
A 67-year-old woman presented with severe low back pain radiating to the thoracic 
region as well as the back and sides of both legs despite oral morphine (260 mg.day-1). Global 
hypesthesia was present from the groin down to the feet in both legs. Five years previously, a 
Grawitz tumor with local-regional spread was resected. A year before start of IT treatment, 
multiple pathological fractures in both humeri and left femur developed, all treated palli­
atively by osteosynthesis and radiotherapy. Because of persistent, severe back pain, a lumbar 
IT catheter was inserted, delivering a combination of morphine and bupivacaine and resulting 
in significant decrease in pain. Following a gradual increase of the infusion rate during the 
three days thereafter, motor blockade in both legs and loss of bladder control developed at a 
bupivacaine dosage of 36 mg.day-1. The bupivacaine dosage was reduced to 15 mg.day-1 while 
morphine remained at around 15 mg.day-1. Epidural compression or lumbar plexopathy was 
suspected. On MRI scanning (see Fig 2.) a large mass could be seen eroding the posterior side 
of the body of L4 with extension into the epidural space, completely occluding the spinal 
subarachnoid space.
Fig 2 . M R I- sc a n  o f  p atien t III (sa g itta l 
p la n e ) at the lu m b ar a rea . A  la rg e  m a ss  
in co n tac t w ith  the the L  IV  v erteb ra , 
c o m p le te ly  f i lls  the sp in a l can a l at th is 
lev e l.
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Oral dexamethasone 16 mg.day-1 was started and despite a slight increase of the 
bupivacaine to 24 mg.day-1 neurological improvement with restoration of assisted walking 
could be attained. The patient died at home free of pain with slight motor weakness at day 42 
without further increase in IT infusion rate.
2.4. Patient no 4
A 45-year-old man underwent sigmoid resection because of adenocarcinoma one year 
before the start of IT treatment. As a child, he contracted poliomyelitis and meningitis. 
However, neither had any deleterious long-term effect on motor function in his legs. Subse­
quent chemotherapy (5 FU, methotrexate) to treat liver metastases during the year following 
the operation, did not result in remission of the disease. Unbearable, lancinating pain attacks 
radiating from the groin into his left leg and foot were accompanied by sensory loss and 
paraesthesiae in a skin area in the left lumbosacral region. Clinically, a lumbosacral ple- 
xopathy due to tumor invasion or compression was suspected. Other neurologic signs were 
limited to slight difficulty with micturition without signs of motor impairment. A plain X-ray 
of the lumbar vertebral column one month previously did not show abnormalities. Further 
radiologic examination was not performed. Slow release oral morphine (MS continR; 30 mg 
bd), amitriptyline and carbamezapine, did not result in adequate pain relief and severe neuro­
pathic pain attacks persisted in combination with bothersome sedative effects. A lumbar 
subcutaneously tunneled IT catheter was inserted. A solution containing morphine HCl 0.5 
mg.ml-1 and bupivacaine 3 mg.ml-1 was started and gradually increased to a rate of 0.3 ml.hr-1 
(3.6 mg morphine and 21.6 mg bupivacaine per day respectively). Progressive neurological 
dysfunction with proximal and distal motor weakness in his left leg and global hypesthesia of 
the dermatomes L5 to S5 with inability to void developed at this dosage within 48 hours, 
whith adequate analgesia. Although bupivacaine induced side-effects were suspected, cauda 
equina compression due to epidural tumor spread was also considered. On MRI scanning, a 
large tumor mass eroding the sacral area from the left and extending to the pelvic cavity was 
observed.
The sacral canal was compressed due to epidural tumor growth. Palliative radiothera­
py and oral dexamethasone were started. The IT infusion was not diminished due to the 
patient's severe anxiety that the pain would return. The paralysis of the left leg did not subsi­
de. The patient was discharged with continuation of the IT treatment and died at home, free of 
pain, without additional analgesics, four weeks later.
2.5. Patient no 5
A 67-year-old man was treated by radiotherapy to the right lung and mediastinum for 
squamous cell bronchial carcinoma three years before admission. Due to progressive tumor 
growth with invasion of the thoracic vertebrae (Th11-12) and spinal canal with imminent 
spinal cord compression, palliative radiotherapy was started.
As conventional pain relief was inadequate and accompanied by severe constipation, an IT
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catheter was inserted at a lumbar (L2-L3) interspace initially delivering morphine 4 mg.day-1. 
As pain persisted, bupivacaine was added IT at a dosage of 2.5 mg.day-1. Despite adequate 
pain relief, 10 days after catheter insertion, paraplegia developed with suspicion of ongoing 
compression of the cord. However, cessation of the IT bupivacaine and increase of morphine 
IT (6 mg.day-1) resulted in complete restoration of motor function of the legs with adequate 
pain relief thereafter. No neurological symptoms recurred before death.
3. Discussion
In progressive cancer syndromes, severe back pain in combination with motor 
and sensory disturbances in a leg and problems with micturition can be caused by 
compression of the spinal cord or cauda equina as well as by tumor infiltration of the 
nerve roots or plexus (Jaekle et al., 1985; Portenoy et al., 1987). In these situations, 
increasing the dosage of analgesics, including morphine, is usually considered first. 
Also co-administration of anticonvulsant, antidepressant drugs or corticosteroids can 
be beneficial (Portenoy, 1991; Cherry and Portenoy, 1993)
Even when morphine is administered intrathecally, pain relief can still be 
insufficient especially when neurogenic pain components are present. Co-administra­
tion of bupivacaine IT has been advocated to improve pain relief substantially in these 
situations and we used this technique in our patients (Sjoberg et al., 1991). Morphine 
IT does not give rise to motor or sensory impairment and IT bupivacaine below a 
dosage of 45 mg.day-1. by continuous infusion has been reported not to produce 
neurological side-effects either (Sjoberg et al., 1994). We did not observe neuro­
logical deficits below a bupivacaine dosage of 30 mg. day-1 IT in a study of patients 
with an undisturbed neurologic history (van Dongen et al., 1993), and thus we did not 
expect to be confronted with such profound neurologic changes with these low IT 
bupivacaine dosages.
Severe pain complaints usually precede the clinical manifestation of compres­
sion of the spinal cord or plexus invasion during a variable period (Gilbert et al., 
1978) in which the patient is usually just able to compensate for the impaired neurolo­
gical function. Moreover, estimation of normal activity is severely impeded by the 
pain complaints. Subsequent effective pain treatment with a combination of IT morp­
hine/ bupivacaine might lead to "unmasking" of the subtle neurological deficits,
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which would otherwise stay undetected for a further period.
One might argue therefore that the neurological deficits found were merely the 
result of ongoing compression. On the other hand, in all patients, neurologic symp­
toms were related to the start of IT bupivacaine infusion or improved following the 
diminution of the IT dose. This is highly suggestive of a bupivacaine-related effect in 
these patients. Early diagnosis and adequate treatment of compression is important as 
the outcome is closely related to the duration of the compression and the neurologic 
deficits at the moment of diagnosis (Portenoy et al., 1987; Schiff et al., 1995).
As a differential diagnosis for neurological deficits in cancer patients with pain
Tabic  I. Differential diagnosis o f  neurologic sym ptom s in cancer patients.
- due to endocrine disturbances (c.g ADH, glucose, Ca, electrclytcs)
- primary treatment related (chcmotherapy-radiothcrapy.)
and dysfunction in a leg, lumbosacral plexopathy should be considered (Jaeckle et al., 
1985). Finally, infectious complications (meningitis, abscess formation), epidural 
hematoma formation both due to the presence of the IT catheter and late effects of 
radiation myelopathy may give rise to similar neurologic dysfunction (Wara and 
Larson, 1991; Table I).
In these patients, however, these causes were excluded due to the absence of 
related clinical manifestations and the partial reversibility of the symptoms following 
the reduction of the bupivacaine administered.
It is unclear what is the exact mechanism of this increased "susceptibility" for 
bupivacaine IT in these patients. We assume that the neurologic disturbances were 
caused primarily by the subclinical compression of the spinal cord and cauda equina, 
which can be overlooked easily during initial patient evaluation. Extreme neurogenic 
pain complaints can hinder ambulation and routine neurologic testing, whereas the 
unselective sensory and motor blocking effects of bupivacaine interfere with this
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compromised neurologic status.
A wide range of IT bupivacaine dosages seems to be tolerated (Sjoberg et al., 
1994) suggesting differences in sensitivity, probably influenced also by 
pharmacological factors. Both pharmacokinetic (e.g., altered distribution of the drug 
in the CSF with locally increased concentrations due to obstruction of normal CSF
T ab le  II. D osages of bup ivacaiae IT and clin ica l si™ns d u rin g  n eu rologica l d eficit.
Patient bupivacaine1 radiography
1 15 mg.day1 compression Thl2-L2
jL 22 mg.day1 compression LI
3 36 mg.day1 compression L4
4 22 mg.day1 compression cauda
5 2.5 mg day1 compression T hll-12
1 Dosage o f bupivacaine in mg.d ay  1 b y  continous IT intusion at moment o f neurologic d efic it
flow; proximity of the catheter tip to a spinal root) as well as pharmacodynamic 
factors (e.g., increased toxicity of local anesthetics in the presence of neurologic 
dysfunction, changes in CSF composition or pH), may be of importance (Jones and 
Healy, 1980).
In our view, the most striking observation in the patients reported here was, 
that neurologic deterioration took place during a low dose IT administration of 
bupivacaine while other symptoms suggestive for spinal cord or cauda equina 
compression were clinically absent or unremarkable.
The continuous IT co-administration of bupivacaine with morphine, necessita­
ted by the pain syndrome, more or less "revealed" the presence of compression. When 
this occurs in patients with previous relatively undisturbed neurology, one should 
consider this as additional diagnostic information. We recommend that besides the 
pain history and diagnosis of the pain syndrome (Arner and Arner, 1985), a neuro­
logical examination combined with radiographic evaluation of the vertebral column 
including CT or MRI is considered before the start of IT treatment. This may even be 
more important when the use of IT local anesthetics seems to be inevitable.
Specific attention should be given to those patients suspected of having 
compression of the cord and cauda equina, as conventional radiologic examination 
may show no abnormalities and MRI scanning is not always available. Early diagno­
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sis of the likely cause of neurological deterioration after initiation of IT morphine/ 
bupivacaine administration is important, not only when there are still palliative 
treatment modalities available but also because neurological deterioration may have 
devastating functional and emotional consequences.
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8.2
Epidural fibrin glue injection stops persistent cerebrospinal fluid leak 
during long-term intrathecal catheterization
Bas M. Gerritse M.D., Robert T.M. van Dongen M.D. and Ben J.P. Crul M.D., Ph.D.
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Introduction.
The leakage of cerebrospinal fluid (CSF), during the initial phase of long term 
intrathecal (IT) infusion of analgesics, can be a bothersome complaint. A series of 98 
cancer patients were treated with an IT catheter in this hospital in one year; 8% 
showed a persistent leakage of CSF via the catheter tract.
In a previous series, 26% of the patients had a persistent CSF leakage (1). Treatment 
of CSF leakage can be undertaken with an epidural blood patch, however in our 
experience this is not always successful in cancer patients. Three patients in whom 
persistent CSF leakage was succesfully treated with an epidural injection of fibrin 
glue (Tissucol R, duo 500, Immuno AG, Austria) are described.
Key W ords: Intrathecal infusion; Cerebrospinal fluid leakage; Fibrin Glue; Epidural blood 
patch; Cancer Pain
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Case Reports
Patient 1
A 50 year old man complained of increasing pain and sensory disorders in his left leg. 
A sigmoid resection for adenocarcinoma was performed two years previously, and chemo­
therapy given. At Magnetic Resonance Imaging, compression of the S1 level cauda equina 
due to massive parasacral tumor growth was confirmed. As analgesia with acetominophen, 
oral morphine and amitryptiline was insufficient, a 20 gauge epidural catheter (Braun Perifix 
R, Melsungen Germany) was inserted using a 18 gauge Tuohy needle by paramedian 
approach at the lumbar level. Pain relief improved significantly during IT infusion of 
morphine and bupivacaine (2). Leakage of CSF at the puncture site was observed six days 
after introduction of the IT catheter. The patient had no symptoms of postdural puncture 
head-ache (PDPH) or meningitis. An epidural blood patch with 10 mL autologous blood was 
performed at an interspace above the catheter entry site, but the CSF leakage continued abun­
dantly necessitating frequent change of dressings. As pain relief was adequate and the patient 
feared return of his symptoms upon cessation of IT infusion, treatment with an epidural 
injection of fibrin glue was suggested. A lumbar epidural injection of 4 mL of fibrin glue was 
given one interspace cephalad of the original puncture level, with the IT catheter in situ. The 
CSF leakage stopped the same day, there was no increase in the neurological impairment of 
the patient. The IT infusion was continued until death due to respiratory insufficiency two 
weeks later, which was attributed to the natural progression of his disease and unrelated to 
our procedure.
Patient 2
A 59 year old woman presented with severe low back pain radiating to the thoracic 
region and the side of both legs despite oral morphine. Global hypesthesia was present from 
the groin down to the feet in both legs. Five years previously, a malignant hypernephroma 
with local spread was resected. A year before starting IT treatment, multiple pathological 
fractures in both humeri and left femur developed. All were treated palliatively by osteosyn­
thesis and radiotherapy. Because of the persistent severe back pain, a lumbar IT catheter was 
inserted using the same technique as described above (20 gauge catheter Braun Perifix 
Melsungen Germany). Cerebrospinal fluid leakage at the puncture site was observed after 
eight days, without signs of PDPH. Despite an epidural blood patch of 10 mL autologous 
blood at the lumbar region, the CSF leakage persisted in the consecutive days.Following 
lumbar epidural injection of 4 mL fibrin glue CSF leakage stopped within an hour. There was 
no aggravation of the neurological complaints. The IT infusion was continued until death 
three weeks later.
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Patient 3
A 63 year old man complained of increasing back pain, radiating into the anterior side 
of both legs despite high oral morphine (480 mg/day) intake. The pain was due to widespread 
bony metastases of prostate carcinoma. Diffuse vertebral metastases were previously shown 
on a bone scan. Global sensory neurologic function was normal. A 20 gauge epidural catheter 
was inserted through a 18 gauge Tuohy needle at the lumbar level. The pain was adequately 
relieved after commencing morphine and bupivacaine infusion. Cerebrospinal fluid leakage 
started one week post puncture, again without signs of PDPH. Three mL of fibrin glue was 
injected epidurally fourteen days post puncture, stopping the CSF leakage within hours. 
There was no increase in neurological symptoms. No CSF leakage occurred up to the time of 
his last visit to the outpatient clinic (ten months later) and analgesia was adequate.
Discussion
In these patients persistent CSF leakage, unresponsive to epidural blood patch, 
responded favorably to epidural injec-tion of fibrin glue.
Fibrin glue is a preparation of pooled human plasma obtained from plasmaphe­
resis. It is prepared by mixing two solutions. The first one contains fibrinogen, factor 
XIII, fibronectin, aprotinin and plasminogen, and the second one contains thrombin 
and calcium. When these solutions are mixed, fibrinogen is converted to fibrin 
monomers which aggregate and form a gel (3). Fibrin glue has a high tensile strength 
and tolerates high moisture environments.
The fibrin clot forms a temporary biological seal of the dura until healing occurs (4).
Fibrin glue is widely applied in otology and neurosurgery as a method to 
achieve a watertight dural closure (5). It has proven to be a satisfactory technique in 
stopping CSF leakage in a series of 20 consecutive craniofacial resections with dural 
defects (6). Percutaneous fibrin sealing has also been successfully applied in cases of 
subcutaneous CSF fistulae following operations to the brain and the spinal cord (7) 
thereby avoiding re-operation.
Using a product of biological origin implies a potential risk of viral infection. 
However, there has not been a documented case of viral transmission by using fibrin 
glue (as manufactured by Immuno AG, Austria). The manufacturer uses a recombi­
nant DNA technique; exponential multiplication of genome by polymerase chain 
reaction results in a very low level of detectable viral load (8). A CSF leak might be 
difficult to differentiate from infusate tracking back along the IT catheter. In the 
patients described, the observation of heavily soaked dressings in the presence of a 
low infusion rate ( 0.1 to 0.4 mL/hr) allowed the diagnosis of CSF leak to be made.
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The routine treatment of CSF leakage after dural puncture consists of initial 
conservative symptomatic treatment with progression to epidural injection of autolo­
gous blood which can be repeated if  necessary (9-11). Since introduction of the 
epidural blood patch (12), it has been widely and safely applied. Alternative therapies 
proposed after a failed blood patch are continuous epidural infusion of saline (13,14) 
or epidural infusion of dextran (15).
The theory behind these methods is the establishment of a stable counterpres­
sure stopping the leak and hence allowing the dura to heal. The epidural blood patch 
was not effective in our first two patients. All three patients responded positively to 
an epidural injection of fibrin glue, which was easily applied by injection through a 
18 gauge Tuohy needle.
The presence of extradural tumor or metastatic mass (patients 1 and 3) through 
which the IT catheter passed might explain the persistent leakage in those cases.
The epidural injection of fibrin glue should be considered in treatment of 
persistent CSF leakage when other measures, including epidural blood patch, fail. It 
should be considered when further palliative treatment of patients with terminal 
disease necessitates continuation of the IT infusion. This technique is not recom­
mended for other PDPH related complaints.
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Lateral C1-C2 Approach
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Introduction
Progressive tumor growth in the head and neck often leads to various types of 
pain, which are usually located within the distribution of the cervical nerve roots and 
the 9th and 10th cranial nerves. Symptomatic pain therapy in these cases consists 
mainly of oral morphine in combination with so-called coanalgesics (e.g., antidepres­
sants, anticonvulsants) and corticosteroids. The pain is seldom limited to one side or 
confined to the distribution of one nerve. These circumstances restrict the usefulness 
of nerve blocks and neuroablative procedures.
A possible solution to the problem of treating persistent pain in these patients is 
to use an intrathecal (IT) application of morphine in combination with bupivacaine. 
Encouraging results have been reported with the use of a combination of morphine 
and bupivacaine in patients suffering from incidence pain and neurogenic pain at the 
low cervical, thoracic, and lumbosacral levels (1-3). For optimal efficacy of the additi­
onal effect of bupivacaine, the tip of the catheter should be as near to the pain conduc­
ting nerves as possible (4).
This report describes the insertion of an IT catheter at the upper cervical (C1-C2) 
level with subsequent continuous IT administration of morphine and bupivacaine in 
two patients suffering from severe pain due to progressive tumor growth in the head 
and neck region.
Case Report
The basic technique is conducted under fluoroscopic guidance. After identificati­
on of the bony landmarks, a 20-gauge Tuohy needle is inserted in a slightly caudocra- 
nial direction aiming at the anterior part of the cervical IT space at the C1-C2 level. 
This technique is slightly modified from the access used in percutaneous cervical 
cordotomy, in which the direction of the needle is perpendicular to the sagittal plane 
and directed more posteriorly to enter the spinal cord. In our technique, the insertion 
point of the needle through the skin corresponds to the arch of the second cervical 
vertebra, the tip of the needle piercing the dura just behind the caudal part of the arch 
of the first cervical vertebra (Figure 1).
The anterior positioning of the needle tip within the IT space avoids contact with 
the spinal cord, since the latter is located more posteriorly in the supine patient. After 
obtaining a free flow of cerebrospinal fluid (CSF), a standard 23-gauge epidural 
catheter is advanced about 3-5 cm intrathecally with the needle bevel directed cranial­
ly.
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I I
F i g u r e  1 . X -ray, fluoroscopy, lateral view  
o f  the upper part o f  the cervical spine.
The insertion point o f  the needle through 
the sk in  corresponds w ith  the arch o f  the 
second cervical vertebra, the tip o f  the 
needle p ierces the dura ju s t behind the arch 
o f  the first cervical vertebra. The needle is 
directed caudo-cranially  and postero-ante- 
riorly  to en ter the an terior part o f  in trathe­
cal space.
Subsequently, the catheter is tunneled subcutaneously over a distance of about 
20 cm along the course of the sternocleidomastoid muscle to the infraclavicular 
region, where it pierces the skin and is secured for long-term immobility by a transpa­
rent adhesive dressing (Figure 2).
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The catheter is finally connected via an antibacterial filter and extension line to a 
portable infusion pump. Immediately after introduction, the position of the catheter tip 
is verified after injection of 1 mL of 240 mg/mL johexol (OmnipaqueTM240; Nycomed 
Imaging A.S., Oslo, Norway) by fluoroscopy.
Two patients were treated in this manner. The first patient, a 50-yr-old female, 
had an inoperable T4N0M1 progressive squamous-cell carcinoma of the base of the 
tongue. During radiotherapy, severe aching pain developed in the right neck region 
with superimposed attacks of severe stabbing pain in the right ear. Pain was rated 9-10 
on a 0 (no pain) to 10 (worst pain possible) visual analog scale (VAS) and was judged 
to be mediated by the upper cervical roots and the vagal nerve on the affected side.
Oral analgetics (i.e., morphine acetaminophen, carbamazepine, and prednisone) 
did not relieve her pain. Drug related complaints such as dizziness, somnolence, and 
constipation, were present. The installation of an IT catheter at the upper cervical level 
was planned.
Because of tissue induration and skin tenderness on the painful right side, a left 
lateral approach of the C1-C2 interspace was chosen. An IT infusion was started with 
morphine HCl 0.5 mg/24 h. The minimum flow rate of the pump was 0.1 mL/h; 
therefore, a solution containing morphine 200 ^g/mL in saline was used. At the same 
time, the oral morphine intake was tapered to 50% of the previous daily dose and 
stopped in 2 days. However, pain relief was still insufficient, despite increasing the 
morphine dosage over a period of 5 days to 7.2 mg/24 h while reducing the VAS from 
9-10 to 6.
At day 5, she again reported a period of severe stabbing pain. Instead of further 
increasing the morphine dosage, bupivacaine was added to the infusion solution. The 
initial dosage of bupivacaine was 4.8 mg/24 h, using a mixture containing bupivacaine 
2 mg/mL and morphine 3 mg/mL with an infusion rate of 0.1 ml/h. During the next 4 
days, the flow rate was increased to 0.3 mL/h, resulting in a dosage of bupivacaine tot 
14.4 mg/24 h and morphine 21.6 mg/24 h. There were no side effects related to the IT 
infusion. Dizziness, muscle weakness, sensory disturbances, or difficulty in swallo­
wing were neither reported nor observed.
Although the position of the catheter tip was verified just after insertion, another 
radiograph was made just before the start of bupivacaine administration because of 
doubt concerning the optimal IT position of the catheter. In both instances, the tip was 
visible at the level of the foramen magnum. On discharge from the hospital, pain was
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rated by the patient as acceptable (VAS 5). Incident pains were no longer reported, 
and the patient was able to sleep. Treatment was continued at home.
Technical support was provided by a commercial nursing firm under the supervi­
sion of the family physician, the medical staff of the pain clinic being available for 
direct consultation.
The patient died 12 days after discharge from the hospital without any apparent relati­
onship between her death and the IT therapy.
The second patient, a 48-yr-old female, presented with a relapse of a squamous­
cell carcinoma of the floor of the mouth that subsequently was resected and followed 
by radiotherapy. Four years previously, she had undergone an operation for carcinoma 
of the hypopharynx. Severe pain attacks (VAS 7-8) in the left ear and pain on swallo­
wing were present, notwithstanding oral medication consisting of acetaminophen, 
morphine, dextromoramide, and amitriptyline. Drug-related side effects limited a 
further dosage increase, and an IT infusion was proposed. The catheter was inserted at 
the C1-C2 level with the catheter tip located at the foramen magnum. IT infusion 
started with morphine, 0.5 mg/24 h. Partial pain relief (VAS 5) was obtained after 
careful dose increments in a few days to morphine 4.8 mg/24 h. To achieve better pain 
relief, bupivacaine 2 mg/mL was added to the morphine 1-mg/mL solution. The 
patient experienced dizziness and vertigo during the infusion of bupivacaine 9.6 
mg/24 h. Adequate pain relief (VAS 0-1) without side effects was accomplished 
duringt IT infusion of bupivacaine 6.6 mg/24 h and morphine 2.9 mg/24 h.
In this patient, injection of contrast dye revealed the catheter tip position close to 
the foramen magnum. At the completion of this report, 6 months after insertion of the 
catheter, pain relief was still satisfactory (VAS 1-2), sleep was undisturbed, and no 
complications had appeared.
Discussion
IT catheter insertion at the C1-C2 level was performed by a modified approach 
of the puncture technique used in percutaneous cervical cordotomy. Access intrathe­
cally by a lateral C1-C2 approach was first described by Mullen et al. (5) for percuta­
neous cervical cordotomy and has proven to the relatively safe (6). The technique is 
also used by radiologists for cervical myelography (7).
Complications related to the lateral puncture are rare, with only a few case 
reports present, including transient paresis in one patient due to contact of the spinal
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needle with the cervical cord, vertebral artery embolus due to presumed damage of the 
vertebral artery (5), and an acute subdural hematoma resulting from puncture of an 
anomalous vertebral artery (8).
The risk of puncturing the spinal cord is minimized when the needle pierces the 
anterior aspect of the dura. A bloody tap at the epidural space can occur as the venous 
plexus at the cervical level is located anteriorly.
IT catheters can be inserted at the T1-T2 or C7-T1 interspace. Here, extreme 
caution is needed to avoid puncture of the spinal cord. Advancing the catheter intrat­
hecally may be painful because of contact of the catheter with the spinal roots. Intra- 
ventricular administration of morphine (9) also relieves pain in the head and neck, 
although it is unknown whether morphine alone at this site relieves incident pain 
adequately.
Another alternative to our approach is a cervical epidural catheter. The most 
convenient place to insert the epidural catheter is at the T1-T2 or C7-T1 interspace, 
with subsequent advancement of the (guide-wired) catheter to the (high) cervical 
level. Since the epidural route can result in the development of epidural fibrosis when 
the treatment period extends to more than 1 month, the IT route in long-term spinal 
treatment is preferred (10).
In our two cancer patients with persistent pain in the upper neck and ear region, 
the application of IT morphine in combination with bupivacaine at the C1-C2 level 
resulted in considerable pain reduction. In both patients, the catheter tip was situated 
near the foramen magnum. Lumbar IT administration of morphine can result in ade­
quate pain relief even at the thoracic or cervical level (11). It was expected that morp­
hine alone would probably lead to inadequate relief of the incident pain in the cervical 
region and that localized bupivacaine would be necessary. A more segmental localiza­
tion of the catheter tip was therefore necessary (4). This guaranteed an effective 
concentration of bupivacaine in the vicinity of the upper cervical nerve roots. Presu­
mably, the rostally directed cerebrospinal fluid flow also exposes the lower cranial 
nerves to the action of bupivacaine.
There were marked differences between the two patients in effective dosages and 
the occurence of side effects. The first patient, with a final IT dosage of morphine 
21.6 mg/24 h and bupivacaine 14.4 mg/24 h did not complain of any side effects. In 
the second patient, a gradual increase of the morphine dosage to 4.8 mg/24 h and 
bupivacaine 9.6 mg/24 h resulted in dizziness and vertigo, which diminished after
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dose reduction of both drugs. This difference in individual susceptibility underlines 
the need for adequate supervision during dose titration.
Our previous clinical experiences with combined IT morphine/bupivacaine 
infusion at the lumbar level, continued at home, showed the safety of this technique 
after careful dose-finding, once a steady state had been reached (2).
We advise close supervision of the patient in a recovery room or intensive care 
unit during the first 12-24 h after starting the infusion. Pain relief, sedation, and 
respiratory function should be monitored every hour until stable. Thereafter, supervisi­
on in a ward by nurses familiar with this technique is necessary. Serious side effects of 
IT morphine are unlikely in patients used to previous opioid therapy, especially when 
continuous-infusion instead of bolus injection techniques are used. The safety of 
bupivacaine at the upper cervical level of the spinal cord is unknown. Therefore, the 
patient is kept in the hospital for at least 2-3 days after reaching a stable dosage. 
Before hospital discharge, the general practitioner, the patient, and the relatives are 
instructed on how to interrupt infusion if  any dizziness, vertigo, or sedation occurs 
during treatment at home. During home treatment, immediate telephone consultation 
with the pain team is possible at any moment. Because the technique is potentially 
hazardous, owing to both the site of puncture and the level of IT infusion of potent 
drugs, we consider the technique a last resort for otherwise unmanageable pain due to 
head and neck cancer.
For those familiar with performing percutaneous cervical cordotomies, the 
technique is not difficult. The C1-C2 level seems to be a suitable entrance place for an 
IT catheter. Further experience with continuous IT infusion at the upper cervical level 
is necessary to determine its ultimate place within our therapeutic armamentarium.
141
References
1. Sjoberg M, Appelgren L, Einarsson S, Hultman E. Long-term intrathecal morphine and 
bupivacaine in 'refractory' cancer pain. I. Results from the first series of 52 patients.
Acta Anaesthesiol Scand 1991;35:30-43.
2. Van Dongen RTM, Crul BJP, Bock de M. Long-term intrathecal infusion of 
morphine/bupivicaine mixtures in the treatment of cancer pain; a retrospective analysis 
of 51 cases. Pain 1993; 55:119-123.
3. Krames ES. The chronic use of opioid and local anesthetic mixtures for the relief of 
intractable pain: when all else fails! Pain 1993;55:1-4.
4. Greene NN. Uptake and elimination of local anesthestics during spinal anesthesia. 
Anesth Analg 1983;62:1013-1024.
5. Mullen S, Haroer PV, Hekmatpanah J et al. Percutaneous interruption of spinal-pain 
tracts by means of a strontium 90 needle. J Neurosurg 1963;20:931-9
6. Lipton S. Percutaneous Cordotomy. In: Wall PD, Melzack R, eds. Textbook of Pain. 
Churchill Livingstone, Edinburgh 1984: 632-8.
7. Orrison WW, Eldevik OP, Sackett JF. Lateral C1-2 puncture for cervical myelography. 
Part III: Historical, anatomic, and technical considerations. Radiology 1983:146;401-8.
8. Rogers LA. Acute subdural hematoma and death following lateral cervical spinal punc­
ture. Case report. J Neurosurg 1983:58;284-6.
9. Crul BJ, Delhaas EM. Technical complications during long-term subarchnoid or 
epidural administration of morphine in terminally ill cancer patients. A review of 140 
cases. Reg Anesthesia 1991;16:209-13.
10. Obbens EA, Stratton Hill C, Leavens ME et al. Intraventricular morphine administration 
for control of chronic cancer pain. Pain 1987;28:61-68.
142
Epilogue
9.1 General discussion
9.2 Summary and Conclusions
9.3 Samenvatting 
References
Chapter 9
143
Chapter 9
9.1 General discussion.
Morphine resistant pain is a major problem in the treatment of patients with advan­
ced cancer. The studies presented in this thesis, however, demonstrate that continuous 
IT infusion of morphine and bupivacaine can provide adequate pain relief in the 
majority of these patients.
We have studied a number of causes for this morphine unresponsiveness, such as 
an altered relationship between the morphine-3-glucuronide and morphine-6-glucuro- 
nide concentrations in plasma and CSF, the presence of pain syndromes which are less 
opioid responsive and the development of tolerance.
The concentrations of morphine and its glucuronides in plasma and CSF were 
studied in a series of cancer patients on oral morphine (Chapter 3). A close relation­
ship was found between the oral morphine dose and the plasma and CSF morphine 
concentrations. As the morphine-6-glucuronide moiety is considered to be the analge­
sic component and because the morphine-3-glucuronide appears to be devoid of 
analgesic activity, their ratio in plasma and CSF is of importance. Also the presence of 
high concentrations of morphine-3-glucuronide, disturbing this ratio, is considered to 
have a negative effect on pain relief. Both metabolites could be detected in the CSF in 
substantial amounts, closely related to their respective plasma concentrations. In these 
patients, however, the ratios of morphine-6-glucuronide and the morphine-3-glucu- 
ronide in both plasma and CSF appeared to be inter-individually constant. From these 
results we concluded that inadequacy of pain relief was not related to a high concen­
tration of morphine-3-glucuronide compared to morphine-6-glucuronide, as was 
suggested in a number of animal and human studies previously (Gong et al. 1992, 
Morley et al. 1993).
Inefficacy of (oral) opioids as well as severe, unmanageable opioid related side- 
effects are still in the literature considered to be the major indications for long-term IT 
morphine administration in cancer patients (Swarm and Cousins 1993, Ballantyne et 
al. 1996) (Chapter 4 ).
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However, in the first series of cancer patients with IT morphine studied retrospecti­
vely (Chapter 5  ), we were unable to alleviate the pain complaints in about 30% of the 
patients.
A more detailed analysis of their pain complaints according to the criteria of 
Arnér (Arnér and Arnér 1985) showed, that they experienced neurogenic, intermittent 
and incident pain more frequently. By subsequently combining morphine with bupiva­
caine IT, it became possible to improve pain relief in 60% of these patients without 
increasing the side-effects.
It was also shown, that the long-term use of a percutaneous IT catheter is a safe 
technique with a low risk of infection, probably mainly due a slow infusion rate and 
thereby a long interval between the disconnections for changing the drug reservoir.
Our results, considering the efficacy and safety of IT morphine and bupivacaine in 
chronic cancer pain, confirmed previous work by Sjöberg and collegues (Sjöberg et al. 
1991). Prospective studies comparing morphine with morphine/ bupivacaine IT had 
not been reported at that time.
We were especially interested in the question as to whether it would be possible to 
predict the efficacy of IT morphine in patients experiencing inadequate relief with 
oral morphine, and also in the (side-) effects of the co-administration of bupivacaine.
A prospective, randomised double blinded study of morphine versus 
morphine/bupivacaine IT in cancer patients was therefore designed. Patients were 
stratified into two groups: one group experiencing inadequate pain relief, the other 
group with unmanageable side-effects and the clinical pain characteristics were deter­
mined (Arnér and Arnér 1985). By dividing the first two groups into sub-groups with 
different morphine responsiveness four of these sub-groups were finally formed. Each 
of these subgroups was subsequently randomised to receive either morphine IT or 
morphine/ bupivacaine IT .
The first part of the question, whether bupivacaine co-administration could improve 
pain relief in relative morphine-unresponsiveness, was addressed by analysing patients 
selected for IT treatment because of either inadequate pain relief or the persistence of 
unmanageable, morphine-induced side-effects (Chapter 6). Here, it was clearly
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shown, that during the double-blinded phase of IT treatment, patients in the IT morp­
hine group experienced inadequate pain relief more frequently. It was impossible to 
decrease the previous (oral) morphine administration, despite comparable IT dose 
adjustments in either group. Patients who responded poorly (57% in the morphine 
group versus 12% in the morphine/ bupivacaine group: P=0.004 Fisher exact test) 
during IT treatment had all entered the study because of inadequate pain relief follo­
wing the previous oral morphine phase, but not because of side-effects. They also 
complained more frequently about intermittent and neurogenic pain and, although 
their mean previous oral morphine intake did not reach statistically significant diffe­
rences between either group (P=0.14), they had a high oral morphine intake.
Considering these results, one could question if  the same mechanisms of diminis­
hed opioid efficacy are responsible during both oral and IT administration of morphi­
ne. If so, it would be unlikely that changing the administration route from oral to IT , 
would have any further benefit in improving pain relief in pain syndromes unresponsi­
ve to extensive previous (oral) morphine administration.
Recent experimental data have supported the idea of a decreased responsiveness to 
opioids irrespective of the route of opioid administration. Also, a close relationship 
and common pathophysiological pathway between opioid tolerance and neuropathic 
pain states has been shown.
The antagonistic effects of morphine-3-glucuronide and other mechanisms have 
been held responsible for this decreased efficacy of morphine such as a "loss" of 
opioid receptors, the presence of anti-opioid peptides, the excitatory effects of dynorp- 
hin and, finally, the involvement of an interaction at the NMDA receptors on the 
nociceptive neurones in the spinal cord (Collin and Cesselin 1991, Dickenson 1994).
From these theories, it is intriguing to note that there is a similarity in the changes 
taking place at the level of the NMDA-receptors in the spinal dorsal horn following 
both tolerance to morphine and the development of neuropathic pain syndromes (Mao 
et al. 1995 (a)). Both events are initiated by an excessive stimulation of the NMDA- 
receptor which can either be accomplished by morphine administration or prolonged 
neuropathic stimulation. The ensuing complicated cascade of intracellular changes 
finally results in a decreased efficacy of morphine.
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These findings will add further to the understanding of the clinical observations and 
the recent discussion in the literature of a variable, unpredictable efficacy of morphine 
in these pain syndromes which is frequently encountered in cancer patients.
To complicate the situation further, another problem arises in cancer patients that 
interferes with these dynamic changes in the nociceptive system. When cancer is 
progressing, its associated nociceptive input frequently increases at the same time. 
Clinically, this can be overcome by increasing the dose of the analgesics that, strictly 
speaking, cannot be considered to be tolerance (Yaksh 1991, 1992, Portenoy 1994).
Finally, there appears to be a complicated interaction between the intensity of the 
nociceptive stimulus and the efficacy of the IT drug used to suppress this stimulus. 
The action of an agonistic drug is related to the receptor-drug affinity and the intrinsic 
activity of the drug. The number of receptors occupied or FRO (Fractional Receptor 
Occupancy) needed to result in the required effects is also important (Yaksh 1991, 
Dirig and Yaksh 1995). The less drug needed to produce this effect and thus, the 
higher concentration of non-occupied or “spare receptors” (i.e. a drug with a low 
FRO) the slower will be the rate of tolerance development.
From this it is clear that it is extremely difficult to determine what is the precise 
contribution of these factors in the individual patient with cancer.
It is important clinically to overcome this diminished responsiveness. This can be 
accomplished by IT co-administration of local anaesthetics (e.g. bupivacaine). Pain 
relief should improve without serious side-effects. Another indication to combine 
morphine and local anaesthetics IT is to try to diminish morphine dose-progression as 
far it is caused by the presence of tolerance. Using a combined technique, extremely 
high IT morphine doses (above 30-40 mg /day) can be prevented. We considered this 
to be the result of a synergistic effect of morphine and bupivacaine.
To substantiate this, we analysed the IT morphine dose progression during a stable 
period of IT treatment in patients with morphine (M) and patients with combined 
morphine/ bupivacaine (M/B) infusion, all experiencing good pain relief (Chapter 7). 
Although both groups showed a gradual dose increase with time, the IT morphine 
progression in the M/B group was statistically significantly lower. This was conside­
red
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to be a synergistic effect of morphine and bupivacaine IT. According to this finding 
we do not consider IT morphine dose progression in cancer patients to be solely the 
result of advancement of disease, but also of tolerance phenomena (Yaksh and Onofri­
o 1987).
During our studies, we encountered a number of patients with neurological deficits 
(hypaesthesia, motor weakness in the limbs) in combination with radiating pain into 
the back and legs (Chapter 8.1 ). In a number of patients, however, paraplegic symp­
toms developed (within 24-48 hours) following a low dose of IT bupivacaine.
These patients turned out to have imminent compression of spinal cord and cauda 
equina which was "unmasked" by the side-effects of the local anaesthetics. Pain 
symptoms no longer responding to morphine administration should therefore alert the 
clinician for these possible complications of cancer.
Clinical evaluation of the patient remains mandatory before starting IT treatment.
The IT technique as described in this thesis is considered to be a safe technique. 
However, catheter related side-effects may present. Persistent leakage of CSF not 
responding to conservative treatment is a bothersome complication. In these palliative 
circumstances, an epidural injection of "fibrin glue" (Tissucol™) may resolve this 
complication (Chapter 8.2).
In those patients in whom, due to the tumour localisation or metastatic spread a 
lumbar approach is not feasible, a lateral cervical approach was used. In two patients 
IT infusion at a high cervical level was accomplished with both morphine and bupiva- 
caine (Chapter 8.3). In patients where local anaesthetics are considered necessary, 
this route should be used instead of the intraventricular route.
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Conclusions.
Long-term IT morphine/ bupivacaine administration is indicated in patients with 
pain syndromes poorly responding to morphine alone. Before initiating this treatment, 
a diagnosis of the causes of the morphine unresponsiveness should be made. Imminent 
compression of the spinal cord and cauda equina should always be considered and 
when present treatment should be aimed at this symptom. When a long treatment 
duration is foreseen due to the slow progression of the tumour process, a combined 
infusion of morphine and bupivacaine should be started from the beginning, thereby 
diminishing the development of tolerance.
Although a clear clinical benefit of this technique is present, there is still a lack of 
prospective studies. Future studies should focus on the relevance of co-administration 
of non-opioid analgesic drugs in these patients. Furthermore, before initiating these 
IT techniques earlier in the disease, or even in chronic pain treatment, prospective 
evaluation, including quality of life studies should be performed, comparing different 
treatment modalities available.
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9.2. Summary.
Chapter 1 gives a general description of the difficulties encountered with pain 
relief in cancer patients using intrathecal (IT) opioids. From these difficulties the aims 
of the study are formulated.
In Chapter 2, pain in cancer is analysed as an important symptom caused by either 
the (progress of the) disease process itself, or its treatment or unrelated to these two 
factors. A subdivision of the pain complaints based on different mechanisms of 
nociception, thereby providing a more rational approach to the various treatment 
modalities, is discussed. After diagnosing the most likely cause(s), the intensity and 
other characteristics, pain is treated mainly by the administration of analgesics. Co­
analgesics may also be used. Anxiety and depression, although frequently co-existent 
and interfering with the sensation of pain, prove to be largely undertreated.
Chemotherapy and/ or radiotherapy must also be considered as an important pallia­
tive treatment modality with pain alleviating effect in these situations.
The action of opioids, specifically morphine is described, as this is the drug of 
choice in step 3 of the World Health Organisation (WHO) analgesic ladder. Due to its 
specific effects on C-fibre mediated nociceptive stimuli and extensive modelling of 
spinal and supraspinal circuitry, pain relief by analgesics is often accompanied by a 
change in mood.
Following a description of the variety of action of opioids at the opioid receptors, a 
relationship is sought between the dynamic changes that take place in the nervous 
system due to long lasting nociceptive and neuropathic stimulation and the efficacy of 
morphine in these progressive pain syndromes.
In Chapter 3 it is confirmed experimentally that oral morphine gives rise to adequa­
te plasma and cerebrospinal fluid (CSF) levels of morphine and its glucuronides. This 
study was performed to investigate the relationship between the morphine levels in 
plasma and CSF. Also, the levels of the morphine-6-glucuronide (M6G) and the 
morphine-3-glucuronide (M3G) in both plasma and CSF and their respective ratios 
were determined. Sixteen patients, scheduled for IT treatment with morphine were 
studied. The morphine concentrations in plasma were correlated closely to the CSF 
morphine concentrations (r = 0.94; P= 0.0001).
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The presence of a concentration gradient across the dura for both M3G and M6G was 
possibly due to the low un-ionised fraction according to the respective pKa values. 
The CSF/ plasma concentration ratio's (s.d., range) were 0.12 (0.05, 0.04-0.24) for 
M3G and 0.09 (0.04, 0.03-0.20) for M6G. No relationship was shown between the 
morphine plus M6G levels in CSF and pain relief.
In chapter 4 a general overview is presented about the status of IT opioids in pain 
management. Soon after the initial reports on pain relief in a limited number of pa­
tients with epidural and IT use, spinal opioids were introduced widely into clinical 
practice. From a pharmacological point of view, for morphine, the IT route is more 
rational than the epidural route as it gives rise to a high drug concentration at the 
receptors in the spinal cord combined with a low systemic availability. For postopera­
tive pain relief morphine IT is also frequently used, leading to reliable analgesia 
following a simple injection technique without the need for the use of a catheter. 
Bothersome side-effects such as itching, nausea and vomiting are, however, more 
frequently reported following IT morphine compared to epidural morphine. The 
incidence of the probably dose related respiratory depression may vary, but its fre­
quency is estimated to range around 0.36 %. Adequate postoperative monitoring of the 
patient and prevention of a combination of different sedative drugs including opioids, 
is essential in this situation. When sedation and/ or repiratory depression do occur, 
prompt treatment can prevent disaster.
For long-term pain relief, a continuous IT infusion with a pump is preferable. 
Depending on the expected duration of treatment, a percutaneous technique, subcuta­
neous portal or totally implanted system or pump can be used. All of these techniques 
have their advantages and disadvantages, but the major problem during long-term 
relief remains those patients who do not respond to IT treatment, or in whom the 
efficacy of the treatment wears off.
In chapter 5, our first results concerning the efficacy and safety of IT morphine in 
51 cancer patients through a tunnelled percutaneous catheter are reported retrospecti­
vely. Pain relief, determined by verbal rating and diminishment of oral morphine, IT 
morphine dose progression and side-effects were noted.
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In 17 patients (30% ) pain re lie f w as insufficient, but im proved significantly in ten 
o f  them  (58% ) follow ing the addition o f  bupivacaine to the IT infusion. Despite the 
addition o f  bupivacaine in four patients (23% ), pain re lie f w as m oderate w hile in three 
patients (18% ) no acceptable analgesia could be reached. These last patients showed 
m ore prom inent depressive signs. Bupivacaine related side-effects w ere absent below  
an IT dosage o f  30 m g/ day by continuous infusion. In all patients a gradual dose 
increase w as observed. N either serious side-effects, nor neurologic sequelae or m e­
ningitis occurred. From  this study w e conclude, that long-term  IT infusion o f  m orphi­
ne through a percutaneous catheter provides adequate pain re lie f in the m ajority o f  
cancer patients, and can be considered a safe technique. However, inadequacy o f  IT 
m orphine m ay necessitate the co-adm inistration o f  bupivacaine. The long-term  effects 
o f  this technique, how ever, can only be studied prospectively.
In  chapter 6, the clinical problem  o f  a dim inishing analgesic effect o f  m orphine is 
discussed. In cancer, a variety o f  reasons can explain the need  for a m orphine dose 
increase. It is often difficult clinically to determ ine the exact cause(s) o f  this. Recently, 
tolerance w as described from  a pharm acological point o f  view, as a sequence o f  
events starting at the level o f  the opioid receptor and follow ed by  a cascade o f  intra­
cellular changes. A ctivation o f  the N M D A  receptor is o f  im portance to initiate these 
changes. In these studies a close relationship has been shown betw een the tolerance 
induced changes at the (sub-) cellular level and the changes induced by the presence 
o f  neuropathic pain syndromes. A part from  increasing the IT m orphine dose to over­
come this dim inished efficacy, adm inistration o f  a (com bination of) drug(s) that 
specifically interferes w ith these cellular changes seems to be m ore rational. For this 
purpose, both local anaesthetics and a 2 agonists have been extensively used.
The efficacy o f  IT m orphine follow ing extensive pretreatm ent w ith  (oral) m orphine 
w as studied prospectively. In 43 cancer patients w ith  inadequate pain re lie f and/ or 
unacceptable, unm anageable, opioid induced side-effects, the IT route w ith a percuta­
neous catheter and portable pum p w as selected. Patients w ere stratified according to 
their m ost prom inent pain com plaints (continuous som atic or visceral versus interm it­
tent or neurogenic) after determ ining the indication for IT treatm ent (inadequate re lie f 
versus side-effects). This resulted in four groups o f  patients. Each o f  these groups was
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then randomised in a double-blinded manner into a morphine (M) and morphine/ 
bupivacaine (M/B) treatment group, resulting in a total of eight subgroups. Patients 
were followed prospectively until death, or to the end of the IT treatment. Quality of 
pain relief, side-effects and complications were noted. In the M group, significantly 
more patients complained of inadequate pain relief in comparison with the M/B group 
(57% versus 12%, P=0.004: Fisher exact test). Also, those patients experiencing 
inadequate effect of morphine, appeared to have more frequently intermittent and 
neurogenic pain components. Subsequent co-administration of bupivacaine in these 
last patients unresponsive to IT morphine alone, finally resulted in good pain relief in 
63%. Bupivacaine induced side-effects were limited and shortlasting, while catheter 
related side-effects were mainly concerned with postspinal headache (37%). Persistent 
leakage of CSF, necessitating an epidural bloodpatch, were present in 8% of the 
patients. One patient developed a meningitis which responded to antibiotic treatment.
The mechanism(s) by which combined M/B infusion improves M "unresponsive­
ness" remains unclear. Animal experiments have suggested changes in the spinal cord 
blood flow due to the bupivacaine, leading to an altered morphine clearance in the 
CSF. Also, an interference by morphine at the neuronal sodium channels and an 
interaction of bupivacaine with the opioid receptors have been postulated. The safety 
of the IT technique was confirmed in our study. However, inefficacy of IT morphine 
in advanced cancer remains a clinical problem that is probably underestimated in the 
literature.
Chapter 7 focusses on the synergistic effects of morphine and bupivacaine adminis­
tered IT. During a prospective follow-up of 20 patients with adequate pain relief (by 
Numerical Rating Score or NRS) during either IT infusion of morphine or morphine/ 
bupivacaine, the dose increase of the IT morphine were studied. A regression analysis 
of the increase in IT morphine infusion rate per day in each group, was performed 
from day 10-30. The M/B group showed a slower morphine dose progression compa­
red to the M group (slope of the regression line 0.0003 versus 0.005, P=0.0001, 
respectively, ANOVA). Bupivacaine did not result in serious side-effects. From these 
results we conclude that there is a synergistic effect of morphine and bupivacaine IT 
in cancer patients. An interference with the neuronal excitability by bupivacaine, in 
addition to the specific effects of morphine at the opioid receptor/ membrane complex 
is one of the mechanisms hypothesised.
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Chapter 8  describes the neurologic complications in cancer patients interfering 
with the IT technique.
8.1: Six patients are described with serious neurologic deficits resembling para­
plegia soon after the start of IT treatment with morphine and bupivacaine. Imminent 
compression of the spinal cord or cauda equina and tumour growth into the lumbosa­
cral plexus was shown in these patients.
As these pain complaints usually do not respond to (conventional) morphine admi­
nistration, subsequent IT administration is frequently considered. Bupivacaine is often 
essential for adequate relief in these patients. In the six patients discussed, bupivacaine 
more or less "unmasked" the subtle neurological deficits probably already present 
before the IT treatment. Development of neurologic deficits (e.g. paraplegia) at a low 
IT bupivacaine dose therefore, should alert the clinician.
8.2: Long-term percutaneous catheterisation of the IT space can be accompanied by 
(visible) loss of CSF in the tissues surrounding the spinal canal, or along the catheter 
tract. Leakage of fluid at the exit site of the catheter at the skin can be particulary 
bothersome. Infections may also occur and loss of drug effect may ensue.
If despite conservative measures (bed-rest, high oral fluid intake) leakage does not 
stop spontaneously, an epidural injection of autologous blood is an alternative. In a 
series of three cancer patients, however, this technique proved to be ineffective and 
the CSF loss at the skin continued. Despite this, pain relief with IT infusion was 
excellent.
An epidural injection one level above the previous puncture site of "fibrin glue" 
(Tissucol®) was therefore performed, and this resolved the leakage without untoward 
effects. In two of these patients, the IT catheter appeared to pass through a pathologi­
cal epidural mass, possibly explaining the persistent CSF leakage and subsequent 
failure of the bloodpatch. This technique should be considered as an alternative for 
epidural blood patching in cancer patients when continuation of the IT treatment is 
desirable.
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8.3: In a number of cancer patients, due to the (supra) cervical localisation of pain 
as a result of tumour growth, lumbar or thoracic IT catheters will not suffice especially 
when local anaesthetics are considered. Introduction of the catheter at a (para-) medi­
an, high cervical level may be considered but can be a hazardous procedure due to the 
location of the spinal cord and its associated vital centres. A modified lateral appro­
ach, closely resembling the fluoroscopically guided technique of a percutaneous 
cervical cordotomy was described and performed in two patients.
A careful increase in IT morphine and meticulous combination with bupivacaine 
during close surveillance for side-effects, resulted in acceptable pain relief.
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9.3 Samenvatting
Hoofdstuk 1 geeft een algemene beschrijving van de problemen welke optreden bij 
de pijnbehandeling van patiënten met kanker met intrathecale (IT) toediening van 
opioïden. Vanuit deze probleemstelling worden de doelen van het vervolgonderzoek 
geformuleerd.
In hoofdstuk 2  wordt pijn bij kanker als een belangrijk symptoom gezien van, 
enerzijds het ziekteproces, alsmede ook van de behandeling dan wel van beiden 
volledig losstaand. Indeling van de pijnklachten overeenkomstig de betrokken noci- 
ceptieve systemen maakt een meer rationele keuze van de verschillende behandelingen 
mogelijk. Na het vaststellen van de meest waarschijnlijke oorzaak (en) van de pijnk- 
lacht, de pijnintensiteit en andere pijnkarakteristieken, wordt de pijnbehandeling 
meestal gestart met het toedienen van analgetica. Vaak worden ook co-analgetica 
hierbij gebruikt. Angst en depressiviteit worden, hoewel frequent aanwezig en van 
invloed op de pijnbeleving, onvoldoende behandeld. Ook moet pijnbehandeling 
middels chemo- dan wel radiotherapie worden overwogen als een belangrijke methode 
van palliatie. De werkingswijze van opioïden, met name van het morfine, dat het 
middel van keuze is voor de derde "trede" van de analgetische ladder van de Wereld- 
gezondheidsraad, wordt beschreven. Door de specifieke effecten van morfine op de 
door de C-vezel voortgeleide nociceptieve stimuli en de uitgebreide beïnvloeding op 
spinaal en supra-spinaal niveau, gaat de door morfine veroorzaakte pijnstilling vaak 
vergezeld van beïnvloeding van het bewustzijn en de stemming. Na een bespreking 
van de verschillende opioïd receptoren en de invloed van morfine hierop, wordt 
getracht een relatie te leggen tussen de dynamische veranderingen die plaatsvinden in 
het zenuwstelsel ten gevolge van langdurige nociceptieve stimulatie en de effectiviteit 
van morfine bij deze (progresieve) pijnsyndromen.
In hoofdstuk 3 wordt aangetoond dat het met orale morfine toediening mogelijk is 
om een adequate morfine en morfine- glucuronide concentratie in het plasma en de 
liquor cerebrospinalis (CSF) te bereiken bij patiënten met kanker. Dit onderzoek werd 
verricht om de relatie te bepalen tussen de morfinespiegels in het plasma en de liquor.
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Tevens werden de concentraties van de morfine-6-glucuronide (M6G) en de morfine- 
3-glucuronide (M3G) in zowel plasma als liquor, alsmede hun onderlinge verhouding 
bepaald.
Er werden 16 patiënten in het onderzoek betrokken. De plasma morfine concentra­
tie bleek zeer nauw met de liquor morfine concentratie gecorreleerd te zijn (r = 0.94; 
P=0.0001). De concentratie gradient aan weerszijden van de dura van zowel M3G 
alsook M6G, werd mede in stand gehouden door de lage on-geïoniseerde fracties 
veroorzaakt door de respectievelijke pKa waardes. De verhouding in de liquor/ plas- 
maconcentraties (s.d.; spreiding) tussen bovengenoemde glucuronides bedroegen 
respectievelijk 0.12 (0.05, 0.04-0.24) voor het M3G en 0.09 (0.04, 0.03-0.20) voor het 
M6G. Er was geen verband aantoonbaar tussen de mate van pijnstilling en de som van 
de morfine plus M6G concentraties in de liquor.
In hoofdstuk 4 wordt een algemeen overzicht gepresenteerd betreffende het gebruik 
van IT opioïden bij de behandeling van pijn. Korte tijd na de eerste publicaties om­
trent het verkrijgen van pijnstilling met epidurale of IT toediening van morfine in 
slechts een beperkt aantal patiënten, werden spinale opioïden op grote schaal klinisch 
toegepast. Vanuit een farmacologisch oogpunt is de IT toedieningsweg van morfine 
rationeler dan de epidurale toedieningsweg, aangezien er hierbij een hoge concentratie 
van morfine aanwezig is ter plaatse van de receptoren in het ruggemerg in combinatie 
met een geringe systemische beschikbaarheid.
Morfine IT wordt veelal toegepast voor postoperatieve pijnstilling en resulteert in 
een betrouwbare pijnstilling, in combinatie met een eenvoudige techniek zonder de 
noodzaak van het gebruik van catheters. Hinderlijke bijwerkingen zoals jeuk, misse­
lijkheid en braken komen frequenter voor bij het gebruik van IT morfine vergeleken 
met epiduraal morfine. De incidentie van de, waarschijnlijk, dosis-gerelateerde adem- 
halingsdepressie varieert maar wordt geschat op 0.36 %. Een goede postoperatieve 
bewaking van de patiënt is naast het voorkómen van het gelijktijdig toedienen van 
verschillende sedatieve medicamenten, waaronder ook opioïden, van belang. Indien 
desondanks ernstige sedatie en /of ademdepressie optreden kan tijdige behandeling 
ernstige complicaties voorkómen.
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Voor langdurige pijnstilling blijkt het gebruik van een continue infusie met behulp 
van een pomp de voorkeur te hebben. Afhankelijk van de te verwachten duur van de 
behandeling kan óf een percutane catheter, een onderhuidse "poort" óf een totaal 
geïmplanteerd systeem of pomp gebruikt worden. Al deze technieken hebben hun 
eigen voor- en nadelen, maar het grootste probleem blijven dié patiënten welke niet 
adequaat op de IT toediening van medicatie reageren, óf waarbij het pijnstillend effect 
(geleidelijk) afneemt.
In hoofdstuk 5  worden onze resultaten betreffende de effectiviteit en veiligheid van 
IT morfine door middel van een getunnelde percutane catheter, in 51 patiënten met 
kanker, na retrospectieve analyse besproken. De kwaliteit van pijnstilling middels een 
verbale pijnscore en afname van de orale morfine behoefte, werden naast toename van 
de IT morfine dosis en het optreden bijwerkingen, genoteerd. Bij 17 patiënten (30%) 
was de pijnstilling onvoldoende maar kon, door het toevoegen van bupivacaïne aan de 
IT infusie bij tien van deze patiënten (58%), aanzienlijk verbeterd worden. Bij de 
overige patiënten trad bij vier van hen (23%) een matige verbetering op terwijl bij drie 
patiënten (18%) geen adequate pijnstilling kon worden bereikt, ondanks deze toevoe­
ging van bupivacaïne. Bij deze laatste patiënten waren er tevens depressieve kenmer­
ken aanwezig. De bijwerkingen die aan het gebruik van bupivacaïne zouden kunnen 
worden toegeschreven bleken afwezig bij een bupivacaïne dosering met behulp van 
een continue infusie beneden de 30 mg /dag. Bij alle patiënten trad een geleidelijke 
toename van de benodigde IT medicatie op. Er manifesteerden zich geen ernstige 
neurologische afwijkingen of infectieuze problemen zoals een meningitis. Op grond 
van de resultaten van dit onderzoek concludeerden wij dat het langdurig toedienen van 
morfine door een percutane catheter een veilige techniek is en bij het merendeel van 
de patiënten met kanker in een adequate pijnstilling resulteert. Echter, indien onvol­
doende pijnstilling optreedt bij het gebruik van IT morfine, kan een combinatie met 
bupivacaïne noodzakelijk zijn. De gevolgen van een dergelijke behandeling dienen 
echter prospectief onderzocht te worden.
In hoofdstuk 6 wordt het klinische probleem van een afname van het pijnstillend 
effect ondanks een toename van de morfine dosis, besproken.
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Aangezien er bij patiënten met kanker een groot aantal redenen aanwezig kunnen 
zijn om een morfine dosistoename te verklaren, is het in de klinische situatie vaak 
moeilijk om de juiste oorzaak te achterhalen.
Onlangs werd aangetoond dat het optreden van tolerantie, vanuit farmacologisch 
oogpunt bekeken, in verband staat met een reeks van veranderingen beginnend op het 
niveau van de opioïd receptor, gevolgd door een groot aantal intracellulaire verande­
ringen. De activatie van de NMDA receptor is van belang om deze veranderingen in 
gang te zetten. In deze onderzoeken wordt ook een direct verband aangetoond tussen 
de door tolerantie ontstane veranderingen op het (sub-) cellulaire niveau en de veran­
deringen welke door (het aanwezig zijn van) neuropathische pijnsyndromen ontstaan. 
Naast het verhogen van de IT morfine dosering om dit verminderd pijnstillend effect 
te compenseren, zou het rationeler zijn om een (combinatie van) medicament (en) toe 
te dienen welke specifiek deze cellulaire processen beïnvloeden. Hiertoe worden 
locaal anesthetica en a 2 agonisten op grote schaal klinisch toegepast. Met het oog op 
de bovenstaande situatie werd getracht de vraag betreffende de effectiviteit van IT 
morfine na uitgebreide voorbehandeling met (oraal) morfine te beantwoorden.
Bij een groep van 43 patiënten met kanker werd, wegens onvoldoende pijnstilling 
en/of onacceptabele opioïd geïnduceerde onbehandelbare bijwerkingen, voor een IT 
toediening door middel van een percutane catheter en draagbare infusie pomp geko­
zen. Na het nader bepalen van de indicatie voor deze IT toediening (onvoldoende 
pijnstilling versus bijwerkingen), werden de patiënten gestratificeerd overeenkomstig 
de meest op de voorgrond staande pijnklachten (continu somatisch of visceraal versus 
intermitterent en neurogeen), waardoor een viertal groepen ontstonden. In elk van 
deze groepen vond vervolgens een dubbel-blinde randomisatie plaats in, enerzijds een 
morfine (M) groep en anderzijds een morfine/bupivacaïne (M/B) behandel groep, 
hetgeen leidde tot een totaal van acht subgroepen. De patiënten werden prospectief 
gevolgd tot aan hun overlijden dan wel tot aan het einde van de IT behandelperiode. 
De kwaliteit van de pijnstilling, bijwerkingen en het optreden van complicaties wer­
den beoordeeld.
In de morfine groep bleek vergeleken met de morfine/ bupivacaïne groep, na het 
beëindigen van de dubbelblinde periode bij een significant groter aantal patiënten een
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onvoldoende pijnstilling opgetreden te zijn (57% versus 12%, P= 0.004: Fisher exact 
test). In deze groep patiënten, welke onvoldoende reageerden op de toediening van 
morfine, bleken vaker pijnklachten van neurogene oorsprong en pijn met een intermit­
terend karakter aanwezig te zijn.
De daarop volgende toevoeging van bupivacaïne bij deze "morfine-ongevoelige" 
patiënten resulteerde uiteindelijk bij 63% van hen in een goede pijnstilling. De door 
het bupivacaïne veroorzaakte bijwerkingen waren kortdurend en niet ernstig van aard. 
De door de catheter veroorzaakte bijwerkingen betroffen voornamelijk het optreden 
van postspinale punctie hoofdpijn (37%). Bij een aantal patiënten presenteerde zich 
een persisterende lekkage van liquor welke in 8% van hen een epidurale injectie van 
autoloog bloed (bloodpatch) noodzakelijk maakte. Bij een patiënt trad een meningitis 
op welke restloos genas na toediening van antibiotica.
Het is vooralsnog onduideijk op grond waarvan de infusie van een gecombineerde 
morfine / bupivacaïne oplossing tot een verbetering leidt van deze morfine “ongevoe­
ligheid”. Dierexperimenteel onderzoek heeft ondermeer een verandering in de door­
bloeding van het ruggemerg gesuggereerd, welke een effect zou kunnen hebben op de 
morfine klaring vanuit de liquor. Ook werd een interactie van het morfine met de 
neuronale Na-kanalen, dan wel een beïnvloeding van de vorm van de opioïd receptor 
door het bupivacaïne verondersteld.
De veiligheid van de IT techniek kon worden bevestigd. Echter, het klinische 
probleem van de ineffectiviteit van IT morfine toediening bij vergevorderde stadia van 
kanker wordt in de literatuur waarschijnlijk onderschat.
Hoofdstuk 7 richt zich op het synergistische effect van IT morfine en bupivacaïne.
Bij twintig patiënten met een adequate pijnstilling (beoordeeld door middel van een 
numerieke schaal) werd gedurende de IT toediening van morfine of morfine/ bupiva- 
caïne de toename van de IT morfine dosering prospectief bestudeerd. In beide groepen 
werd een regressie-analyse uitgevoerd van de morfine dosis per dag uitgezet tegen de 
tijd, gedurende dag 10 tot dag 30.
In de morfine / bupivacaïne groep was een statistisch significant geringere progres­
sie van de morfine dosering vergeleken met de morfine groep (de helling van de
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dosistoename bedroeg 0.0003 versus 0.005, P= 0.0001, ANOVA). Er traden geen 
ernstige bupivacaïne geïnduceerde bijwerkingen op. Uit deze resultaten wordt gecon­
cludeerd dat er een synergistisch effect optreedt bij het gelijktijdig IT toedienen van 
morfine en bupivacaïne bij patiënten met kanker. Een beïnvloeding van de cellulaire, 
neuronale, prikkelbaarheid door het bupivacaïne in combinatie met de specifieke 
effecten van morfine op het niveau van de opioïd receptor in de celmembraan is 
hierbij van belang.
Hoofdstuk 8  heeft betrekking op het optreden van neurologische complicaties bij 
patiënten met kanker welke een invloed kunnen hebben op de IT toediening van 
medicatie.
8.1: Allereerst worden er zes patiënten beschreven met ernstige neurologische 
uitval, gelijkend op een paraplegie, kort na het starten met een IT behandeling met 
morfine en bupivacaïne.
Een dreigende compressie van het ruggemerg of de cauda equina en het optreden 
van ingroei in de lumbosacrale plexus door de progressie van het tumorproces konden 
hier worden aangetoond. Aangezien deze pijnklachten meestal niet goed reageren op 
(conventionele) toediening van morfine wordt toevoeging van bupivacaïne hierbij 
overwogen. Bij deze patiënten bleek het bupivacaïne de al aanwezige neurologische 
uitval te "ontmaskeren". Het optreden van (ernstige) neurologische verschijnselen bij 
een lage dosering IT bupivacaïne moet derhalve een waarschuwingssignaal voor de 
klinicus zijn.
8.2: Langdurige percutane catheterisatie van de IT ruimte kan vergezeld gaan van 
(een zichtbaar) verlies van liquor in de weefsels rondom het spinale kanaal en in het 
traject van de catheter. Met name het uitwendig verlies van liquor bij de uittredeplaats 
aan de huid kan hinderlijk zijn. Daarnaast kan er een infectie optreden en kan door 
verlies van medicatie de effectiviteit van de behandeling afnemen. Indien door conser­
vatieve maatregelen (bedrust, veel drinken e.d.) de lekkage niet spontaan tot staan 
komt, is een epidurale injectie van autoloog bloed een mogelijkheid. Bij een drietal 
patiënten met kanker echter, was ook deze behandeling niet effectief en werd vanwege 
de adequate pijnstilling voortzetting van de IT toediening gewenst geacht. Door 
middel van een epidurale injectie, één niveau boven de plaats van de catheter insertie, 
van zogenaamde "fibrine lijm" (Tissucol®) kon de lekkage tot staan gebracht worden
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zonder het optreden van bijwerkingen. Bij twee patiënten bleek de catheter dóór een 
pathologische epidurale massa ingebracht te zijn, hetgeen een mogelijke verklaring 
vormde voor de persisterende liquor lekkage en het falen van de epidurale injectie van 
bloed. Deze methode zou als een alternatief beschouwd kunnen worden voor de 
behandeling van persisterende liquorlekkage na het falen van een epidurale "blood 
patch" bij patiënten met kanker waarbij voortzetten van de infusie noodzakelijk is.
8.3: Bij een aantal patiënten met kanker zal door de localisatie van het pijnsyn- 
droom op cervicaal niveau of meer rostraal, een lumbale of thoracale localisatie van de 
IT catheter niet voldoen, met name als er locaal anesthetica dienen te worden toege­
voegd. Het inbrengen van de catheter via een (para-) mediane benadering op hoog 
cervicaal niveau kan overwogen worden, maar is vanwege de aanwezigheid van het 
ruggemerg met de verschillende vitale centra cervicaal, een potentieel risicovolle 
ingreep. Een gemodificeerde laterale benadering, welke sterke overeenkomsten ver­
toont met een onder Röntgendoorlichting uit te voeren percutane cervicale chordoto­
mie werd beschreven en toegepast bij twee patiënten.
Een geleidelijke IT morfine dosisverhoging met een voorzichtige combinatie van 
bupivacaïne onder goede observatie van het effect, resulteerde in adequate pijnstilling.
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